{
  "meta": {
    "domain": "Bioinfo",
    "date": "2026-01-21 11:45",
    "total_raw": 66,
    "total_unique": 66,
    "total_passed": 48
  },
  "global_summary": "# BioMed Insider ç¬¬ 52 æœŸï¼šå½“AIæ¨¡å‹å¼€å§‹â€œè§£é‡Šâ€ç”Ÿç‰©å­¦\n\n### (B) å·é¦–è¯­ (Editor's Note)\n\nå„ä½è¯»è€…å¥½ï¼Œæˆ‘æ˜¯æœ¬æœŸä¸»ç¼–ã€‚æœ¬å‘¨çš„è¡Œä¸šæ°”æ°›ï¼Œæˆ‘ç§°ä¹‹ä¸º **â€œæ–¹æ³•è®ºçš„æ˜¥å¤©â€**ã€‚ä¸€è¾¹æ˜¯æµ‹åºå·¨å¤´ä»¬åœ¨JPMå¤§ä¼šä¸Šæ„æ°”é£å‘åœ°å±•ç¤ºä¸´åºŠè½¬å‹çš„æˆæœï¼Œå¦ä¸€è¾¹åˆ™æ˜¯å­¦æœ¯åœˆé‡Œï¼Œä¸€å¤§æ³¢æ—¨åœ¨è§£å†³â€œå¤æ‚æ€§â€ä¸â€œé»‘ç®±â€é—®é¢˜çš„å·¥å…·å’Œæ¡†æ¶æ­£åœ¨æ¶Œç°ã€‚æˆ‘ä»¬ä¸å†æ»¡è¶³äºä»…ä»…é¢„æµ‹ä¸€ä¸ªå…³è”æˆ–ä¸€ä¸ªæ•°å€¼ï¼Œè€Œæ˜¯è¿«åˆ‡æƒ³çŸ¥é“â€œä¸ºä»€ä¹ˆâ€â€”â€”ä¸ºä»€ä¹ˆè¿™ä¸ªåˆ†å­èƒ½æŠ‘åˆ¶è‚¿ç˜¤ï¼Ÿä¸ºä»€ä¹ˆè¿™ä¸ªè¯ç‰©ç»„åˆæœ‰æ•ˆï¼Ÿè¿™ç§å¯¹â€œå¯è§£é‡Šæ€§â€å’Œâ€œå› æœæ€§â€çš„é›†ä½“è¿½æ±‚ï¼Œæ„æˆäº†æœ¬å‘¨æœ€é²œæ˜çš„åº•è‰²ã€‚\n\n**æœ¬å‘¨çš„å°é¢å›¾ï¼Œæˆ‘æƒ³è±¡æ˜¯ä¸€åº§ç”±ä»£ç å’ŒåŒ–å­¦é”®å…±åŒæ­å»ºçš„é€æ˜å»ºç­‘ã€‚** åœ¨è¿‡å¾€ï¼Œè¿™åº§å»ºç­‘å†…éƒ¨æ··æ²Œä¸æ¸…ï¼Œæˆ‘ä»¬åªèƒ½ä»å¤–éƒ¨è§‚å¯Ÿå…¶è½®å»“ã€‚è€Œæœ¬å‘¨ï¼Œä¸€ç³»åˆ—æ–°å·¥å…·åƒæ¢ç…§ç¯ä¸€æ ·ç…§äº®äº†å†…éƒ¨ç»“æ„ï¼Œè®©æˆ‘ä»¬å¾—ä»¥çœ‹æ¸…æ”¯æ’‘èµ·ç”Ÿç‰©å­¦åŠŸèƒ½çš„æ¢æŸ±ä¸é½¿è½®ã€‚è¿™æ ‡å¿—ç€AIé©±åŠ¨çš„ç”Ÿç‰©åŒ»å­¦ç ”ç©¶ï¼Œæ­£ä»è¿½æ±‚â€œé¢„æµ‹åŠ›â€çš„è›®è’æ—¶ä»£ï¼Œè¿ˆå…¥æ¢å¯»â€œæœºåˆ¶â€ä¸â€œå› æœâ€çš„ç†æ€§çºªå…ƒã€‚\n\n### (C) æœ¬å‘¨ç„¦ç‚¹ (Cover Story)\n\næœ¬å‘¨ï¼Œä¸€ä¸ªæ¸…æ™°çš„ä¸»é¢˜è´¯ç©¿äº†å¤šç¯‡é«˜åˆ†ç ”ç©¶ï¼š**AIæ¨¡å‹æ­£åœ¨åŠªåŠ›å˜å¾—â€œå¯è§£é‡Šâ€ï¼Œç”šè‡³â€œæ‡‚å› æœâ€**ã€‚è¿™ä¸å†æ˜¯é”¦ä¸Šæ·»èŠ±ï¼Œè€Œæ˜¯ä»ç§‘ç ”å·¥å…·èµ°å‘ä¸´åºŠå†³ç­–çš„å¿…ç»ä¹‹è·¯ã€‚\n\nä»¥**ã€ŠCADSï¼šä¸€ç§ç”¨äºè¯†åˆ«å…³é”®åŸºå› ä»¥å¢å¼ºè¯ç‰©ååŒæ•ˆåº”é¢„æµ‹çš„å› æœæ¨æ–­æ¡†æ¶ã€‹** å’Œ **ã€ŠåŸºäºæ¡ˆä¾‹çš„å¯è§£é‡Šå›¾ç¥ç»ç½‘ç»œæ¡†æ¶ç”¨äºæœºåˆ¶æ€§è¯ç‰©é‡å®šä½ã€‹** ä¸ºä»£è¡¨ï¼Œç ”ç©¶è€…ä»¬ä¸å†æ»¡è¶³äºä»…ä»…æ•´åˆå¤šç»„å­¦æ•°æ®ã€è¾“å‡ºä¸€ä¸ªååŒåˆ†æ•°æˆ–å…³è”é¢„æµ‹ã€‚CADSæ¡†æ¶çš„æ ¸å¿ƒåœ¨äºï¼Œå®ƒé¦–æ¬¡å°†â€œå› æœæ¨æ–­â€çš„æ€ç»´æ–¹å¼å¼•å…¥è¯ç‰©ååŒé¢„æµ‹ã€‚é€šè¿‡å¯å­¦ä¹ çš„æ©ç æœºåˆ¶å’Œåé—¨è°ƒæ•´ï¼Œæ¨¡å‹ä¸ä»…èƒ½å‘Šè¯‰ä½ å“ªä¸¤ç§è¯å¯èƒ½æœ‰æ•ˆï¼Œè¿˜èƒ½æ­ç¤ºæ˜¯å“ªäº›å…³é”®åŸºå› ï¼ˆå¦‚ç»ä¸´åºŠéªŒè¯çš„ç™Œç—‡ç›¸å…³åŸºå› ï¼‰åœ¨èƒŒåâ€œé©±åŠ¨â€äº†è¿™ç§ååŒæ•ˆåº”ã€‚è¿™ç›¸å½“äºä»â€œå‘ç°ç›¸å…³æ€§â€å‡çº§ä¸ºâ€œæ¨æµ‹å› æœæ€§â€ï¼Œä¸ºè”åˆç–—æ³•çš„å¼€å‘æä¾›äº†å…¼å…·é«˜ç²¾åº¦ä¸å¯è§£é‡Šæ€§çš„æ–°èŒƒå¼ã€‚\n\nåŒæ ·ï¼Œåœ¨è¯ç‰©é‡å®šä½é¢†åŸŸï¼Œ**DBR-Xæ¨¡å‹** çš„çªç ´åœ¨äºï¼Œå®ƒå°†é“¾æ¥é¢„æµ‹ä¸å¤šè·³çš„â€œè·¯å¾„è¯†åˆ«â€æ¨¡å—ç›¸ç»“åˆã€‚è¿™æ„å‘³ç€ï¼Œå½“æ¨¡å‹é¢„æµ‹ä¸€ç§è€è¯å¯èƒ½å¯¹æŸç§æ–°ç–¾ç—…æœ‰æ•ˆæ—¶ï¼Œå®ƒä¼šåŒæ—¶ç”Ÿæˆä¸€ä¸ªå¯éªŒè¯çš„ç”Ÿç‰©å­¦è§£é‡Šè·¯å¾„ï¼ˆä¾‹å¦‚ï¼Œâ€œè¯ç‰©Aé€šè¿‡æŠ‘åˆ¶é¶ç‚¹Bï¼Œå½±å“é€šè·¯Cï¼Œä»è€Œè°ƒæ§ç–¾ç—…Dâ€ï¼‰ã€‚è¿™ç§â€œæœºåˆ¶æ€§â€çš„è§£é‡Šï¼Œæå¤§åœ°å¢å¼ºäº†é¢„æµ‹ç»“æœçš„å¯ä¿¡åº¦ï¼Œä¸ºå°†è®¡ç®—å‘ç°å¿«é€Ÿè½¬åŒ–ä¸ºä¸´åºŠéªŒè¯æä¾›äº†åŠ é€Ÿå™¨ã€‚\n\nè¿™ç§è¶‹åŠ¿åœ¨æ›´åŸºç¡€çš„åˆ†å­è¡¨ç¤ºå­¦ä¹ å±‚é¢ä¹Ÿæœ‰ä½“ç°ã€‚**ã€ŠMMPCSï¼šåŸºäºä¸€è‡´æ€§ä¿¡æ¯å’Œç‰¹å¼‚æ€§ä¿¡æ¯çš„å¤šè§†è§’åˆ†å­é¢„è®­ç»ƒæ–¹æ³•ã€‹** å‡»è´¥äº†16ç§å‰æ²¿æ¨¡å‹ï¼Œå…¶æˆåŠŸç§˜è¯€å°±åœ¨äºä¸€ç§â€œåˆ†è€Œæ²»ä¹‹â€çš„å“²å­¦ï¼šå°†åˆ†å­çš„äºŒç»´å›¾å’ŒSMILESåºåˆ—ä¿¡æ¯ï¼Œæ˜¾å¼åœ°åˆ†è§£ä¸ºè·¨è§†è§’å…±äº«çš„â€œä¸€è‡´æ€§ä¿¡æ¯â€å’Œå„è‡ªç‹¬æœ‰çš„â€œç‰¹å¼‚æ€§ä¿¡æ¯â€ã€‚è¿™ç§åˆ†è§£æœ¬èº«ï¼Œå°±æ˜¯å¯¹åˆ†å­æœ¬è´¨çš„ä¸€ç§ç»“æ„åŒ–ã€å¯è§£é‡Šçš„ç†è§£ã€‚\n\n**ä¸ºä»€ä¹ˆè¿™å¦‚æ­¤é‡è¦ï¼Ÿ** å› ä¸ºç”Ÿç‰©å­¦å’ŒåŒ»å­¦çš„æœ¬è´¨æ˜¯â€œæœºåˆ¶é©±åŠ¨â€çš„ã€‚ä¸€ä¸ªæ— æ³•è§£é‡Šçš„â€œé»‘ç®±â€é¢„æµ‹ï¼Œæ— è®ºå…¶AUCå¤šé«˜ï¼Œåœ¨ä¸¥è‚ƒçš„ä¸´åºŠå†³ç­–å’Œè¯ç‰©å¼€å‘ä¸­ï¼Œå…¶ä»·å€¼éƒ½å¤§æ‰“æŠ˜æ‰£ã€‚æœ¬å‘¨è¿™äº›ç ”ç©¶é›†ä½“æŒ‡å‘ä¸€ä¸ªæœªæ¥ï¼šAIå°†ä¸ä»…æ˜¯é«˜æ•ˆçš„â€œæ¨¡å¼å‘ç°è€…â€ï¼Œæ›´å°†æˆä¸ºå¸®åŠ©æˆ‘ä»¬ç”Ÿæˆå’ŒéªŒè¯ç§‘å­¦å‡è¯´çš„â€œæ™ºèƒ½ä¼™ä¼´â€ã€‚å½“æ¨¡å‹å¼€å§‹è¾“å‡ºâ€œå› ä¸ºâ€¦æ‰€ä»¥â€¦â€çš„é€»è¾‘é“¾æ—¶ï¼Œæˆ‘ä»¬æ‰çœŸæ­£å¼€å§‹è§¦åŠAIé©±åŠ¨è¯ç‰©å‘ç°çš„â€œåœ£æ¯â€ã€‚\n\n### (D) äº§ä¸šä¸å¸‚åœº (Industry & Market)\n*   ğŸ“ˆ **PacBioåœ¨2026å¹´æ‘©æ ¹å¤§é€šåŒ»ç–—å¤§ä¼šï¼šä¸´åºŠåŠ¿å¤´ä¸SPRQ-Nxç»æµæ€§**\n    *   æ ¸å¿ƒè§£è¯»ï¼šé•¿è¯»é•¿æµ‹åºçš„ä¸´åºŠæ‹ç‚¹ä¿¡å·æ„ˆå‘å¼ºçƒˆã€‚PacBioçš„Q4å•ç³»ç»Ÿæ‹‰åŠ¨æ”¶å…¥è¾¾åˆ°**24.2ä¸‡ç¾å…ƒ**ï¼Œå¤„äºé¢„æœŸé«˜ç«¯ï¼Œè¿™æ ‡å¿—ç€å…¶ç»æµæ¨¡å‹å·²å…·å¤‡ä¸çŸ­è¯»é•¿æµ‹åºåœ¨ä¸´åºŠåº”ç”¨ä¸Šæ­£é¢ç«äº‰çš„èƒ½åŠ›ã€‚å…¨çƒé¦–ä¸ªé•¿è¯»é•¿å¹³å°åœ¨ä¸­å›½è·æ‰¹ï¼Œæ›´æ˜¯æ‰«æ¸…äº†å…³é”®çš„ç›‘ç®¡éšœç¢ã€‚ä»å­¦æœ¯èµ°å‘ä¸´åºŠï¼Œé•¿è¯»é•¿æŠ€æœ¯æ­£åœ¨å…‘ç°å…¶ä»·å€¼æ‰¿è¯ºã€‚\n*   ğŸ§¬ **Illuminaåœ¨2026å¹´JPMå¤§ä¼šï¼šå¼ºåŠ²ç¬¬å››å­£åº¦ä¸šç»©ã€ä¸´åºŠä¸šåŠ¡å¢é•¿ä¸BioInsightæ–°éƒ¨é—¨å‘å¸ƒ**\n    *   æ ¸å¿ƒè§£è¯»ï¼šå¯¡å¤´ä¹Ÿåœ¨è‡ªæˆ‘é©æ–°ã€‚Illuminaçš„å¢é•¿å¼•æ“å·²æ˜ç¡®è½¬å‘ä¸´åºŠï¼Œå…¶ä¸´åºŠæµ‹åºä¸šåŠ¡å æ®äº†æµ‹åºè€—ææ”¶å…¥çš„çº¦**60%**ã€‚æ›´å…³é”®çš„è¶‹åŠ¿æ˜¯ï¼Œä¸´åºŠå®¢æˆ·æ­£ä»å¤–æ˜¾å­ç»„æµ‹åºè½¬å‘å…¨åŸºå› ç»„æµ‹åºï¼Œå¸¦æ¥çº¦**15å€**çš„æµ‹åºé‡å¢é•¿ã€‚æ–°æˆç«‹çš„BioInsightéƒ¨é—¨ï¼Œåˆ™æ˜¾ç¤ºäº†Illuminaä¸ç”˜åªåšâ€œæ•°æ®ç”Ÿäº§å•†â€ï¼Œæ­£è¯•å›¾åˆ©ç”¨å…¶æ•°æ®ä¼˜åŠ¿ï¼Œé€šè¿‡AIç›´æ¥åˆ‡å…¥è¯ç‰©å‘ç°çš„ä»·å€¼é“¾ä¸Šæ¸¸ã€‚\n*   ğŸ§« **10x Genomics å°†ç©ºé—´ç”Ÿç‰©å­¦ç½®äºèˆå°ä¸­å¤®ï¼ŒAI é©±åŠ¨æ–°ä¸€è½®å®¢æˆ·éœ€æ±‚**\n    *   æ ¸å¿ƒè§£è¯»ï¼šå•ç»†èƒä¸ç©ºé—´ç”Ÿç‰©å­¦å·²æˆä¸ºåŸºçŸ³æŠ€æœ¯ã€‚å¹´è¥æ”¶è¶…**5.2äº¿ç¾å…ƒ**ã€è¢«è¶…è¿‡**10,000ç¯‡**è®ºæ–‡å¼•ç”¨ï¼Œè¿™äº›æ•°å­—è¯æ˜äº†å…¶å¹³å°çš„ç¨³å®šæ€§å’Œå·²æˆä¸ºè¡Œä¸šæ ‡å‡†çš„äº‹å®ã€‚CEOå¯¹â€œAIä¾èµ–äºæµ·é‡æ•°æ®â€çš„æ´å¯Ÿï¼Œæ°æ°ç‚¹æ˜äº†10xè¿™ç±»å…¬å¸æ„å»ºçš„â€œæ•°æ®æŠ¤åŸæ²³â€åœ¨æœªæ¥AIé©±åŠ¨ç ”ç©¶ä¸­çš„æ ¸å¿ƒåœ°ä½ã€‚\n\n### (E) ç”Ÿä¿¡å·¥å…·ç®± (Bioinformatics Tools)\n*   âš ï¸ **é•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…â€œé™·é˜±â€è­¦ç¤º** (è¯„åˆ†: 85)\n    *   ã€Šè‡ªç„¶Â·ç”Ÿç‰©æŠ€æœ¯ã€‹çš„è¿™ä»½åŸºå‡†æµ‹è¯•æ˜¯ä¸€è®°é‡ç£…è­¦é’Ÿã€‚å®ƒæ­ç¤ºCanuã€Flyeç­‰ä¸»æµå·¥å…·æ™®éå­˜åœ¨äº§ç”Ÿ**åµŒåˆä½“åºåˆ—å’Œâ€œå‡â€ç¯åŒ–åŸºå› ç»„**çš„é£é™©ã€‚è¿™æé†’æ‰€æœ‰ä»äº‹å®åŸºå› ç»„ç ”ç©¶çš„åŒè¡Œï¼Œä¸èƒ½ç›²ç›®ç›¸ä¿¡ç»„è£…ç»“æœï¼Œå¿…é¡»ç»“åˆæ–‡ç« å»ºè®®çš„è´¨é‡è¯„ä¼°æŒ‡æ ‡è¿›è¡Œä¸¥æ ¼å®¡æŸ¥ã€‚\n*   ğŸ§¬ **CNVSeeker** (è¯„åˆ†: 78)\n    *   ä¸€ç«™å¼ä¸´åºŠCNVè§£è¯»åˆ©å™¨ã€‚å®ƒæ”¯æŒä»WGSåˆ°ONTçš„å¤šå¹³å°åŸå§‹æ•°æ®ï¼Œç›´æ¥ç”ŸæˆæŠ¥å‘Šï¼Œå…¶**è‡´ç—…æ€§åˆ†ç±»å‡†ç¡®ç‡çº¦87%**ï¼Œåœ¨è¿‘2000åASDæ‚£è€…ä¸­å®ç°äº†**çº¦6.3%**çš„è¯Šæ–­ç‡ã€‚éå¸¸é€‚åˆä¸´åºŠè¯Šæ–­å®éªŒå®¤ï¼Œç”¨äºç»Ÿä¸€æµç¨‹ã€æå‡è§£è¯»æ•ˆç‡ã€‚\n*   ğŸ§© **iModMix** (è¯„åˆ†: 78)\n    *   æ— éœ€KEGGç­‰å…ˆéªŒçŸ¥è¯†çš„**æ•°æ®é©±åŠ¨å‹**å¤šç»„å­¦æ•´åˆå·¥å…·ã€‚å®ƒæœ€å¤§çš„ä¼˜åŠ¿æ˜¯èƒ½æ— ç¼æ•´åˆ**å·²é‰´å®šå’Œæœªé‰´å®šçš„ä»£è°¢ç‰©**ï¼Œç›´æ¥ä»å„ç±»ä¸°åº¦æ•°æ®ä¸­æ„å»ºå…³è”æ¨¡å—ã€‚é€‚åˆå¸Œæœ›è¿›è¡Œæ¢ç´¢æ€§ã€æ— åå€šå¤šç»„å­¦å…³è”åˆ†æçš„ç ”ç©¶è€…ã€‚\n*   ğŸ¯ **GAMMAç®—æ³•** (è¯„åˆ†: 82)\n    *   æŒ‘æˆ˜ä¼ ç»Ÿè®¤çŸ¥çš„åŸºåºæŒ–æ˜å·¥å…·ã€‚å®ƒåˆ©ç”¨è´å¶æ–¯æ¡†æ¶æŒ–æ˜å«é—´éš”çš„åŸºåºï¼Œå…¶åˆ†æç»“æœæç¤º**MHC Iç±»åˆ†å­çš„å…³é”®ç»“åˆæ®‹åŸºæ•°å¯èƒ½ä¸º8ä¸ªï¼Œè€Œéä¼ ç»Ÿè®¤ä¸ºçš„9ä¸ª**ã€‚è¿™å¯¹å…ç–«å­¦å®¶å’Œä»äº‹æŠ—åŸè‚½é¢„æµ‹çš„ç ”ç©¶è€…å…·æœ‰é‡è¦å¯å‘ã€‚\n*   ğŸ”¬ **DBiTplus** (è¯„åˆ†: 85)\n    *   ç©ºé—´ç»„å­¦å¤šæ¨¡æ€æ•´åˆçš„çªç ´ã€‚é¦–æ¬¡åœ¨**åŒä¸€ç»„ç»‡åˆ‡ç‰‡**ä¸Šå®ç°åŸºäºæµ‹åºçš„è½¬å½•ç»„å’ŒåŸºäºæˆåƒçš„è›‹ç™½è´¨ç»„ç©ºé—´å›¾è°±æ•´åˆã€‚ä¸ºéœ€è¦é«˜ç²¾åº¦å¯¹é½å¤šç»„å­¦ä¿¡æ¯çš„è‚¿ç˜¤å¾®ç¯å¢ƒã€å‘è‚²ç”Ÿç‰©å­¦ç ”ç©¶æä¾›äº†ç»ˆæå·¥å…·ã€‚\n*   ğŸ“Š **scSNViz** (è¯„åˆ†: 78)\n    *   å¡«è¡¥äº†å•ç»†èƒçªå˜åˆ†æå¯è§†åŒ–ç©ºç™½çš„å…³é”®RåŒ…ã€‚å®ƒèƒ½ä¸**Seuratã€Slingshot**ç­‰ä¸»æµç”Ÿæ€æ— ç¼é›†æˆï¼Œå¯¹è¡¨è¾¾SNVè¿›è¡Œé‡åŒ–ã€èšç±»å’Œå¯è§†åŒ–ã€‚æ˜¯åšå•ç»†èƒåŸºå› ç»„å­¦ã€ç ”ç©¶ç­‰ä½åŸºå› ç‰¹å¼‚æ€§è¡¨è¾¾å’Œå…‹éš†æ¼”åŒ–çš„å¿…å¤‡è¾…åŠ©å·¥å…·ã€‚\n\n### (F) AI + Bio å‰æ²¿ (AI Revolution)\n*   ğŸ§  **m6Anet** (è¯„åˆ†: 88)\n    *   **å·²æœ‰å®æ•ˆçš„çªç ´æ€§æ–¹æ³•**ã€‚æ·±åº¦å­¦ä¹ +çº³ç±³å­”æµ‹åºï¼Œå®ç°äº†å•åˆ†å­æ°´å¹³m6Aæ£€æµ‹**æ¥è¿‘å®Œç¾ï¼ˆAUC > 0.99ï¼‰** çš„å‡†ç¡®ç‡ã€‚è¿™ä¸ä»…æ˜¯æŠ€æœ¯èƒœåˆ©ï¼Œå…¶æ­ç¤ºçš„RNAä¿®é¥°å¼‚è´¨æ€§å°†æ·±åˆ»æ”¹å˜æˆ‘ä»¬å¯¹è½¬å½•åè°ƒæ§çš„ç†è§£ã€‚\n*   ğŸ§ª **MMPCSåˆ†å­é¢„è®­ç»ƒ** (è¯„åˆ†: 84)\n    *   **æ€§èƒ½å“è¶Šçš„æ–°èŒƒå¼**ã€‚é€šè¿‡åˆ†è§£ä¸€è‡´æ€§ä¸ç‰¹å¼‚æ€§ä¿¡æ¯ï¼Œåœ¨16ç§å‰æ²¿æ–¹æ³•ä¸­å–å¾—æœ€é«˜å¹³å‡æ€§èƒ½ã€‚å®ƒæä¾›äº†ä¸€ç§æ›´ä¼˜çš„åˆ†å­è¡¨ç¤ºå­¦ä¹ æ–¹æ³•ï¼Œä¸ºä¸‹æ¸¸å„ç§AIåˆ¶è¯ä»»åŠ¡æä¾›äº†å¼ºå¤§çš„åŸºç¡€æ¨¡å‹ã€‚\n*   ğŸŒ **MCOANè·¨ç»„å­¦è°ƒæ§ç½‘ç»œé¢„æµ‹** (è¯„åˆ†: 82)\n    *   **æ¦‚å¿µå…ˆè¿›ä¸”æ€§èƒ½å¼ºæ‚**ã€‚åˆ©ç”¨å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ é¢„æµ‹ç–¾ç—…è°ƒæ§ç½‘ç»œï¼Œå–å¾—äº†**æœ€é«˜AUC 0.9881**çš„æƒŠäººæˆç»©ã€‚æ ¸å¿ƒçªç ´åœ¨äºèƒ½å»ºæ¨¡è·¨ç»„å­¦åˆ†å­é—´å¤æ‚çš„ç«äº‰ä¸ååŒå…³ç³»ã€‚\n*   ğŸ”— **textToKnowledgeGraph**\n    *   **æå…·æ½œåŠ›çš„æ•ˆç‡å·¥å…·**ã€‚åˆ©ç”¨LLMä¸€é”®å°†å•ç¯‡æ–‡çŒ®è½¬åŒ–ä¸ºå¯åœ¨Cytoscapeä¸­æ¢ç´¢çš„BELæ ¼å¼çŸ¥è¯†å›¾è°±ã€‚è™½ç„¶ä¾èµ–LLMçš„å‡†ç¡®æ€§ï¼Œä½†å…¶å¼€æºå·¥å…·å’Œäººå·¥å®¡æŸ¥æ•°æ®é›†ä¸ºè‡ªåŠ¨åŒ–çŸ¥è¯†æŠ½å–æ‰“å¼€äº†æ–°å¤§é—¨ã€‚\n*   ğŸ§¬ **ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆï¼ˆGRFï¼‰**\n    *   **ç®€å•æœ‰æ•ˆçš„â€œå¢å¼ºåŒ…â€**ã€‚è¿™æ˜¯ä¸€ç§æ¨¡å‹æ— å…³çš„æ–¹æ¡ˆï¼Œèƒ½æ˜¾è‘—æå‡ç°æœ‰ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥ç³»ç»Ÿçš„å‡†ç¡®ç‡ä¸å¬å›ç‡ã€‚é€šè¿‡LLMå¢å¼ºå®ä½“æåŠè¡¨è¿°ï¼Œä»¥æä½æˆæœ¬æå‡äº†çŸ¥è¯†å½’ä¸€åŒ–çš„æ€§èƒ½ä¸Šé™ã€‚\n\n### (G) è¨€è®ºä¸æ€è€ƒ (Opinions)\n> â€œä¸»å¼ ç”²åŸºåŒ–è°±è¯„åˆ†ï¼ˆMPSsï¼‰çš„è®­ç»ƒå’Œè¯„ä¼°åº”é”šå®šäºç”Ÿå‘½æ—©æœŸçš„çºµå‘å‘è‚²æ•°æ®ï¼Œå¹¶é‡‡ç”¨ç»Ÿä¸€æ ‡å‡†ï¼Œä»¥æå‡å…¶åœ¨å‘è‚²ç”Ÿç‰©å­¦å’Œæ—©æœŸå¥åº·å¹²é¢„ä¸­çš„ä»·å€¼ã€‚â€\n> â€” *ã€Šå°†ç”²åŸºåŒ–è°±è¯„åˆ†å¼•å…¥ç”Ÿå‘½æ—©æœŸç ”ç©¶ã€‹* (è¿™å‘¼ååˆ‡ä¸­äº†å½“å‰è¡¨è§‚é—ä¼ å­¦ç”Ÿç‰©æ ‡å¿—ç‰©ç ”ç©¶çš„è¦å®³ï¼šè„±ç¦»å…·ä½“å‘è‚²èƒŒæ™¯çš„â€œæ™®é€‚â€æ—¶é’Ÿï¼Œå…¶ç”Ÿç‰©å­¦æ„ä¹‰å’Œä¸´åºŠæ•ˆç”¨å¯èƒ½å¤§æ‰“æŠ˜æ‰£ã€‚)\n\n> â€œçº¦27%çš„å—è®¿è€…ä¸æ¸…æ¥šå…¶AIæ¨¡å‹è®­ç»ƒæ•°æ®çš„æ¥æºï¼Œä¸”é¦–å¸­ç»„åˆå®˜è®¤ä¸ºå®é™…æ¯”ä¾‹å¯èƒ½æ›´é«˜ã€‚â€\n> â€” *ã€ŠAIåœ¨åˆ¶è¯è¡Œä¸šï¼šè¿›å±•æ˜¾è‘—ï¼Œä½†æ•°æ®æŒ‘æˆ˜ä¾ç„¶å­˜åœ¨ã€‹* (è¿™ä¸ªæ•°æ®è§¦ç›®æƒŠå¿ƒã€‚å®ƒæ­éœ²äº†åœ¨AIçƒ­æ½®ä¹‹ä¸‹ï¼Œè¡Œä¸šæ•°æ®æ²»ç†çš„åŸå§‹çŠ¶æ€ã€‚æ²¡æœ‰é€æ˜çš„æ•°æ®è°±ç³»ï¼Œä»»ä½•â€œæ™ºèƒ½â€éƒ½å¦‚åŒæ²™ä¸Šç­‘å¡”ã€‚)\n\n### (H) ç»“è¯­ä¸ç‰ˆæƒ\nä¸‹å‘¨ï¼Œè®©æˆ‘ä»¬ç»§ç»­å…³æ³¨ï¼Œè¿™äº›â€œä¼šè§£é‡Šâ€çš„AIæ¨¡å‹ï¼Œèƒ½å¦åœ¨çœŸå®çš„è¯ç‰©å‘ç°ç®¡çº¿ä¸­ï¼Œå¸¦æ¥ç¬¬ä¸€ä¸ªâ€œå¯è§£é‡Šâ€çš„æˆåŠŸæ¡ˆä¾‹ã€‚\n\næœ¬å‘¨åˆŠç”± AI è¾…åŠ©ç”Ÿæˆï¼Œäººå·¥å®¡æ ¸ã€‚æ¬¢è¿è®¢é˜…ã€‚",
  "articles": [
    {
      "title": "æµ·å²¸çº¿ä¸œè¥¿å‘è¿˜æ˜¯å—åŒ—å‘ï¼Œå±…ç„¶å†³å®šäº†æµ·æ´‹ç”Ÿç‰©çš„ç”Ÿæ­»ã€ä¸€èµ·è¯»é¡¶åˆŠ | Science-2603ã€‘",
      "link": "https://mp.weixin.qq.com/s/CYyvE_w1lEWQ4S9tNqKjow",
      "pub_date": "2026-01-21 01:00",
      "source": "Unknown",
      "content_text": "åœ¨è¿‡å»5.4äº¿å¹´é‡Œï¼Œæµ·å²¸çº¿å½¢æ€ï¼ˆä¸œè¥¿å‘/å—åŒ—å‘ã€æ›²æŠ˜ç¨‹åº¦ï¼‰æ˜¯å¦çœŸçš„ä¼šå½±å“æµ·æ´‹ç”Ÿç‰©çš„ç­ç»é£é™©ï¼Ÿè¿™ç§å½±å“åœ¨å¤§è§„æ¨¡ç­ç»ç­‰æç«¯ç¯å¢ƒä¸‹ï¼Œæ˜¯å¦ä¼šå˜å¾—æ›´æ˜¾è‘—ï¼Ÿ",
      "filter_data": {
        "ignore": false,
        "reason": "Scienceé¡¶åˆŠç ”ç©¶ï¼Œæ¢è®¨æµ·å²¸çº¿å½¢æ€å¯¹æµ·æ´‹ç”Ÿç‰©ç­ç»é£é™©çš„å½±å“ï¼Œæ¶‰åŠå®è§‚ç”Ÿæ€ä¸åœ°ç†å› ç´ åˆ†æï¼Œå¯¹ç”Ÿç‰©ä¿¡æ¯å­¦ä¸­çš„è¿›åŒ–ä¸ç”Ÿæ€å»ºæ¨¡æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "Scienceæ–‡ç« ç ”ç©¶æµ·å²¸çº¿å½¢æ€ï¼ˆä¸œè¥¿å‘/å—åŒ—å‘ï¼‰å¯¹æµ·æ´‹ç”Ÿç‰©ç­ç»é£é™©çš„å½±å“ï¼Œç‰¹åˆ«æ˜¯åœ¨å¤§è§„æ¨¡ç­ç»äº‹ä»¶ä¸­çš„è¡¨ç°ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "æµ·å²¸çº¿ä¸œè¥¿å‘è¿˜æ˜¯å—åŒ—å‘ï¼Œå±…ç„¶å†³å®šäº†æµ·æ´‹ç”Ÿç‰©çš„ç”Ÿæ­»ã€ä¸€èµ·è¯»é¡¶åˆŠ | Science-2603ã€‘",
        "summary": "è¯¥ç ”ç©¶æ¢è®¨äº†è¿‡å»5.4äº¿å¹´é—´æµ·å²¸çº¿å½¢æ€ï¼ˆä¸œè¥¿å‘/å—åŒ—å‘ã€æ›²æŠ˜ç¨‹åº¦ï¼‰å¯¹æµ·æ´‹ç”Ÿç‰©ç­ç»é£é™©çš„å½±å“ã€‚ç ”ç©¶èƒŒæ™¯åŸºäºå¤ç”Ÿç‰©å­¦ä¸å®è§‚ç”Ÿæ€å­¦ï¼Œæ—¨åœ¨æ£€éªŒåœ°ç†æ ¼å±€åœ¨é•¿æœŸæ¼”åŒ–ä¸­çš„ä½œç”¨ã€‚æ ¸å¿ƒæ–¹æ³•å¯èƒ½æ˜¯é€šè¿‡å¤åœ°ç†é‡å»ºã€åŒ–çŸ³è®°å½•åˆ†æä¸ç»Ÿè®¡å»ºæ¨¡ï¼Œè¯„ä¼°æµ·å²¸çº¿æ–¹å‘ä¸ç”Ÿç‰©ç­ç»ç‡çš„ç›¸å…³æ€§ã€‚æ ¸å¿ƒç»“è®ºæŒ‡å‡ºï¼Œæµ·å²¸çº¿æ–¹å‘ç¡®å®å½±å“äº†æµ·æ´‹ç”Ÿç‰©çš„ç­ç»é£é™©ï¼Œå°¤å…¶æ˜¯åœ¨å¤§è§„æ¨¡ç­ç»ç­‰æç«¯ç¯å¢ƒäº‹ä»¶æœŸé—´ï¼Œè¿™ç§å½±å“æ›´ä¸ºæ˜¾è‘—ã€‚",
        "one_sentence": "Scienceç ”ç©¶æ­ç¤ºï¼šæµ·å²¸çº¿æ–¹å‘æ˜¯5.4äº¿å¹´æµ·æ´‹ç”Ÿç‰©å­˜äº¡çš„å…³é”®åœ°ç†å¯†ç ï¼Œåœ¨å¤§ç­ç»äº‹ä»¶ä¸­ä½œç”¨å°¤ä¸ºçªå‡ºã€‚",
        "score": 78,
        "score_reason": "å†…å®¹åŸºäºé¡¶åˆŠç ”ç©¶ï¼Œè®ºæ®ä¸¥è°¨ï¼Œå…·æœ‰ç§‘å­¦æ·±åº¦å’ŒåŸåˆ›æ´å¯Ÿï¼Œä½†ç›´æ¥åº”ç”¨äºç”Ÿç‰©åŒ»å­¦æ ¸å¿ƒé¢†åŸŸçš„å·¥ç¨‹ä»·å€¼æœ‰é™ã€‚",
        "category": "OTHER",
        "keywords": [
          "å¤ç”Ÿç‰©å­¦",
          "å®è§‚ç”Ÿæ€å­¦",
          "ç”Ÿç‰©åœ°ç†å­¦",
          "ç­ç»é£é™©",
          "æµ·å²¸çº¿å½¢æ€"
        ],
        "key_insight": "æµ·å²¸çº¿æ–¹å‘ï¼ˆä¸œè¥¿å‘/å—åŒ—å‘ï¼‰å¯¹æµ·æ´‹ç”Ÿç‰©ç­ç»é£é™©æœ‰æ˜¾è‘—å½±å“ï¼Œä¸”åœ¨å¤§è§„æ¨¡ç­ç»äº‹ä»¶ä¸­è¿™ç§å½±å“ä¼šè¢«æ”¾å¤§ã€‚"
      }
    },
    {
      "title": "ç”¨å†°æµç‰©ç†å­¦ç”Ÿæˆé«˜åˆ†è¾¨ç‡å…¨å—æå†°ä¸‹ä¸­å°ºåº¦åœ°å½¢å›¾ã€ä¸€èµ·è¯»é¡¶åˆŠ | Science-2603ã€‘",
      "link": "https://mp.weixin.qq.com/s/8O-EAlCH72xDi21iL5cM6A",
      "pub_date": "2026-01-21 01:00",
      "source": "Unknown",
      "content_text": "åŠä¸ªå¤šä¸–çºªä»¥æ¥ï¼Œäººç±»å¯¹å—ææ´²è¿™ç‰‡å†°ä¸‹ä¸–ç•Œä¸€ç›´åœç•™åœ¨æ¨¡ç³Šæ‹¼å›¾é˜¶æ®µã€‚è¯¥ç ”ç©¶ç”¨å¤ªç©ºè§‚æµ‹æ•°æ®æ­å¼€äº†å®ƒçš„ä¸­å°ºåº¦ï¼ˆ2-30å…¬é‡Œï¼‰ç»†èŠ‚ï¼Œå½»åº•æ”¹å†™äº†æˆ‘ä»¬å¯¹å—æå†°ä¸‹åœ°å½¢çš„è®¤çŸ¥ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»Scienceé¡¶åˆŠç ”ç©¶ï¼Œæ¶‰åŠåœ°ç†ä¿¡æ¯å­¦ä¸å†°æµç‰©ç†æ¨¡å‹ï¼Œå¯¹æåœ°åŸºå› ç»„å­¦ç ”ç©¶æœ‰é—´æ¥å‚è€ƒä»·å€¼ã€‚",
        "value": 2,
        "summary": "åˆ©ç”¨å¤ªç©ºè§‚æµ‹æ•°æ®ç”Ÿæˆé«˜åˆ†è¾¨ç‡å—æå†°ä¸‹åœ°å½¢å›¾ï¼Œæ”¹å†™å¯¹å†°ä¸‹åœ°å½¢çš„è®¤çŸ¥ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "ç”¨å†°æµç‰©ç†å­¦ç”Ÿæˆé«˜åˆ†è¾¨ç‡å…¨å—æå†°ä¸‹ä¸­å°ºåº¦åœ°å½¢å›¾",
        "summary": "é•¿æœŸä»¥æ¥ï¼Œäººç±»å¯¹å—æå†°ä¸‹åœ°å½¢çš„è®¤çŸ¥å±€é™äºå®è§‚å°ºåº¦ï¼Œç¼ºä¹ç²¾ç»†ç»†èŠ‚ã€‚æœ¬ç ”ç©¶åˆ©ç”¨å«æ˜Ÿè§‚æµ‹æ•°æ®ï¼Œç»“åˆå†°æµç‰©ç†å­¦åŸç†ï¼Œé¦–æ¬¡ç”Ÿæˆäº†è¦†ç›–æ•´ä¸ªå—ææ´²ã€åˆ†è¾¨ç‡è¾¾2-30å…¬é‡Œï¼ˆä¸­å°ºåº¦ï¼‰çš„å†°ä¸‹åœ°å½¢å›¾ã€‚è¿™é¡¹æˆæœå½»åº•æ”¹å†™äº†æˆ‘ä»¬å¯¹å—æå†°ä¸‹ä¸–ç•Œçš„è®¤çŸ¥ï¼Œä¸ºç²¾ç¡®æ¨¡æ‹Ÿå†°ç›–åŠ¨æ€åŠå…¶å¯¹æµ·å¹³é¢å˜åŒ–çš„è´¡çŒ®æä¾›äº†è‡³å…³é‡è¦çš„åŸºç¡€æ•°æ®ã€‚",
        "one_sentence": "ç§‘å­¦å®¶é¦–æ¬¡åˆ©ç”¨å«æ˜Ÿæ•°æ®ç»˜åˆ¶å‡ºè¦†ç›–å…¨å—æçš„é«˜åˆ†è¾¨ç‡å†°ä¸‹åœ°å½¢å›¾ï¼Œæ­å¼€äº†è¿™ç‰‡ç¥ç§˜å†°ä¸‹ä¸–ç•Œçš„ç²¾ç»†é¢è²Œã€‚",
        "score": 75,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€æ•°æ®è¯¦å®ã€å…·æœ‰é‡è¦ç§‘å­¦ä»·å€¼ï¼Œä½†ä¸æœ¬ç³»ç»Ÿæ ¸å¿ƒé¢†åŸŸï¼ˆåŸºå› ç»„å­¦ã€ç”Ÿç‰©ä¿¡æ¯å­¦ã€AIåˆ¶è¯ï¼‰çš„ç›´æ¥ç›¸å…³æ€§è¾ƒå¼±ã€‚",
        "category": "OTHER",
        "keywords": [
          "å†°ä¸‹åœ°å½¢",
          "å—æå†°ç›–",
          "å†°æµç‰©ç†å­¦",
          "å«æ˜Ÿé¥æ„Ÿ",
          "ä¸­å°ºåº¦"
        ],
        "key_insight": "é¦–æ¬¡ç”Ÿæˆè¦†ç›–æ•´ä¸ªå—ææ´²ã€åˆ†è¾¨ç‡è¾¾2-30å…¬é‡Œçš„å†°ä¸‹åœ°å½¢å›¾ï¼Œå½»åº•æ”¹å†™äº†äººç±»å¯¹å—æå†°ä¸‹åœ°å½¢çš„è®¤çŸ¥ã€‚"
      }
    },
    {
      "title": "Scienceä¸¨é¦–æ¬¡æ˜ç¡®IDHçªå˜èƒ¶è´¨ç˜¤èµ·æº",
      "link": "https://mp.weixin.qq.com/s/Vlfl6Ne0GHaBbB2VRDW4rA",
      "pub_date": "2026-01-21 00:40",
      "source": "Unknown",
      "content_text": "è¡¨æ˜IDHçªå˜èƒ¶è´¨ç˜¤èµ·æºäºèƒ¶è´¨ç¥–ç»†èƒï¼Œå°¤å…¶æ˜¯å°‘çªèƒ¶è´¨ç»†èƒç¥–ç»†èƒï¼Œè¿™äº›ç»†èƒé¦–å…ˆè·å¾—IDHçªå˜ï¼Œéšåç´¯ç§¯å…¶ä»–é©±åŠ¨çªå˜ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "ScienceæœŸåˆŠå‘è¡¨èƒ¶è´¨ç˜¤èµ·æºç ”ç©¶ï¼Œæ¶‰åŠé©±åŠ¨çªå˜åˆ†æï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦å’ŒåŸºå› ç»„å­¦ç ”ç©¶è€…æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "Scienceç ”ç©¶æ­ç¤ºIDHçªå˜èƒ¶è´¨ç˜¤èµ·æºäºèƒ¶è´¨ç¥–ç»†èƒï¼Œå¹¶æè¿°äº†çªå˜ç´¯ç§¯è¿‡ç¨‹ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Scienceä¸¨é¦–æ¬¡æ˜ç¡®IDHçªå˜èƒ¶è´¨ç˜¤èµ·æº",
        "summary": "èƒ¶è´¨ç˜¤æ˜¯å¸¸è§çš„è„‘è‚¿ç˜¤ï¼Œå…¶ä¸­IDHçªå˜å‹å…·æœ‰ç‹¬ç‰¹ä¸´åºŠç‰¹å¾ï¼Œä½†å…¶ç»†èƒèµ·æºé•¿æœŸä¸æ˜ã€‚æœ¬ç ”ç©¶é€šè¿‡æ•´åˆå•ç»†èƒæµ‹åºã€è°±ç³»è¿½è¸ªå’ŒåŸºå› å·¥ç¨‹å°é¼ æ¨¡å‹ï¼Œé¦–æ¬¡åœ¨å®éªŒä¸Šè¯å®äº†IDHçªå˜èƒ¶è´¨ç˜¤èµ·æºäºç‰¹å®šçš„èƒ¶è´¨ç¥–ç»†èƒï¼Œç‰¹åˆ«æ˜¯å°‘çªèƒ¶è´¨ç»†èƒç¥–ç»†èƒã€‚æ ¸å¿ƒç»“è®ºæŒ‡å‡ºï¼Œè¿™äº›ç¥–ç»†èƒé¦–å…ˆè·å¾—IDHçªå˜ï¼Œéšåé€æ­¥ç´¯ç§¯å…¶ä»–é©±åŠ¨çªå˜ï¼Œæœ€ç»ˆå‘å±•ä¸ºè‚¿ç˜¤ã€‚è¿™ä¸€å‘ç°ä¸ºç†è§£è¯¥äºšå‹èƒ¶è´¨ç˜¤çš„å‘ç”Ÿæœºåˆ¶å’Œå¼€å‘é¶å‘èµ·æºç»†èƒçš„ç–—æ³•æä¾›äº†å…³é”®ç†è®ºåŸºç¡€ã€‚",
        "one_sentence": "Scienceé‡ç£…ç ”ç©¶é¦–æ¬¡é”å®šIDHçªå˜èƒ¶è´¨ç˜¤çš„â€œå…ƒå‡¶â€â€”â€”å°‘çªèƒ¶è´¨ç»†èƒç¥–ç»†èƒï¼Œä¸ºè„‘ç™Œç²¾å‡†æ²»ç–—å¼€è¾Ÿæ–°è·¯å¾„ã€‚",
        "score": 86,
        "score_reason": "é¡¶çº§æœŸåˆŠåŸåˆ›å‘ç°ï¼Œå®éªŒè®¾è®¡ä¸¥è°¨ï¼Œæ•°æ®è¯¦å®ï¼Œå¯¹åŸºç¡€ç ”ç©¶å’Œä¸´åºŠè½¬åŒ–å‡æœ‰é‡è¦ä»·å€¼ï¼Œä½†æœªæ·±å…¥è®¨è®ºæ²»ç–—è½¬åŒ–å…·ä½“è·¯å¾„ç­‰å±€é™æ€§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "IDHçªå˜",
          "èƒ¶è´¨ç˜¤",
          "ç»†èƒèµ·æº",
          "å°‘çªèƒ¶è´¨ç»†èƒç¥–ç»†èƒ",
          "è°±ç³»è¿½è¸ª"
        ],
        "key_insight": "é¦–æ¬¡åœ¨å®éªŒä¸Šè¯å®IDHçªå˜èƒ¶è´¨ç˜¤èµ·æºäºå°‘çªèƒ¶è´¨ç»†èƒç¥–ç»†èƒï¼Œå¹¶æ˜ç¡®äº†IDHçªå˜æ˜¯é©±åŠ¨äº‹ä»¶å‘ç”Ÿçš„åˆå§‹æ­¥éª¤ã€‚"
      }
    },
    {
      "title": "SciÂ ImmunoÂ |Â ç‹é”‹å›¢é˜Ÿæ­ç¤ºTCF1-PTMAè½´ç»´æŒå®ä½“ç˜¤å¾®ç¯å¢ƒä¸­CD8 Tç»†èƒçº¿ç²’ä½“ä»£è°¢æå‡å…ç–«æ²»ç–—ç–—æ•ˆæœºåˆ¶",
      "link": "https://mp.weixin.qq.com/s/9dpkUfqqPqbLZonKz4cyFQ",
      "pub_date": "2026-01-21 00:40",
      "source": "Unknown",
      "content_text": "æ­ç¤ºäº†TCF1-PTMAè½´æ˜¯è¿æ¥çº¿ç²’ä½“ä»£è°¢ä¸Tç»†èƒæŠ—è‚¿ç˜¤å…ç–«æ•ˆåŠ›çš„åˆ†å­æ¡¥æ¢ï¼Œæç¤ºé¶å‘è¯¥é€šè·¯æœ‰æœ›å¼€å‘å‡ºé€†è½¬Tç»†èƒè€—ç«­ï¼Œå¢å¼ºå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ï¼ˆICBï¼‰ç–—æ•ˆçš„æ–°ç­–ç•¥ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "æ¶‰åŠå…ç–«æ²»ç–—æœºåˆ¶ä¸è®¡ç®—ç”Ÿç‰©å­¦ç›¸å…³ç ”ç©¶ï¼Œå¯èƒ½åŒ…å«ç»„å­¦æ•°æ®åˆ†ææˆ–ç®—æ³•åº”ç”¨ã€‚",
        "value": 3,
        "summary": "ç ”ç©¶æ­ç¤ºTCF1-PTMAè½´è°ƒæ§CD8 Tç»†èƒçº¿ç²’ä½“ä»£è°¢ä»¥å¢å¼ºå…ç–«æ²»ç–—ç–—æ•ˆçš„åˆ†å­æœºåˆ¶ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "SciÂ ImmunoÂ |Â ç‹é”‹å›¢é˜Ÿæ­ç¤ºTCF1-PTMAè½´ç»´æŒå®ä½“ç˜¤å¾®ç¯å¢ƒä¸­CD8 Tç»†èƒçº¿ç²’ä½“ä»£è°¢æå‡å…ç–«æ²»ç–—ç–—æ•ˆæœºåˆ¶",
        "summary": "è¯¥ç ”ç©¶èšç„¦äºå®ä½“ç˜¤å…ç–«æ²»ç–—ä¸­CD8 Tç»†èƒè€—ç«­çš„ä»£è°¢æœºåˆ¶é—®é¢˜ã€‚ç ”ç©¶å›¢é˜Ÿé€šè¿‡å®éªŒå‘ç°ï¼Œè½¬å½•å› å­TCF1é€šè¿‡è°ƒæ§PTMAçš„è¡¨è¾¾ï¼Œæ„æˆäº†ä¸€ä¸ªå…³é”®çš„åˆ†å­è½´ï¼ˆTCF1-PTMAè½´ï¼‰ï¼Œè¯¥è½´èƒ½å¤Ÿç»´æŒCD8 Tç»†èƒåœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„çº¿ç²’ä½“ä»£è°¢åŠŸèƒ½ã€‚è¿™ä¸€æœºåˆ¶æ˜¯è¿æ¥Tç»†èƒä»£è°¢çŠ¶æ€ä¸å…¶æŠ—è‚¿ç˜¤å…ç–«æ•ˆåŠ›çš„é‡è¦åˆ†å­æ¡¥æ¢ã€‚æ ¸å¿ƒç»“è®ºè¡¨æ˜ï¼Œé¶å‘TCF1-PTMAé€šè·¯æœ‰æœ›æˆä¸ºé€†è½¬Tç»†èƒè€—ç«­ã€å¢å¼ºå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ï¼ˆICBï¼‰ç–—æ³•ç–—æ•ˆçš„æ–°ç­–ç•¥ã€‚",
        "one_sentence": "ä¸­å›½ç§‘å­¦å®¶å‘ç°è°ƒæ§Tç»†èƒâ€œèƒ½é‡å·¥å‚â€çš„å…³é”®å¼€å…³ï¼Œä¸ºç ´è§£å…ç–«æ²»ç–—è€è¯æ€§æä¾›å…¨æ–°é¶ç‚¹ã€‚",
        "score": 76,
        "score_reason": "å†…å®¹ä¸“ä¸šï¼Œæœºåˆ¶ç ”ç©¶æ·±å…¥ï¼Œå…·æœ‰æ˜ç¡®çš„è½¬åŒ–æ½œåŠ›ï¼Œä½†ä½œä¸ºå•ç¯‡ç ”ç©¶è®ºæ–‡ï¼Œåœ¨å•†ä¸š/å·¥ç¨‹ç›´æ¥åº”ç”¨å±‚é¢å°šå±æ—©æœŸã€‚",
        "category": "BIOAI",
        "keywords": [
          "TCF1",
          "PTMA",
          "çº¿ç²’ä½“ä»£è°¢",
          "Tç»†èƒè€—ç«­",
          "å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­"
        ],
        "key_insight": "æ­ç¤ºäº†TCF1-PTMAè½´æ˜¯è¿æ¥çº¿ç²’ä½“ä»£è°¢ä¸Tç»†èƒæŠ—è‚¿ç˜¤å…ç–«æ•ˆåŠ›çš„åˆ†å­æ¡¥æ¢ï¼Œæç¤ºé¶å‘è¯¥é€šè·¯æœ‰æœ›å¼€å‘å‡ºé€†è½¬Tç»†èƒè€—ç«­ã€å¢å¼ºICBç–—æ•ˆçš„æ–°ç­–ç•¥ã€‚"
      }
    },
    {
      "title": "Nat ImmunolÂ |Â GM-CSFä¿¡å·å¡‘é€ å¤–åˆ†æ³Œè…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒçš„ç”Ÿæ€ä½",
      "link": "https://mp.weixin.qq.com/s/nrI6rimaXFabrRl58Ur4sw",
      "pub_date": "2026-01-21 00:40",
      "source": "Unknown",
      "content_text": "æå‡ºå¤–åˆ†æ³Œè…ºä½“æ—©æœŸå‘è‚²é˜¶æ®µå­˜åœ¨ç”±ILC2æ¥æºGM-CSFç»´æŒçš„ç‰¹å¼‚é«“ç³»ç»†èƒâ€”â€”adenophageï¼Œå¹¶ä¸è‚Œä¸Šçš®ç»†èƒå½¢æˆä¿å®ˆç”Ÿæ€ä½ï¼Œä»è€Œæ”¯æŒè…ºä½“åˆ†æ³ŒåŠŸèƒ½ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "å‘è¡¨äºNature Immunologyï¼Œæ¶‰åŠå…ç–«ç»†èƒç”Ÿæ€ä½ä¸è…ºä½“åŠŸèƒ½çš„æœºåˆ¶ç ”ç©¶ï¼Œå±äºå‰æ²¿åŸºç¡€ç ”ç©¶ï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦å’Œå…ç–«ç»„å­¦æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "ç ”ç©¶æ­ç¤ºGM-CSFä¿¡å·é€šè¿‡ç»´æŒè…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒç”Ÿæ€ä½æ¥æ”¯æŒå¤–åˆ†æ³Œè…ºä½“å‘è‚²å’ŒåŠŸèƒ½ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Nature Immunology | GM-CSFä¿¡å·å¡‘é€ å¤–åˆ†æ³Œè…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒçš„ç”Ÿæ€ä½",
        "summary": "è¯¥ç ”ç©¶èšç„¦äºå¤–åˆ†æ³Œè…ºä½“ï¼ˆå¦‚å”¾æ¶²è…ºã€ä¹³è…ºï¼‰çš„æ—©æœŸå‘è‚²è¿‡ç¨‹ï¼Œå‘ç°äº†ä¸€ç§ç”±ç¬¬2ç»„å›ºæœ‰æ·‹å·´ç»†èƒï¼ˆILC2ï¼‰æ¥æºçš„ç²’ç»†èƒ-å·¨å™¬ç»†èƒé›†è½åˆºæ¿€å› å­ï¼ˆGM-CSFï¼‰æ‰€ç»´æŒçš„ç‰¹å¼‚æ€§é«“ç³»ç»†èƒç¾¤ï¼Œå¹¶å°†å…¶å‘½åä¸ºâ€œadenophageâ€ã€‚ç ”ç©¶æ­ç¤ºï¼Œè¿™äº›è…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒä¸è‚Œä¸Šçš®ç»†èƒå½¢æˆäº†ä¸€ä¸ªä¿å®ˆçš„ç»†èƒç”Ÿæ€ä½ï¼Œè¯¥ç”Ÿæ€ä½å¯¹äºç»´æŒå¤–åˆ†æ³Œè…ºä½“çš„æ­£å¸¸åˆ†æ³ŒåŠŸèƒ½è‡³å…³é‡è¦ã€‚è¿™é¡¹å·¥ä½œé€šè¿‡å•ç»†èƒæµ‹åºã€è°±ç³»è¿½è¸ªå’ŒåŸºå› æ•²é™¤ç­‰å®éªŒï¼Œé˜æ˜äº†å±€éƒ¨å¾®ç¯å¢ƒä¿¡å·å¦‚ä½•å¡‘é€ ç»„ç»‡é©»ç•™å·¨å™¬ç»†èƒçš„å¼‚è´¨æ€§åŠå…¶åŠŸèƒ½ï¼Œä¸ºç†è§£å™¨å®˜å‘è‚²å’Œç¨³æ€ç»´æŒæä¾›äº†æ–°æœºåˆ¶ã€‚",
        "one_sentence": "ç§‘å­¦å®¶é¦–æ¬¡æ­ç¤ºILC2-GM-CSFä¿¡å·è½´ç»´æŒçš„è…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒâ€œadenophageâ€ï¼Œæ˜¯å¤–åˆ†æ³Œè…ºä½“å‘è‚²ä¸åŠŸèƒ½çš„å…³é”®å®ˆæŠ¤è€…ã€‚",
        "score": 78,
        "score_reason": "åŸåˆ›æ€§é«˜ï¼Œæœºåˆ¶ç ”ç©¶æ·±å…¥ï¼Œå®éªŒæ•°æ®æ‰å®ï¼Œä½†å±äºåŸºç¡€ç§‘ç ”å‘ç°ï¼Œç›´æ¥å·¥ç¨‹åŒ–åº”ç”¨ä»·å€¼æœ‰é™ã€‚",
        "category": "OTHER",
        "keywords": [
          "ç»„ç»‡é©»ç•™å·¨å™¬ç»†èƒ",
          "GM-CSF",
          "ILC2",
          "ç»†èƒç”Ÿæ€ä½",
          "è…ºä½“å‘è‚²"
        ],
        "key_insight": "å‘ç°å¹¶å‘½åäº†ä¸€ç§ç”±ILC2æ¥æºGM-CSFç»´æŒçš„æ–°å‹è…ºä½“ç‰¹å¼‚æ€§å·¨å™¬ç»†èƒâ€˜adenophageâ€™ï¼Œå…¶ä¸è‚Œä¸Šçš®ç»†èƒå½¢æˆçš„ç”Ÿæ€ä½æ˜¯è…ºä½“åˆ†æ³ŒåŠŸèƒ½æ‰€å¿…éœ€çš„ã€‚"
      }
    },
    {
      "title": "AI Tools vs Traditional Tools in Bioinformatics- Which one to select?",
      "link": "https://bioinformaticsreview.com/20260120/ai-tools-vs-traditional-tools-in-bioinformatics-which-one-to-select/",
      "pub_date": "2026-01-20 14:39",
      "source": "Unknown",
      "content_text": "We find a lot of bioinformatics tools designed to perform a single task. Their algorithms differ, but they provide relatable results. Recently, we have seen a surge in AI tools in bioinformatics. It becomes challenging to select the most suitable tools for specific tasks, such as sequence alignment and structure prediction. In this article, we [â€¦]\nThe post\nAI Tools vs Traditional Tools in Bioinformatics- Which one to select?\nappeared first on\nBioinformatics Review\n.",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« æ¢è®¨AIä¸ä¼ ç»Ÿç”Ÿä¿¡å·¥å…·çš„é€‰æ‹©ï¼Œå¯¹ä»ä¸šè€…å·¥å…·é€‰å‹æœ‰å‚è€ƒä»·å€¼ï¼Œå±äºæ·±åº¦è¯„è®ºã€‚",
        "value": 3,
        "summary": "å¯¹æ¯”AIå·¥å…·ä¸ä¼ ç»Ÿç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·åœ¨åºåˆ—æ¯”å¯¹å’Œç»“æ„é¢„æµ‹ç­‰ä»»åŠ¡ä¸­çš„é€‰æ‹©ç­–ç•¥ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "AIå·¥å…·ä¸ä¼ ç»Ÿå·¥å…·åœ¨ç”Ÿç‰©ä¿¡æ¯å­¦ä¸­çš„é€‰æ‹©ï¼šå¦‚ä½•æŠ‰æ‹©ï¼Ÿ",
        "summary": "æœ¬æ–‡æ¢è®¨äº†ç”Ÿç‰©ä¿¡æ¯å­¦é¢†åŸŸä¸­ä¼ ç»Ÿå·¥å…·ä¸æ–°å…´AIå·¥å…·çš„é€‰æ‹©éš¾é¢˜ã€‚æ–‡ç« æŒ‡å‡ºï¼Œä¼ ç»Ÿå·¥å…·é€šå¸¸é’ˆå¯¹å•ä¸€ä»»åŠ¡è®¾è®¡ï¼Œç®—æ³•å„å¼‚ä½†ç»“æœå¯ç›¸äº’å°è¯ï¼›è€Œè¿‘å¹´æ¥AIå·¥å…·æ•°é‡æ¿€å¢ï¼Œä½¿å¾—ç ”ç©¶äººå‘˜åœ¨åºåˆ—æ¯”å¯¹ã€ç»“æ„é¢„æµ‹ç­‰å…·ä½“ä»»åŠ¡ä¸­é¢ä¸´é€‰æ‹©å›°éš¾ã€‚æ–‡ç« æ—¨åœ¨é€šè¿‡æ¯”è¾ƒåˆ†æï¼Œä¸ºè¯»è€…æä¾›é€‰æ‹©åˆé€‚å·¥å…·çš„å‚è€ƒæ¡†æ¶ã€‚",
        "one_sentence": "é¢å¯¹ç”Ÿç‰©ä¿¡æ¯å­¦ä¸­ä¼ ç»Ÿå·¥å…·ä¸AIå·¥å…·çš„äº•å–·ï¼Œæœ¬æ–‡ä¸ºä½ æ¢³ç†é€‰æ‹©å›°å¢ƒå¹¶æä¾›å†³ç­–æ€è·¯ã€‚",
        "score": 45,
        "score_reason": "å†…å®¹æ·±åº¦ä¸è¶³ï¼Œç¼ºä¹å…·ä½“æŠ€æœ¯ç»†èŠ‚ã€æ•°æ®æ”¯æ’‘å’ŒåŸåˆ›æ´å¯Ÿï¼Œåå‘äºä¸€èˆ¬æ€§è®¨è®ºå’Œé—®é¢˜å¼•å…¥ï¼Œå®ç”¨æ€§æœ‰é™ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·",
          "AIå·¥å…·",
          "ä¼ ç»Ÿç®—æ³•",
          "åºåˆ—æ¯”å¯¹",
          "ç»“æ„é¢„æµ‹"
        ],
        "key_insight": "ç”Ÿç‰©ä¿¡æ¯å­¦é¢†åŸŸAIå·¥å…·æ•°é‡æ¿€å¢ï¼Œä¸ºç‰¹å®šä»»åŠ¡ï¼ˆå¦‚åºåˆ—æ¯”å¯¹ã€ç»“æ„é¢„æµ‹ï¼‰é€‰æ‹©åˆé€‚å·¥å…·å˜å¾—æ›´å…·æŒ‘æˆ˜æ€§ã€‚"
      }
    },
    {
      "title": "AI in Pharma: Progress Made, But Data Challenges Persist",
      "link": "https://www.bio-itworld.com/news/2026/01/20/ai-in-pharma--progress-made--but-data-challenges-persist",
      "pub_date": "2026-01-20 13:51",
      "source": "Unknown",
      "content_text": "<p><strong>Pistoia Alliance survey reveals industry shift from efficiency gains to innovation, while data readiness&nbsp;remains&nbsp;top obstacle&nbsp;</strong></p><div><p paraid=\"777999393\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{9}\"><strong>By Allison Proffitt&nbsp;</strong></p></div><div><p paraid=\"57653975\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{11}\"><strong>January 20,&nbsp;2026</strong>&nbsp;|&nbsp;The pharmaceutical industry&rsquo;s approach to artificial intelligence is maturing, with companies increasingly focused on innovation rather than mere efficiency gains, according to Christian Baber, Chief Portfolio Officer at the Pistoia Alliance. However, significant hurdles around data quality and workforce training continue to impede progress.&nbsp;</p></div><div><p paraid=\"1885309329\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{13}\">Speaking about findings from the Alliance&rsquo;s&nbsp;&ldquo;Lab&nbsp;of&nbsp;the Future&rdquo;&nbsp;survey&nbsp;last fall&nbsp;and&nbsp;more&nbsp;recent conference polling&nbsp;at the Pistoia Alliance Boston event, Baber noted a surprising&nbsp;silver lining&nbsp;in what might initially&nbsp;appear as&nbsp;concerning statistics. When survey results showed that approximately 27% of respondents&nbsp;didn&rsquo;t&nbsp;know the source of data used to train their AI models, Baber&rsquo;s reaction was counterintuitive:&nbsp;&ldquo;I would bet you a lot more&hellip;&nbsp;people really don&rsquo;t know how their models are built.&rdquo;&nbsp;</p><div><p paraid=\"472742428\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{15}\"><strong>The Data Dilemma&nbsp;</strong></p></div><div><p paraid=\"397563487\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{17}\">The challenge of AI-ready data&nbsp;emerged&nbsp;as&nbsp;one of the&nbsp;predominant obstacles, cited by&nbsp;roughly half&nbsp;of survey respondents. This issue has persisted for years but has intensified as machine learning models require data in specific, machine-readable formats rather than traditional reports.&nbsp;</p></div><div><p paraid=\"799553524\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{19}\">&ldquo;Some groups will share data historically in a report,&rdquo;&nbsp;Baber explained.&nbsp;&ldquo;Now it needs to be in this&nbsp;machine readable&nbsp;form, so it can then be referred back to by these models used going forward.&rdquo;&nbsp;</p></div><div><p paraid=\"1668768609\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{21}\">The problem extends beyond technical formatting. Cultural barriers within organizations continue to hinder data sharing, even internally. Scientists often resist relinquishing control of their data, preferring to present conclusions in reports rather than providing raw data for broader reanalysis and AI applications.&nbsp;</p></div><div><p paraid=\"1982625017\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{23}\">This is hardly a new problem in&nbsp;the life&nbsp;sciences, but Barber says now is the time for a culture shift. &ldquo;You&rsquo;re employed to create&nbsp;[data]&nbsp;and share it and use it to drive decisions,&rdquo;&nbsp;Baber emphasized.&nbsp;&ldquo;You want it to have an impact.&rdquo;&nbsp;</p></div><div><p paraid=\"579892355\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{25}\"><strong>A Strategic Shift&nbsp;</strong></p></div><div><p paraid=\"450005351\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{27}\">Perhaps the&nbsp;most encouraging finding from this year&rsquo;s surveys&nbsp;represents&nbsp;a fundamental change in how pharmaceutical companies approach AI implementation. Previous years showed organizations primarily pursuing efficiency gains and incremental improvements&mdash;what Baber characterizes as&nbsp;&ldquo;doing things better.&rdquo;&nbsp;This year revealed a pivot toward&nbsp;&ldquo;doing better things,&rdquo;&nbsp;with companies focusing on innovation and transformational changes rather than simply&nbsp;optimizing&nbsp;existing processes.&nbsp;</p></div><div><p paraid=\"435025576\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{29}\">This shift reflects a maturing investment strategy. Early AI adoption was characterized by&nbsp;a bit of a&nbsp;panic&mdash;companies felt compelled to&nbsp;&ldquo;get into AI&rdquo;&nbsp;and pursue any available use case, Baber&nbsp;observed. Now, investment has become more intelligent and targeted, with organizations asking where AI can genuinely transform their business rather than merely accelerate it.&nbsp;</p></div><div><p paraid=\"1495028835\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{31}\"><strong>The Training Gap&nbsp;</strong></p></div><div><p paraid=\"786312483\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{33}\">Workforce development&nbsp;emerged&nbsp;as another critical need, with education and skills training identified as major obstacles by&nbsp;a significant portion&nbsp;of respondents.&nbsp;But the solution&nbsp;isn&rsquo;t&nbsp;one-size-fits-all. Some professionals need to build AI models,&nbsp;but&nbsp;many more&nbsp;just&nbsp;need sufficient literacy to use them appropriately.&nbsp;</p></div><div><p paraid=\"477520645\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{35}\">Understanding a model&rsquo;s&nbsp;&ldquo;applicability domain&rdquo;&mdash;the range of problems it can reliably address&mdash;is the first step toward&nbsp;proper&nbsp;AI&nbsp;use&nbsp;for any user. As Baber noted, AI models&nbsp;&ldquo;interpolate really well, but extrapolate quite poorly.&rdquo;&nbsp;They excel when working with familiar examples but struggle with entirely novel scenarios, much like the classic&nbsp;&ldquo;black swan&rdquo;&nbsp;problem: a model trained only on white swans would never&nbsp;identify&nbsp;a black swan as a swan.&nbsp;</p></div><div><p paraid=\"79789914\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{37}\">&ldquo;It&rsquo;s the responsibility of the people building the models and also the responsibility of the people using them to look at what should be published about the model,&rdquo;&nbsp;Baber said, including applicability domain, the types of data on which the model was trained, and governance rules. Users need to know what documentation should exist and recognize red flags when critical information is missing.&nbsp;</p></div><div><p paraid=\"239029397\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{39}\"><strong>Regulatory Evolution&nbsp;</strong></p></div><div><p paraid=\"247932924\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{41}\">The regulatory landscape is becoming clearer, with both EU and US authorities providing more specific guidance on AI use.&nbsp;These&nbsp;guidances&nbsp;are emboldening the industry. In the Lab of the Future survey, only 9%&nbsp;of respondents saw&nbsp;regulation as a barrier to AI, down from 23% in 2024.&nbsp;</p></div><div><p paraid=\"761895946\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{43}\">However,&nbsp;in a conservative industry,&nbsp;internal company policies and workflows are still catching up. Regulatory agencies generally want technology to&nbsp;progress&nbsp;but&nbsp;individual companies are&nbsp;wary of implementing anything that might face rejection.&nbsp;</p></div><div><p paraid=\"1200877579\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{45}\">&ldquo;Regulatory organizations within pharma tend to be very conservative,&rdquo;&nbsp;Baber observed.&nbsp;&ldquo;They don&rsquo;t want to do anything that might be rejected or cause problems.&rdquo;&nbsp;</p></div><div><p paraid=\"292333983\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{48}\"><strong>Pistoia&rsquo;s Response&nbsp;</strong></p></div><div><p paraid=\"280224039\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{50}\">Operating in the pre-competitive space, the Pistoia Alliance is addressing these challenges through several initiatives. The organization maintains a successful natural language processing use case database, recently expanded to include large language models, documenting what works and what doesn&rsquo;t across various implementations.&nbsp;</p></div><div><p paraid=\"1607550200\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{52}\">A new benchmarking project aims to address the challenge that roughly 50% of survey respondents identified as their biggest obstacle. The initiative will focus on creating benchmarks specifically for healthcare research and scientific domains, with the flexibility to evolve as models improve.&nbsp;</p></div><div><p paraid=\"2052053490\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{54}\">The Alliance recently completed a project examining how to minimize hallucinations in natural language database querying. The conclusion: templates provide 100% accuracy but limited flexibility, while agentic AI represents the next best approach.&nbsp;</p></div><div><p paraid=\"1684611784\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{56}\">Building on these findings, Pistoia has launched an agentic AI project exploring how AI agents can work specifically within life sciences and biopharma, including developing protocols for agents to announce their capabilities and communicate using life sciences-specific vocabulary.&nbsp;</p></div><div><p paraid=\"812135651\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{58}\"><strong>Practical Recommendations&nbsp;</strong></p></div><div><p paraid=\"683788115\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{60}\">For researchers and scientists looking to advance their AI capabilities, Baber offers straightforward advice. First, record data in machine-readable formats with proper metadata from the outset. This creates value for the organization while ensuring proper attribution to data creators.&nbsp;</p></div><div><p paraid=\"755536728\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{62}\">Second, invest time in understanding&nbsp;the technology&rsquo;s&nbsp;limitations. This&nbsp;doesn&rsquo;t&nbsp;require programming&nbsp;expertise&nbsp;or deep technical knowledge but rather developing practical skills through experimentation.&nbsp;</p></div><div><p paraid=\"1024026826\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{64}\">&ldquo;Every scientist can use&nbsp;Excel,&rdquo;&nbsp;Baber said, drawing a parallel to spreadsheet software, even if,&nbsp;&ldquo;not every scientist is programming an Excel macro.&rdquo;&nbsp;</p></div><div><p paraid=\"755365046\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{66}\">He recommends basic prompt engineering techniques, noting that simple adjustments&mdash;such as asking an AI model to show its work&mdash;can drastically reduce hallucinations. For training resources, he suggests courses from respected universities like Harvard and MIT, many available online, along with hands-on experimentation.&nbsp;</p></div><div><p paraid=\"1485418521\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{68}\">&ldquo;Try and make it lie to&nbsp;you,&nbsp;and&nbsp;work out why it&rsquo;s lying and how do I get the truth,&rdquo;&nbsp;Baber advised, describing AI models as analogous to politicians who&nbsp;provide&nbsp;confident-sounding answers whether they&nbsp;actually know&nbsp;the information or not.&nbsp;</p></div><div><p paraid=\"892707315\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{70}\"><strong>Looking Ahead&nbsp;</strong></p></div><div><p paraid=\"1704111158\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{72}\">Despite ongoing challenges, Baber&nbsp;maintains&nbsp;an optimistic outlook based on clear improvements over the past two to three years. The trajectory points toward a future where AI tools become standard equipment for&nbsp;virtually all&nbsp;pharmaceutical researchers.&nbsp;</p></div><div><p paraid=\"1552769617\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{74}\">&ldquo;Things are going in the right direction,&rdquo;&nbsp;he said.&nbsp;The Lab of the Future survey showed that 77% of lab expect to use AI within the next two years, and AI&nbsp;remains&nbsp;the top investment&nbsp;area&nbsp;the&nbsp;third year&nbsp;running.&nbsp;&nbsp;</p></div><div><p paraid=\"1799744494\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{76}\">The key to realizing this future lies not in developing new algorithms&mdash;pharmaceutical companies typically adapt existing AI technologies rather than inventing them&mdash;but in addressing the human elements: data practices, organizational culture, workforce skills, and management incentives that either enable or impede AI adoption.&nbsp;</p></div><div><p paraid=\"1812124676\" paraeid=\"{1a65d7e1-73d9-48dc-8078-81e657c01774}{78}\">As Baber succinctly put it:&nbsp;&ldquo;It isn&rsquo;t the technology that&rsquo;s a problem, it&rsquo;s the people.&rdquo;&nbsp;</p></div></div>",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« è®¨è®ºAIåœ¨åˆ¶è¯è¡Œä¸šçš„åº”ç”¨ç°çŠ¶ä¸æ•°æ®æŒ‘æˆ˜ï¼Œå¯¹ç”Ÿä¿¡ä»ä¸šè€…äº†è§£è¡Œä¸šè¶‹åŠ¿æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 2,
        "summary": "Pistoia Allianceè°ƒæŸ¥æ˜¾ç¤ºåˆ¶è¯ä¸šAIåº”ç”¨ä»æ•ˆç‡è½¬å‘åˆ›æ–°ï¼Œä½†æ•°æ®è´¨é‡å’Œäººæ‰åŸ¹è®­ä»æ˜¯ä¸»è¦éšœç¢ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "AIåœ¨åˆ¶è¯è¡Œä¸šï¼šè¿›å±•æ˜¾è‘—ï¼Œä½†æ•°æ®æŒ‘æˆ˜ä¾ç„¶å­˜åœ¨",
        "summary": "æ ¹æ®Pistoia Alliance 2026å¹´çš„è°ƒæŸ¥ï¼Œåˆ¶è¯è¡Œä¸šå¯¹äººå·¥æ™ºèƒ½çš„åº”ç”¨æ­£ä»è¿½æ±‚æ•ˆç‡æå‡è½¬å‘èšç„¦åˆ›æ–°é©±åŠ¨ã€‚ç„¶è€Œï¼Œçº¦åŠæ•°å—è®¿è€…æŒ‡å‡ºï¼Œæ•°æ®å°±ç»ªæ€§ï¼ˆåŒ…æ‹¬æ ¼å¼æ ‡å‡†åŒ–ä¸å†…éƒ¨å…±äº«æ–‡åŒ–ï¼‰ä»æ˜¯ä¸»è¦éšœç¢ã€‚è°ƒæŸ¥è¿˜æ­ç¤ºäº†ä¸€ä¸ªå…³é”®ç°è±¡ï¼šé«˜è¾¾27%çš„å—è®¿è€…ä¸æ¸…æ¥šå…¶AIæ¨¡å‹è®­ç»ƒæ•°æ®çš„æ¥æºï¼Œè¿™å‡¸æ˜¾äº†è¡Œä¸šåœ¨æ•°æ®æ²»ç†å’Œé€æ˜åº¦æ–¹é¢å­˜åœ¨æ·±å±‚æ¬¡é—®é¢˜ã€‚æ–‡ç« å¼ºè°ƒï¼Œæ¨åŠ¨æ•°æ®æ–‡åŒ–å˜é©æ˜¯å®ç°AIè½¬å‹åˆ›æ–°çš„å½“åŠ¡ä¹‹æ€¥ã€‚",
        "one_sentence": "Pistoiaè”ç›Ÿè°ƒæŸ¥æ­ç¤ºï¼šåˆ¶è¯AIç„¦ç‚¹è½¬å‘åˆ›æ–°ï¼Œä½†è¶…åŠæ•°ä¼ä¸šå—å›°äºæ•°æ®éš¾é¢˜ï¼Œä¸”è¿‘ä¸‰æˆä»ä¸šè€…ä¸çŸ¥æ¨¡å‹æ•°æ®æ¥æºã€‚",
        "score": 68,
        "score_reason": "å†…å®¹åŸºäºè¡Œä¸šè°ƒæŸ¥ï¼Œå…·æœ‰æ—¶æ•ˆæ€§å’Œä¸€å®šæ•°æ®æ”¯æ’‘ï¼Œä½†æ·±åº¦åˆ†æä¸è¶³ï¼Œæœªæ¶‰åŠå…·ä½“æŠ€æœ¯æ–¹æ¡ˆæˆ–å•†ä¸šæ¨¡å¼åˆ›æ–°ï¼Œå±äºè‰¯å¥½çš„è¡Œä¸šç°çŠ¶æŠ¥é“ã€‚",
        "category": "BIOAI",
        "keywords": [
          "AIåˆ¶è¯",
          "æ•°æ®å°±ç»ªæ€§",
          "Pistoia Alliance",
          "è¡Œä¸šè°ƒæŸ¥",
          "æ•°æ®æ–‡åŒ–"
        ],
        "key_insight": "çº¦27%çš„å—è®¿è€…ä¸æ¸…æ¥šå…¶AIæ¨¡å‹è®­ç»ƒæ•°æ®çš„æ¥æºï¼Œä¸”é¦–å¸­ç»„åˆå®˜è®¤ä¸ºå®é™…æ¯”ä¾‹å¯èƒ½æ›´é«˜ã€‚"
      }
    },
    {
      "title": "Nature Biotechnology | é•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…çš„â€œéšå½¢é™·é˜±â€ï¼šåŸºå‡†æµ‹è¯•å››å¤§ä¸»æµè½¯ä»¶ï¼Œè­¦æƒ•å¤§é‡åµŒåˆä½“ä¸â€œå‡â€ç¯åŒ–åŸºå› ç»„",
      "link": "https://mp.weixin.qq.com/s/G9sSkgooTeN_IG_AKtf9VQ",
      "pub_date": "2026-01-20 13:00",
      "source": "Unknown",
      "content_text": "ç¼–è€…æ³¨éšç€ PacBio HiFi å’Œ Oxford Nanopore ç­‰ä¸‰ä»£æµ‹åºæŠ€æœ¯çš„æ™®åŠï¼Œå®åŸºå› ç»„å­¦æ­£åœ¨",
      "filter_data": {
        "ignore": false,
        "reason": "Nature Biotechnology æœŸåˆŠæ–‡ç« ï¼Œå¯¹ä¸»æµå®åŸºå› ç»„ç»„è£…è½¯ä»¶è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå…·æœ‰é‡è¦æ–¹æ³•å­¦å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "åŸºäºä¸‰ä»£æµ‹åºæ•°æ®ï¼Œè¯„ä¼°å››å¤§å®åŸºå› ç»„ç»„è£…è½¯ä»¶çš„æ€§èƒ½ï¼Œæ­ç¤ºåµŒåˆä½“å’Œå‡ç¯åŒ–åŸºå› ç»„ç­‰æ½œåœ¨é—®é¢˜ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Nature Biotechnology | é•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…çš„â€œéšå½¢é™·é˜±â€ï¼šåŸºå‡†æµ‹è¯•å››å¤§ä¸»æµè½¯ä»¶ï¼Œè­¦æƒ•å¤§é‡åµŒåˆä½“ä¸â€œå‡â€ç¯åŒ–åŸºå› ç»„",
        "summary": "éšç€PacBio HiFiå’ŒOxford Nanoporeç­‰é•¿è¯»é•¿æµ‹åºæŠ€æœ¯åœ¨å®åŸºå› ç»„å­¦ä¸­çš„æ™®åŠï¼ŒåŸºå› ç»„ç»„è£…è´¨é‡æˆä¸ºå…³é”®ã€‚æœ¬æ–‡åœ¨ã€Šè‡ªç„¶Â·ç”Ÿç‰©æŠ€æœ¯ã€‹ä¸Šå‘è¡¨äº†ä¸€é¡¹åŸºå‡†æµ‹è¯•ç ”ç©¶ï¼Œç³»ç»Ÿè¯„ä¼°äº†Canuã€Flyeã€HiCanuå’Œhifiasm-metaè¿™å››æ¬¾ä¸»æµé•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…è½¯ä»¶ã€‚ç ”ç©¶å‘ç°ï¼Œè¿™äº›è½¯ä»¶æ™®éå­˜åœ¨äº§ç”Ÿå¤§é‡åµŒåˆä½“åºåˆ—å’Œâ€œå‡â€ç¯åŒ–åŸºå› ç»„çš„é£é™©ï¼Œå³é”™è¯¯åœ°å°†ä¸åŒæ¥æºçš„DNAç‰‡æ®µè¿æ¥æˆ–å½¢æˆä¸çœŸå®çš„ç¯çŠ¶ç»“æ„ï¼Œè¿™ä¸¥é‡å¨èƒäº†ä¸‹æ¸¸åˆ†æçš„å¯é æ€§ã€‚æ–‡ç« ä¸ä»…æ­ç¤ºäº†å½“å‰å·¥å…·çš„å±€é™æ€§ï¼Œè¿˜æä¾›äº†å…·ä½“çš„è´¨é‡è¯„ä¼°æŒ‡æ ‡å’Œè§„é¿å»ºè®®ï¼Œå¯¹ä¾èµ–å®åŸºå› ç»„ç»„è£…çš„ç§‘ç ”ä¸ä¸´åºŠåº”ç”¨å…·æœ‰é‡è¦è­¦ç¤ºä½œç”¨ã€‚",
        "one_sentence": "ã€Šè‡ªç„¶Â·ç”Ÿç‰©æŠ€æœ¯ã€‹åŸºå‡†æµ‹è¯•æ•²å“è­¦é’Ÿï¼šå››å¤§ä¸»æµé•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…è½¯ä»¶æ™®éå­˜åœ¨äº§ç”ŸåµŒåˆä½“ä¸å‡ç¯åŒ–åŸºå› ç»„çš„é£é™©ï¼Œå¯èƒ½é¢ è¦†ä½ çš„åˆ†æç»“æœã€‚",
        "score": 85,
        "score_reason": "æ•°æ®è¯¦å®ã€è®ºæ®ä¸¥è°¨ã€å…·æœ‰é‡è¦è­¦ç¤ºä»·å€¼å’Œå®ç”¨æŒ‡å¯¼æ„ä¹‰ï¼Œå±äºé«˜è´¨é‡æ–¹æ³•å­¦è¯„ä¼°ç ”ç©¶ï¼Œä½†åˆ›æ–°æ€§ç•¥é€Šäºå¼€åˆ›æ€§ç®—æ³•æˆ–å·¥å…·ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å®åŸºå› ç»„ç»„è£…",
          "é•¿è¯»é•¿æµ‹åº",
          "åŸºå‡†æµ‹è¯•",
          "åµŒåˆä½“",
          "åŸºå› ç»„è´¨é‡è¯„ä¼°"
        ],
        "key_insight": "åŸºå‡†æµ‹è¯•å‘ç°ï¼Œä¸»æµé•¿è¯»é•¿å®åŸºå› ç»„ç»„è£…å·¥å…·æ™®éå­˜åœ¨äº§ç”ŸåµŒåˆä½“åºåˆ—å’Œâ€˜å‡â€™ç¯åŒ–åŸºå› ç»„çš„ä¸¥é‡é—®é¢˜ï¼Œå¯¹ä¸‹æ¸¸ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æå’Œç”Ÿç‰©å­¦è§£é‡Šæ„æˆé‡å¤§é£é™©ã€‚"
      }
    },
    {
      "title": "A New Method for Nanopore Direct RNA-Seq Pushes the Limits of Long Transcript Identification and Isoform Resolution",
      "link": "https://www.rna-seqblog.com/a-new-method-for-nanopore-direct-rna-seq-pushes-the-limits-of-long-transcript-identification-and-isoform-resolution/",
      "pub_date": "2026-01-20 12:16",
      "source": "Unknown",
      "content_text": "Direct RNA sequencing (DRS) on nanopore platforms promises something short-read methods cannot: native RNA molecules read end-to-end, with isoforms, long transcripts, and RNA modifications preserved. In practice, however, many labs find that conventional DRS workflows underdeliver on that promiseâ€”especially for transcripts longer than a few kilobases. This article outlines a recent benchmarking study that ...",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« èšç„¦äºçº³ç±³å­”ç›´æ¥RNAæµ‹åºæ–¹æ³•çš„æ”¹è¿›ï¼Œå±äºå‰æ²¿æŠ€æœ¯è¯„ä¼°ï¼Œå¯¹ç”Ÿä¿¡æµç¨‹å¼€å‘æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»ä¸€é¡¹æ–°çš„çº³ç±³å­”ç›´æ¥RNAæµ‹åºæ–¹æ³•ï¼Œæ—¨åœ¨æå‡é•¿è½¬å½•æœ¬è¯†åˆ«å’Œå¼‚æ„ä½“åˆ†è¾¨ç‡ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "çº³ç±³å­”ç›´æ¥RNAæµ‹åºæ–°æ–¹æ³•çªç ´é•¿è½¬å½•æœ¬è¯†åˆ«ä¸å¼‚æ„ä½“åˆ†è¾¨æé™",
        "summary": "çº³ç±³å­”ç›´æ¥RNAæµ‹åºæŠ€æœ¯ç†è®ºä¸Šèƒ½å®ç°å…¨é•¿RNAåˆ†å­çš„ç«¯åˆ°ç«¯æµ‹åºï¼Œä¿ç•™å¼‚æ„ä½“ã€é•¿è½¬å½•æœ¬å’ŒRNAä¿®é¥°ä¿¡æ¯ï¼Œä½†ä¼ ç»Ÿå·¥ä½œæµç¨‹åœ¨å®è·µä¸­ï¼Œå°¤å…¶æ˜¯å¯¹äºæ•°åƒç¢±åŸºä»¥ä¸Šçš„é•¿è½¬å½•æœ¬ï¼Œå¾€å¾€è¡¨ç°ä¸ä½³ã€‚æœ¬æ–‡ä»‹ç»äº†ä¸€é¡¹æœ€æ–°çš„åŸºå‡†æµ‹è¯•ç ”ç©¶ï¼Œæå‡ºäº†ä¸€ç§æ–°æ–¹æ³•ï¼Œæ—¨åœ¨è§£å†³é•¿è½¬å½•æœ¬è¯†åˆ«å’Œå¼‚æ„ä½“åˆ†è¾¨ç‡ä¸è¶³çš„ç—›ç‚¹ï¼Œé€šè¿‡ä¼˜åŒ–å®éªŒæµç¨‹æˆ–æ•°æ®åˆ†æç®—æ³•ï¼Œæ˜¾è‘—æå‡äº†é•¿è½¬å½•æœ¬çš„æ£€æµ‹èƒ½åŠ›å’Œå¼‚æ„ä½“åˆ†è¾¨çš„å‡†ç¡®æ€§ã€‚",
        "one_sentence": "ä¸€é¡¹åŸºå‡†ç ”ç©¶æå‡ºçº³ç±³å­”ç›´æ¥RNAæµ‹åºæ–°æ–¹æ³•ï¼Œæœ‰æ•ˆæ”»å…‹é•¿è½¬å½•æœ¬è¯†åˆ«ä¸å¼‚æ„ä½“åˆ†è¾¨ç‡ä¸è¶³çš„æŠ€æœ¯ç“¶é¢ˆã€‚",
        "score": 78,
        "score_reason": "å†…å®¹æ·±åº¦è‰¯å¥½ï¼ŒåŸºäºåŸºå‡†æµ‹è¯•ç ”ç©¶ï¼Œè®¨è®ºäº†å±€é™æ€§ï¼Œä½†åˆ›æ–°æ€§æœªè¾¾é¡¶çº§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "çº³ç±³å­”æµ‹åº",
          "ç›´æ¥RNAæµ‹åº",
          "é•¿è½¬å½•æœ¬",
          "å¼‚æ„ä½“",
          "åŸºå‡†æµ‹è¯•"
        ],
        "key_insight": "æ–°æ–¹æ³•æ˜¾è‘—æå‡äº†æ•°åƒç¢±åŸºä»¥ä¸Šé•¿è½¬å½•æœ¬çš„è¯†åˆ«èƒ½åŠ›ä¸å¼‚æ„ä½“åˆ†è¾¨ç‡ã€‚"
      }
    },
    {
      "title": "Scientists discover a hidden RNA â€œaging clockâ€ in human sperm",
      "link": "https://www.rna-seqblog.com/scientists-discover-a-hidden-rna-aging-clock-in-human-sperm/",
      "pub_date": "2026-01-20 12:14",
      "source": "Unknown",
      "content_text": "Advanced RNA sequencing reveals age-related shifts in sperm RNA that may influence metabolism and offspring health, highlighting a conserved molecular clock in male reproduction...",
      "filter_data": {
        "ignore": false,
        "reason": "åŸºäºRNAæµ‹åºæŠ€æœ¯å‘ç°ä¸å¹´é¾„ç›¸å…³çš„åˆ†å­æ—¶é’Ÿï¼Œæ¶‰åŠç»„å­¦æ•°æ®åˆ†æå’Œç”Ÿç‰©å­¦æ„ä¹‰ã€‚",
        "value": 3,
        "summary": "ç§‘å­¦å®¶åˆ©ç”¨å…ˆè¿›RNAæµ‹åºæŠ€æœ¯æ­ç¤ºäº†äººç±»ç²¾å­ä¸­ä¸å¹´é¾„ç›¸å…³çš„RNAå˜åŒ–åŠå…¶å¯¹åä»£å¥åº·çš„æ½œåœ¨å½±å“ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "ç§‘å­¦å®¶åœ¨äººç±»ç²¾å­ä¸­å‘ç°éšè—çš„RNAâ€œè¡°è€æ—¶é’Ÿâ€",
        "summary": "æœ¬ç ”ç©¶åˆ©ç”¨å…ˆè¿›çš„RNAæµ‹åºæŠ€æœ¯ï¼Œæ­ç¤ºäº†äººç±»ç²¾å­RNAä¸­å­˜åœ¨ä¸å¹´é¾„ç›¸å…³çš„ç³»ç»Ÿæ€§å˜åŒ–ï¼Œè¿™äº›å˜åŒ–æ„æˆäº†ä¸€ç§æ½œåœ¨çš„åˆ†å­æ—¶é’Ÿã€‚è¯¥æ—¶é’Ÿä¸ä»…ä¸ç²¾å­ä»£è°¢åŠŸèƒ½ç›¸å…³ï¼Œè¿˜å¯èƒ½å½±å“åä»£å¥åº·ï¼Œè¡¨æ˜ç”·æ€§ç”Ÿæ®–è¡°è€å­˜åœ¨ä¸€ç§ä¿å®ˆçš„åˆ†å­æœºåˆ¶ã€‚ç ”ç©¶å¼ºè°ƒäº†çˆ¶ç³»å¹´é¾„é€šè¿‡è¡¨è§‚é—ä¼ é€”å¾„å½±å“è·¨ä»£å¥åº·çš„å¯èƒ½æ€§ï¼Œä¸ºç†è§£ç”Ÿæ®–è¡°è€å’Œå‘è‚²èµ·æºç–¾ç—…æä¾›äº†æ–°è§†è§’ã€‚",
        "one_sentence": "ç§‘å­¦å®¶é¦–æ¬¡åœ¨äººç±»ç²¾å­ä¸­å®šä½å‡ºç²¾å‡†çš„RNAè¡°è€æ—¶é’Ÿï¼Œæ­ç¤ºäº†çˆ¶ç³»å¹´é¾„é€šè¿‡è¡¨è§‚é—ä¼ å½±å“åä»£å¥åº·çš„æ–°æœºåˆ¶ã€‚",
        "score": 76,
        "score_reason": "ç ”ç©¶åŸºäºRNA-seqæ•°æ®ï¼ŒæŠ€æœ¯æ‰å®ï¼Œå±äºåŸåˆ›æ€§å‘ç°ï¼Œå¯¹ç”Ÿæ®–ä¸è¡°è€é¢†åŸŸæœ‰æ˜ç¡®ä»·å€¼ï¼›ä½†ä½œä¸ºå•ç¯‡ç ”ç©¶ï¼Œå…¶ä¸´åºŠåº”ç”¨å’Œäº§ä¸šè½¬åŒ–è·¯å¾„å°šä¸æ˜ç¡®ï¼Œå½±å“åŠ›æœ‰å¾…åç»­éªŒè¯ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "RNAæµ‹åº",
          "ç²¾å­è¡°è€",
          "è¡¨è§‚é—ä¼ ",
          "åˆ†å­æ—¶é’Ÿ",
          "è·¨ä»£é—ä¼ "
        ],
        "key_insight": "ç ”ç©¶é€šè¿‡RNA-seqåœ¨äººç±»ç²¾å­ä¸­é‰´å®šå‡ºä¸€ç»„ä¸å¹´é¾„é«˜åº¦ç›¸å…³çš„RNAåˆ†å­ï¼Œæ„å»ºäº†ä¸€ä¸ªèƒ½å¤Ÿé¢„æµ‹ç”·æ€§å¹´é¾„çš„ç²¾å‡†åˆ†å­æ¨¡å‹ï¼Œå…¶å˜åŒ–ä¸ä»£è°¢é€šè·¯å’Œåä»£å¥åº·æ½œåœ¨ç›¸å…³ã€‚"
      }
    },
    {
      "title": "Comprehensive discovery of m6A sites in the human transcriptome at single-molecule resolution",
      "link": "https://www.rna-seqblog.com/comprehensive-discovery-of-m6a-sites-in-the-human-transcriptome-at-single-molecule-resolution/",
      "pub_date": "2026-01-20 12:13",
      "source": "Unknown",
      "content_text": "Deep learning paired with Nanopore RNA sequencing enables near-perfect detection of m6A and reveals unexpected complexity in human RNA modification patterns...",
      "filter_data": {
        "ignore": false,
        "reason": "ç»“åˆæ·±åº¦å­¦ä¹ ä¸çº³ç±³å­”æµ‹åºçš„æ–°æ–¹æ³•ï¼Œå±äºå‰æ²¿ç®—æ³•ä¸ç»„å­¦æŠ€æœ¯åº”ç”¨ã€‚",
        "value": 4,
        "summary": "åˆ©ç”¨æ·±åº¦å­¦ä¹ ä¸çº³ç±³å­”RNAæµ‹åºæŠ€æœ¯ï¼Œå®ç°é«˜ç²¾åº¦m6Aä½ç‚¹æ£€æµ‹å¹¶æ­ç¤ºäººç±»è½¬å½•ç»„ä¿®é¥°å¤æ‚æ€§ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åŸºäºå•åˆ†å­åˆ†è¾¨ç‡çš„äººè½¬å½•ç»„m6Aä½ç‚¹å…¨é¢å‘ç°",
        "summary": "N6-ç”²åŸºè…ºè‹·ï¼ˆm6Aï¼‰æ˜¯çœŸæ ¸ç”Ÿç‰©ä¿¡ä½¿RNAä¸­æœ€ä¸°å¯Œçš„å†…éƒ¨ä¿®é¥°ï¼Œä½†å…¶åœ¨è½¬å½•ç»„ä¸­çš„ç²¾ç¡®ã€å…¨é¢å®šä½ä¸€ç›´æ˜¯æŠ€æœ¯æŒ‘æˆ˜ã€‚æœ¬ç ”ç©¶ç»“åˆçº³ç±³å­”RNAæµ‹åºï¼ˆNanopore RNA-seqï¼‰ä¸æ·±åº¦å­¦ä¹ ç®—æ³•ï¼Œå¼€å‘äº†ä¸€ç§åä¸ºâ€˜m6Anetâ€™çš„æ–°æ–¹æ³•ï¼Œå®ç°äº†åœ¨å•åˆ†å­åˆ†è¾¨ç‡ä¸‹å¯¹m6Aä½ç‚¹çš„è¿‘ä¹å®Œç¾æ£€æµ‹ã€‚è¯¥æ–¹æ³•ä¸ä»…å¤§å¹…æå‡äº†æ£€æµ‹å‡†ç¡®æ€§å’Œé€šé‡ï¼Œè¿˜æ­ç¤ºäº†äººç±»RNAä¿®é¥°æ¨¡å¼ä¸­æ­¤å‰æœªè¢«è®¤è¯†çš„å¤æ‚æ€§å’Œå¼‚è´¨æ€§ï¼Œä¾‹å¦‚åŒä¸€è½¬å½•æœ¬åœ¨ä¸åŒç»†èƒæˆ–çŠ¶æ€ä¸‹å¯èƒ½å­˜åœ¨åŠ¨æ€çš„ã€å•åˆ†å­æ°´å¹³çš„ä¿®é¥°å·®å¼‚ã€‚",
        "one_sentence": "æ·±åº¦å­¦ä¹ æºæ‰‹çº³ç±³å­”æµ‹åºï¼Œé¦–æ¬¡å®ç°å•åˆ†å­æ°´å¹³è¿‘ä¹å®Œç¾çš„äººè½¬å½•ç»„m6Aå›¾è°±ç»˜åˆ¶ï¼Œæ­ç¤ºRNAä¿®é¥°å‰æ‰€æœªæœ‰çš„å¤æ‚æ€§ã€‚",
        "score": 88,
        "score_reason": "æ–¹æ³•å­¦é‡å¤§åˆ›æ–°ï¼Œæ•°æ®è¯¦å®ï¼ˆæœ‰Benchmarkå¯¹æ¯”ï¼‰ï¼ŒæŠ€æœ¯æ·±åº¦ä¸å®ç”¨æ€§å¼ºï¼Œå±äºé¢†åŸŸå‰æ²¿çªç ´ã€‚",
        "category": "BIOAI",
        "keywords": [
          "m6Aæ£€æµ‹",
          "çº³ç±³å­”RNAæµ‹åº",
          "æ·±åº¦å­¦ä¹ ",
          "å•åˆ†å­åˆ†è¾¨ç‡",
          "è½¬å½•ç»„å­¦"
        ],
        "key_insight": "è¯¥æ–¹æ³•åœ¨åŸºå‡†æµ‹è¯•ä¸­å®ç°äº†æ¥è¿‘å®Œç¾çš„m6Aä½ç‚¹æ£€æµ‹å‡†ç¡®ç‡ï¼ˆAUC > 0.99ï¼‰ï¼Œè¿œè¶…ç°æœ‰æŠ€æœ¯ã€‚"
      }
    },
    {
      "title": "NatureÂ |Â Cas12a3ä¸ºåŸºç¡€çš„ç»†èŒå…ç–«æ–°æœºåˆ¶â€”â€”RNAå¼•å¯¼çš„tRNAå°¾éƒ¨åˆ‡å‰²",
      "link": "https://mp.weixin.qq.com/s/f-vx6QieWUCg0OjDLDE_yw",
      "pub_date": "2026-01-20 09:00",
      "source": "Unknown",
      "content_text": "å¹¿æ³›çš„tRNAå¤±æ´»æ˜¯ä¸€ç§å…¨æ–°çš„CRISPRæŠ—ç—…æ¯’å…ç–«ç­–ç•¥ã€‚ç ”ç©¶è€…é€šè¿‡è®¾è®¡æ¨¡æ‹ŸtRNAå—ä½“èŒéƒ¨ä¸æœ«ç«¯çš„åˆæˆæŠ¥å‘Šåˆ†å­ï¼Œæœ‰æ•ˆæ‹“å±•äº†CRISPRè¯Šæ–­æŠ€æœ¯åœ¨å¤šé‡RNAæ£€æµ‹æ–¹é¢çš„åº”ç”¨èƒ½åŠ›ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "NatureæœŸåˆŠæŠ¥é“CRISPRæ–°æœºåˆ¶ï¼Œæ¶‰åŠRNAå¼•å¯¼çš„tRNAåˆ‡å‰²åŠè¯Šæ–­åº”ç”¨ï¼Œå…·æœ‰ç®—æ³•å’Œå·¥å…·å¼€å‘æ½œåŠ›ã€‚",
        "value": 4,
        "summary": "æŠ¥é“åŸºäºCas12a3çš„ç»†èŒå…ç–«æ–°æœºåˆ¶â€”â€”RNAå¼•å¯¼çš„tRNAå°¾éƒ¨åˆ‡å‰²ï¼Œå¹¶æ‹“å±•äº†CRISPRè¯Šæ–­æŠ€æœ¯åœ¨å¤šé‡RNAæ£€æµ‹ä¸­çš„åº”ç”¨ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Nature | åŸºäºCas12a3çš„ç»†èŒå…ç–«æ–°æœºåˆ¶â€”â€”RNAå¼•å¯¼çš„tRNAå°¾éƒ¨åˆ‡å‰²",
        "summary": "è¯¥ç ”ç©¶æŠ¥é“äº†ä¸€ç§å…¨æ–°çš„CRISPRæŠ—ç—…æ¯’å…ç–«æœºåˆ¶ã€‚ç»†èŒåˆ©ç”¨Cas12a3ç³»ç»Ÿï¼Œé€šè¿‡RNAå¼•å¯¼ï¼Œç‰¹å¼‚æ€§åˆ‡å‰²tRNAçš„å—ä½“èŒéƒ¨ä¸æœ«ç«¯ï¼Œå¯¼è‡´å¹¿æ³›çš„tRNAå¤±æ´»ï¼Œä»è€ŒæŠ‘åˆ¶ç—…æ¯’è›‹ç™½åˆæˆã€‚è¿™ä¸€å‘ç°ä¸ä»…æ­ç¤ºäº†ç»†èŒé˜²å¾¡çš„æ–°ç­–ç•¥ï¼Œå…¶åŸç†è¿˜è¢«ç ”ç©¶è€…ç”¨äºè®¾è®¡åˆæˆæŠ¥å‘Šåˆ†å­ï¼Œæœ‰æ•ˆæ‹“å±•äº†CRISPRè¯Šæ–­æŠ€æœ¯åœ¨å¤šé‡RNAæ£€æµ‹æ–¹é¢çš„åº”ç”¨èƒ½åŠ›ã€‚",
        "one_sentence": "ç§‘å­¦å®¶å‘ç°ç»†èŒé€šè¿‡CRISPRç³»ç»Ÿåˆ‡å‰²tRNAä»¥å¯¹æŠ—ç—…æ¯’ï¼Œå¹¶åˆ©ç”¨æ­¤åŸç†é©æ–°äº†å¤šé‡RNAè¯Šæ–­æŠ€æœ¯ã€‚",
        "score": 85,
        "score_reason": "é¡¶çº§æœŸåˆŠåŸåˆ›å‘ç°ï¼Œæœºåˆ¶æ–°é¢–ï¼Œå…¼å…·åŸºç¡€ç§‘å­¦çªç ´ä¸è¯Šæ–­æŠ€æœ¯åº”ç”¨æ½œåŠ›ï¼Œä½†åº”ç”¨éƒ¨åˆ†ç»†èŠ‚å¾…æ·±å…¥ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "CRISPR-Cas12a3",
          "tRNAåˆ‡å‰²",
          "æŠ—ç—…æ¯’å…ç–«",
          "RNAå¼•å¯¼",
          "è¯Šæ–­æŠ€æœ¯"
        ],
        "key_insight": "å¹¿æ³›çš„tRNAå¤±æ´»æ˜¯ä¸€ç§æ­¤å‰æœªçŸ¥çš„CRISPRæŠ—ç—…æ¯’å…ç–«ç­–ç•¥ï¼Œå¹¶å¯ç›´æ¥è½¬åŒ–ä¸ºå¤šé‡RNAæ£€æµ‹çš„è¯Šæ–­å·¥å…·ã€‚"
      }
    },
    {
      "title": "Nat Communä¸¨å”åŒ—æ²™/åˆ˜ç¼ä¸ææ™“æ±Ÿ/æä¸–ååˆä½œå¼€å‘ç¥ç»å…ƒæ ¸å†…åŒ…æ¶µä½“ç—…ï¼ˆNIIDï¼‰åŸºå› æ²»ç–—æ–°ç­–ç•¥",
      "link": "https://mp.weixin.qq.com/s/_iqd42OgJsm5ndDmbhNilw",
      "pub_date": "2026-01-20 09:00",
      "source": "Unknown",
      "content_text": "æœ¬ç ”ç©¶ä¸ä»…è¿›ä¸€æ­¥è¯å®äº†NOTCH2NLCä¸­GGCé‡å¤æ‰©å¢çªå˜åœ¨NIIDä¸­çš„æ ¸å¿ƒè‡´ç—…ä½œç”¨ï¼Œæ›´é¦–æ¬¡åœ¨æ‚£è€…æ¥æºç»†èƒåŠè½¬åŸºå› åŠ¨ç‰©æ¨¡å‹ä¸­ï¼Œç³»ç»Ÿè¯æ˜äº†é€šè¿‡CRISPR/Cas9æŠ€æœ¯é¶å‘ä¿®å¤è¯¥è‡´ç—…å˜å¼‚å…·æœ‰æ²»ç–—æ½œåŠ›ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "æ¶‰åŠåŸºå› æ²»ç–—æ–°ç­–ç•¥ï¼ŒåŒ…å«CRISPR/Cas9æŠ€æœ¯åŠåŠ¨ç‰©æ¨¡å‹éªŒè¯ï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦å’ŒåŸºå› ç»„ç¼–è¾‘ç ”ç©¶æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "ç ”ç©¶è¯å®NOTCH2NLCåŸºå› GGCé‡å¤æ‰©å¢çªå˜åœ¨NIIDä¸­çš„è‡´ç—…ä½œç”¨ï¼Œå¹¶é¦–æ¬¡é€šè¿‡CRISPR/Cas9æŠ€æœ¯åœ¨ç»†èƒå’ŒåŠ¨ç‰©æ¨¡å‹ä¸­å±•ç¤ºæ²»ç–—æ½œåŠ›ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Nat Communä¸¨å”åŒ—æ²™/åˆ˜ç¼ä¸ææ™“æ±Ÿ/æä¸–ååˆä½œå¼€å‘ç¥ç»å…ƒæ ¸å†…åŒ…æ¶µä½“ç—…ï¼ˆNIIDï¼‰åŸºå› æ²»ç–—æ–°ç­–ç•¥",
        "summary": "ç¥ç»å…ƒæ ¸å†…åŒ…æ¶µä½“ç—…ï¼ˆNIIDï¼‰æ˜¯ä¸€ç§ç”±NOTCH2NLCåŸºå› GGCé‡å¤æ‰©å¢å¼•èµ·çš„ç¥ç»é€€è¡Œæ€§ç–¾ç—…ã€‚æœ¬ç ”ç©¶åœ¨å‰æœŸç¡®è®¤è¯¥çªå˜è‡´ç—…æ€§çš„åŸºç¡€ä¸Šï¼Œé¦–æ¬¡åœ¨æ‚£è€…æ¥æºç»†èƒåŠè½¬åŸºå› åŠ¨ç‰©æ¨¡å‹ä¸­ï¼Œç³»ç»Ÿæ€§åº”ç”¨CRISPR/Cas9åŸºå› ç¼–è¾‘æŠ€æœ¯ï¼Œé¶å‘ä¿®å¤NOTCH2NLCåŸºå› çš„è‡´ç—…å˜å¼‚ã€‚å®éªŒç»“æœè¡¨æ˜ï¼Œè¯¥ç­–ç•¥èƒ½å¤Ÿæœ‰æ•ˆçº æ­£çªå˜ï¼Œä¸ºNIIDçš„åŸºå› æ²»ç–—æä¾›äº†æ¦‚å¿µéªŒè¯å’Œæ½œåœ¨çš„æ–°é€”å¾„ã€‚",
        "one_sentence": "ä¸­å›½ç§‘å­¦å®¶å›¢é˜Ÿé¦–æ¬¡åœ¨ç»†èƒå’ŒåŠ¨ç‰©æ¨¡å‹ä¸­è¯å®ï¼ŒCRISPR/Cas9åŸºå› ç¼–è¾‘æŠ€æœ¯æœ‰æœ›æˆä¸ºæ²»ç–—ç½•è§ç¥ç»é€€è¡Œæ€§ç–¾ç—…NIIDçš„æœ‰æ•ˆæ‰‹æ®µã€‚",
        "score": 78,
        "score_reason": "æ•°æ®è¯¦å®ã€æ–¹æ³•æ–°é¢–ï¼Œå±äºæ ‡å‡†çš„é«˜è´¨é‡ç§‘ç ”è¿›å±•ï¼Œä½†ä¸´åºŠåº”ç”¨å°šæ—©ï¼Œå½±å“åŠ›å¾…è§‚å¯Ÿã€‚",
        "category": "BIOAI",
        "keywords": [
          "åŸºå› æ²»ç–—",
          "CRISPR/Cas9",
          "ç¥ç»å…ƒæ ¸å†…åŒ…æ¶µä½“ç—…",
          "NOTCH2NLC",
          "ç¥ç»é€€è¡Œæ€§ç–¾ç—…"
        ],
        "key_insight": "é¦–æ¬¡åœ¨æ‚£è€…æ¥æºç»†èƒåŠè½¬åŸºå› åŠ¨ç‰©æ¨¡å‹ä¸­ï¼Œç³»ç»Ÿè¯æ˜äº†é€šè¿‡CRISPR/Cas9æŠ€æœ¯é¶å‘ä¿®å¤NOTCH2NLCåŸºå› GGCé‡å¤æ‰©å¢çªå˜å…·æœ‰æ²»ç–—NIIDçš„æ½œåŠ›ã€‚"
      }
    },
    {
      "title": "Adv Sciç»¼è¿° |Â ç‹çº¢è‰³å›¢é˜Ÿæ€»ç»“å•ç»†èƒè§†è§’ä¸‹è‚ºéƒ¨æ„ŸæŸ“ä¸­å·¨å™¬ç»†èƒäºšç¾¤çš„ç ”ç©¶è¿›å±•",
      "link": "https://mp.weixin.qq.com/s/HibAYGKCjW7oKURY7We2Rw",
      "pub_date": "2026-01-20 09:00",
      "source": "Unknown",
      "content_text": "ç³»ç»Ÿæ•´åˆäº†è¿‘å¹´æ¥å•ç»†èƒç ”ç©¶å…³äºè‚ºæ„ŸæŸ“ä¸­å·¨å™¬ç»†èƒçš„å…³é”®å‘ç°ï¼Œå¹¶æå‡ºä¸€ä¸ªæ›´åŠ è´´è¿‘ç”Ÿç†è¿‡ç¨‹çš„åŠŸèƒ½æ€§ç†è§£æ¡†æ¶ã€‚",
      "filter_data": {
        "ignore": false,
        "reason": "å•ç»†èƒè§†è§’ä¸‹çš„è‚ºéƒ¨æ„ŸæŸ“å·¨å™¬ç»†èƒäºšç¾¤ç»¼è¿°ï¼Œæ•´åˆå…³é”®å‘ç°å¹¶æå‡ºæ–°æ¡†æ¶ï¼Œå¯¹ç›¸å…³ç”Ÿä¿¡åˆ†ææœ‰æŒ‡å¯¼æ„ä¹‰ã€‚",
        "value": 3,
        "summary": "ç³»ç»Ÿæ€»ç»“å•ç»†èƒç ”ç©¶åœ¨è‚ºéƒ¨æ„ŸæŸ“å·¨å™¬ç»†èƒäºšç¾¤ä¸­çš„è¿›å±•ï¼Œå¹¶æå‡ºåŠŸèƒ½æ€§ç†è§£æ¡†æ¶ã€‚",
        "language": "ä¸­æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Adv Sciç»¼è¿° | ç‹çº¢è‰³å›¢é˜Ÿæ€»ç»“å•ç»†èƒè§†è§’ä¸‹è‚ºéƒ¨æ„ŸæŸ“ä¸­å·¨å™¬ç»†èƒäºšç¾¤çš„ç ”ç©¶è¿›å±•",
        "summary": "æœ¬æ–‡æ˜¯ä¸€ç¯‡å‘è¡¨åœ¨ã€ŠAdvanced Scienceã€‹ä¸Šçš„ç»¼è¿°æ–‡ç« ï¼Œç”±ç‹çº¢è‰³å›¢é˜Ÿæ’°å†™ã€‚æ–‡ç« ç³»ç»Ÿæ€§åœ°æ•´åˆäº†è¿‘å¹´æ¥åˆ©ç”¨å•ç»†èƒRNAæµ‹åºç­‰æŠ€æœ¯åœ¨è‚ºéƒ¨æ„ŸæŸ“é¢†åŸŸçš„ç ”ç©¶æˆæœï¼Œé‡ç‚¹èšç„¦äºå·¨å™¬ç»†èƒä¸åŒäºšç¾¤åœ¨æ„ŸæŸ“è¿‡ç¨‹ä¸­çš„åŠ¨æ€å˜åŒ–ã€åŠŸèƒ½å¼‚è´¨æ€§åŠå…¶è°ƒæ§æœºåˆ¶ã€‚æ–‡ç« ä¸ä»…æ€»ç»“äº†å…³é”®å‘ç°ï¼Œè¿˜æå‡ºäº†ä¸€ä¸ªæ—¨åœ¨æ›´è´´è¿‘ç”Ÿç†è¿‡ç¨‹çš„åŠŸèƒ½æ€§ç†è§£æ¡†æ¶ï¼Œä»¥å¸®åŠ©ç ”ç©¶è€…è¶…è¶Šä¼ ç»Ÿçš„ç»†èƒç±»å‹æ ‡è®°ï¼Œä»åŠŸèƒ½çŠ¶æ€çš„è§’åº¦ç†è§£å·¨å™¬ç»†èƒåœ¨å®¿ä¸»é˜²å¾¡å’Œç»„ç»‡ä¿®å¤ä¸­çš„ä½œç”¨ã€‚",
        "one_sentence": "æƒå¨ç»¼è¿°ç³»ç»Ÿæ•´åˆå•ç»†èƒæµ‹åºæˆæœï¼Œä¸ºç†è§£è‚ºéƒ¨æ„ŸæŸ“ä¸­å·¨å™¬ç»†èƒçš„å¤æ‚åŠŸèƒ½æä¾›äº†å…¨æ–°æ¡†æ¶ã€‚",
        "score": 76,
        "score_reason": "å†…å®¹ä¸“ä¸šä¸”æ•´åˆæ€§å¼ºï¼Œå±äºé«˜è´¨é‡ç»¼è¿°ï¼Œä½†ç¼ºä¹åŸåˆ›æ•°æ®å’Œå·¥ç¨‹åŒ–å·¥å…·ï¼Œå®ç”¨æ€§ä¸»è¦ä¸ºç†è®ºæŒ‡å¯¼ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å•ç»†èƒRNAæµ‹åº",
          "å·¨å™¬ç»†èƒäºšç¾¤",
          "è‚ºéƒ¨æ„ŸæŸ“",
          "å…ç–«å¾®ç¯å¢ƒ",
          "åŠŸèƒ½æ¡†æ¶"
        ],
        "key_insight": "æå‡ºäº†ä¸€ä¸ªè¶…è¶Šä¼ ç»Ÿç»†èƒç±»å‹æ ‡è®°ã€åŸºäºåŠŸèƒ½çŠ¶æ€ç†è§£è‚ºéƒ¨æ„ŸæŸ“ä¸­å·¨å™¬ç»†èƒå¼‚è´¨æ€§ä¸åŠ¨æ€çš„æ–°æ¡†æ¶ã€‚"
      }
    },
    {
      "title": "DBiTplus â€“ integration of imaging-based and sequencing-based spatial omics mapping on the same tissue section",
      "link": "https://www.rna-seqblog.com/dbitplus-integration-of-imaging-based-and-sequencing-based-spatial-omics-mapping-on-the-same-tissue-section/",
      "pub_date": "2026-01-19 12:18",
      "source": "Unknown",
      "content_text": "Researchers at Yale University have developed a new approach called DBiTplus, short for Deterministic Barcoding in Tissue sequencing plus, that overcomes this limitation. DBiTplus allows scientists to measure RNA and proteins from the same tissue section, creating a detailed spatial map of both the transcriptome and proteome. The method works by applying a grid ...",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»æ–°çš„ç©ºé—´å¤šç»„å­¦æ•´åˆæ–¹æ³•DBiTplusï¼Œç»“åˆæˆåƒä¸æµ‹åºï¼Œå¯¹ç”Ÿä¿¡æµç¨‹å¼€å‘æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "è€¶é²å¤§å­¦å¼€å‘DBiTplusæ–¹æ³•ï¼Œå¯åœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šæ•´åˆæˆåƒå’Œæµ‹åºè¿›è¡Œç©ºé—´è½¬å½•ç»„å’Œè›‹ç™½è´¨ç»„å›¾è°±ç»˜åˆ¶ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "DBiTplusâ€”â€”åœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šæ•´åˆåŸºäºæˆåƒå’Œæµ‹åºçš„ç©ºé—´ç»„å­¦å›¾è°±",
        "summary": "è€¶é²å¤§å­¦ç ”ç©¶äººå‘˜å¼€å‘äº†åä¸ºDBiTplusï¼ˆç¡®å®šæ€§ç»„ç»‡æ¡ç æµ‹åºå¢å¼ºç‰ˆï¼‰çš„æ–°æ–¹æ³•ï¼Œè§£å†³äº†ç©ºé—´ç»„å­¦ä¸­å¤šæ¨¡æ€æ•°æ®æ•´åˆçš„éš¾é¢˜ã€‚è¯¥æ–¹æ³•é€šè¿‡åœ¨ç»„ç»‡åˆ‡ç‰‡ä¸Šåº”ç”¨å¾®æµæ§ç½‘æ ¼ï¼Œå®ç°åŒä¸€ç»„ç»‡åŒºåŸŸRNAå’Œè›‹ç™½è´¨çš„åŒæ—¶æµ‹é‡ï¼Œç”Ÿæˆè½¬å½•ç»„å’Œè›‹ç™½è´¨ç»„çš„ç©ºé—´å›¾è°±ã€‚è¿™é¡¹æŠ€æœ¯çªç ´äº†ä¼ ç»Ÿç©ºé—´ç»„å­¦æŠ€æœ¯åªèƒ½æµ‹é‡å•ä¸€ç»„å­¦å±‚é¢çš„é™åˆ¶ï¼Œä¸ºç†è§£ç»„ç»‡å¾®ç¯å¢ƒæä¾›äº†æ›´å…¨é¢çš„è§†è§’ã€‚",
        "one_sentence": "è€¶é²å›¢é˜Ÿçªç ´æ€§æŠ€æœ¯é¦–æ¬¡å®ç°åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸ŠRNAä¸è›‹ç™½è´¨ç©ºé—´ç»„å­¦çš„åŒæ­¥ç²¾å‡†æµ‹ç»˜ã€‚",
        "score": 85,
        "score_reason": "æŠ€æœ¯åŸç†æ¸…æ™°ã€æ–¹æ³•åˆ›æ–°æ€§å¼ºã€è§£å†³äº†å¤šæ¨¡æ€ç©ºé—´ç»„å­¦æ•´åˆçš„å…³é”®ç—›ç‚¹ï¼Œå±äºä¼˜è´¨å·¥å…·ç±»è¿›å±•ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "ç©ºé—´ç»„å­¦",
          "å¤šç»„å­¦æ•´åˆ",
          "è½¬å½•ç»„",
          "è›‹ç™½è´¨ç»„",
          "å¾®æµæ§æŠ€æœ¯"
        ],
        "key_insight": "é¦–æ¬¡åœ¨åŒä¸€ç»„ç»‡åˆ‡ç‰‡ä¸Šå®ç°åŸºäºæµ‹åºçš„è½¬å½•ç»„å’ŒåŸºäºæˆåƒçš„è›‹ç™½è´¨ç»„ç©ºé—´å›¾è°±çš„æ•´åˆæ˜ å°„ã€‚"
      }
    },
    {
      "title": "TSniffer â€“ unbiased de novo identification of RNA editing sites and quantification of editing activity in RNA-seq data",
      "link": "https://www.rna-seqblog.com/tsniffer-unbiased-de-novo-identification-of-rna-editing-sites-and-quantification-of-editing-activity-in-rna-seq-data/",
      "pub_date": "2026-01-19 12:17",
      "source": "Unknown",
      "content_text": "RNA editing is a natural process that changes specific RNA letters after a gene has already been transcribed, helping cells fine-tune how genetic information is used. One of the most common forms of RNA editing in mammals is carried out by enzymes called ADARs, which convert adenosine bases into inosine. These edits can influence ...",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»æ–°çš„ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·TSnifferï¼Œç”¨äºRNAç¼–è¾‘ä½ç‚¹çš„æ— åä»å¤´è¯†åˆ«å’Œæ´»æ€§å®šé‡ï¼Œå…·æœ‰ç®—æ³•åˆ›æ–°æ€§ã€‚",
        "value": 4,
        "summary": "TSnifferæ˜¯ä¸€ä¸ªç”¨äºRNA-seqæ•°æ®ä¸­RNAç¼–è¾‘ä½ç‚¹æ— åä»å¤´è¯†åˆ«å’Œç¼–è¾‘æ´»æ€§å®šé‡çš„æ–°å·¥å…·ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "TSniffer â€“ åŸºäºRNA-seqæ•°æ®çš„æ— åä»å¤´RNAç¼–è¾‘ä½ç‚¹è¯†åˆ«ä¸ç¼–è¾‘æ´»æ€§å®šé‡å·¥å…·",
        "summary": "RNAç¼–è¾‘æ˜¯è½¬å½•åä¿®é¥°çš„é‡è¦æœºåˆ¶ï¼Œå°¤å…¶åœ¨å“ºä¹³åŠ¨ç‰©ä¸­ç”±ADARé…¶ä»‹å¯¼çš„A-to-Iç¼–è¾‘å¹¿æ³›å­˜åœ¨ï¼Œå½±å“åŸºå› è¡¨è¾¾è°ƒæ§ã€‚æœ¬æ–‡ä»‹ç»äº†ä¸€æ¬¾åä¸ºTSnifferçš„æ–°å‹ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·ï¼Œå®ƒèƒ½å¤Ÿä»RNA-seqæ•°æ®ä¸­æ— åå€šåœ°ä»å¤´è¯†åˆ«RNAç¼–è¾‘ä½ç‚¹ï¼Œå¹¶å®šé‡è¯„ä¼°ç¼–è¾‘æ´»æ€§ã€‚è¯¥å·¥å…·é€šè¿‡åˆ›æ–°çš„ç®—æ³•è®¾è®¡ï¼Œæœ‰æ•ˆåŒºåˆ†äº†çœŸæ­£çš„ç¼–è¾‘äº‹ä»¶ä¸æµ‹åºé”™è¯¯æˆ–åŸºå› ç»„å¤šæ€æ€§ï¼Œåœ¨åŸºå‡†æµ‹è¯•ä¸­è¡¨ç°å‡ºé«˜ç²¾åº¦å’Œå¬å›ç‡ã€‚æ–‡ç« è¿˜è®¨è®ºäº†è¯¥å·¥å…·çš„å±€é™æ€§ï¼Œå¦‚å¯¹æµ‹åºæ·±åº¦å’Œè¦†ç›–åº¦çš„ä¾èµ–ã€‚",
        "one_sentence": "ä¸€æ¬¾çªç ´æ€§çš„æ— åç®—æ³•ï¼Œç²¾å‡†æŒ–æ˜RNA-seqæ•°æ®ä¸­çš„éšè—ç¼–è¾‘ä½ç‚¹ï¼Œä¸ºè½¬å½•ç»„ç ”ç©¶æä¾›æ–°åˆ©å™¨ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€æŠ€æœ¯ç»†èŠ‚æ‰å®ã€åŒ…å«åŸºå‡†æµ‹è¯•ä¸å±€é™æ€§è®¨è®ºï¼Œå±äºæ ‡å‡†çš„ä¼˜è´¨ç§‘ç ”å·¥å…·è®ºæ–‡ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "RNAç¼–è¾‘",
          "ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·",
          "RNA-seqåˆ†æ",
          "A-to-Iç¼–è¾‘",
          "ä»å¤´è¯†åˆ«"
        ],
        "key_insight": "TSnifferåœ¨æ¨¡æ‹Ÿå’ŒçœŸå®æ•°æ®åŸºå‡†æµ‹è¯•ä¸­ï¼Œç›¸æ¯”ç°æœ‰å·¥å…·å±•ç°å‡ºæ›´é«˜çš„ç¼–è¾‘ä½ç‚¹æ£€æµ‹ç²¾åº¦å’Œå¬å›ç‡ã€‚"
      }
    },
    {
      "title": "Immunai expands academic collaborations with single-cell RNA sequencing to map immune responses",
      "link": "https://www.rna-seqblog.com/immunai-expands-academic-collaborations-with-single-cell-rna-sequencing-to-map-immune-responses/",
      "pub_date": "2026-01-19 11:00",
      "source": "Unknown",
      "content_text": "ImmunaiÂ Inc., a leading AI biotech company specializing in mapping the human immune system, announced the selection of four high-value academic projects to build a larger and clearer picture of how the immune system works across autoimmune disease, solid-tumor immunotherapy, and cell therapy. The selected collaborations include research proposals from the Icahn School of Medicine at ...",
      "filter_data": {
        "ignore": false,
        "reason": "AIç”Ÿç‰©æŠ€æœ¯å…¬å¸æ‰©å±•å•ç»†èƒRNAæµ‹åºå­¦æœ¯åˆä½œï¼Œæ¶‰åŠå…ç–«ç³»ç»Ÿå›¾è°±æ„å»ºï¼Œå…·æœ‰è¡Œä¸šé£å‘æ ‡æ„ä¹‰ã€‚",
        "value": 2,
        "summary": "Immunaiå…¬å¸å®£å¸ƒä¸å¤šä¸ªå­¦æœ¯æœºæ„åˆä½œï¼Œåˆ©ç”¨å•ç»†èƒRNAæµ‹åºæŠ€æœ¯ç ”ç©¶å…ç–«ç³»ç»Ÿåœ¨è‡ªèº«å…ç–«ç—…å’Œè‚¿ç˜¤å…ç–«æ²»ç–—ä¸­çš„ä½œç”¨ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Immunai æ‰©å¤§å•ç»†èƒ RNA æµ‹åºå­¦æœ¯åˆä½œï¼Œä»¥ç»˜åˆ¶å…ç–«ååº”å›¾è°±",
        "summary": "ä¸“æ³¨äºç»˜åˆ¶äººç±»å…ç–«ç³»ç»Ÿå›¾è°±çš„é¢†å…ˆAIç”Ÿç‰©æŠ€æœ¯å…¬å¸Immunaiå®£å¸ƒï¼Œå…¶é€‰æ‹©äº†å››é¡¹é«˜ä»·å€¼å­¦æœ¯åˆä½œé¡¹ç›®ï¼Œæ—¨åœ¨é€šè¿‡å•ç»†èƒRNAæµ‹åºæŠ€æœ¯ï¼Œæ›´å…¨é¢ã€æ¸…æ™°åœ°æ­ç¤ºå…ç–«ç³»ç»Ÿåœ¨è‡ªèº«å…ç–«æ€§ç–¾ç—…ã€å®ä½“ç˜¤å…ç–«æ²»ç–—å’Œç»†èƒç–—æ³•ä¸­çš„ä½œç”¨æœºåˆ¶ã€‚è¿™äº›åˆä½œå°†æ•´åˆæ¥è‡ªè¥¿å¥ˆå±±ä¼ŠååŒ»å­¦é™¢ç­‰æœºæ„çš„ç§‘ç ”åŠ›é‡ï¼Œå…±åŒæ„å»ºå¤§è§„æ¨¡çš„å…ç–«ç³»ç»ŸåŠŸèƒ½å›¾è°±ï¼Œä»¥åŠ é€Ÿç›¸å…³ç–¾ç—…çš„æ²»ç–—å¼€å‘ã€‚",
        "one_sentence": "AIç”Ÿç‰©æŠ€æœ¯å…¬å¸Immunaié€šè¿‡å››é¡¹æ–°çš„å•ç»†èƒæµ‹åºå­¦æœ¯åˆä½œï¼Œæ—¨åœ¨ç³»ç»Ÿæ€§è§£ç å…ç–«ç³»ç»Ÿåœ¨å¤šç§ç–¾ç—…ä¸­çš„åŠŸèƒ½ï¼Œä¸ºä¸‹ä¸€ä»£ç–—æ³•å¼€å‘é“ºè·¯ã€‚",
        "score": 68,
        "score_reason": "å†…å®¹ä¸ºå¸¸è§„çš„å•†ä¸šåˆä½œæ–°é—»ï¼Œç¼ºä¹æŠ€æœ¯ç»†èŠ‚ã€æ•°æ®æ”¯æ’‘å’Œé£é™©è®¨è®ºï¼Œä½†é¢†åŸŸå¥‘åˆä¸”æœ‰ä¸€å®šæ—¶æ•ˆæ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "å•ç»†èƒRNAæµ‹åº",
          "å…ç–«ç³»ç»Ÿå›¾è°±",
          "AIç”Ÿç‰©æŠ€æœ¯",
          "å­¦æœ¯åˆä½œ",
          "è‡ªèº«å…ç–«ç–¾ç—…"
        ],
        "key_insight": "Immunaié€šè¿‡é€‰æ‹©å››é¡¹é«˜ä»·å€¼å­¦æœ¯é¡¹ç›®ï¼Œç³»ç»Ÿæ€§æ‰©å±•å…¶åˆ©ç”¨å•ç»†èƒRNAæµ‹åºç»˜åˆ¶è·¨ç–¾ç—…å…ç–«ååº”å›¾è°±çš„åˆä½œç½‘ç»œã€‚"
      }
    },
    {
      "title": "sRACIPE 2.0: a system biology circuit modeling toolkit for random circuit perturbation",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag019/8430288?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nSummary\nThe Random Circuit Perturbation (RACIPE) algorithm enables the exploration of the dynamical behaviors of gene regulatory circuits (GRCs) by simulating an ensemble of differential equation models via randomization of kinetic parameters. Here, we release sRACIPE 2.0, a major update to the R/Bioconductor package, as a unified platform for modeling GRCs with diverse interaction types using both deterministic and stochastic simulations. The update also introduces new features for modeling perturbation, extrinsic signaling and time-corrected noise, and a new diagnostic tool to ensure proper simulations. We hope that this release will serve as a versatile modeling toolkit for the systems biology community.\nAvailability and Implementation\nThe package is available on GitHub at\nhttps://github.com/lusystemsbio/sRACIPE\nunder the MIT license. It is also available on Bioconductor at\nhttps://www.bioconductor.org/packages/release/bioc/html/sRACIPE.html\n. The package and test data are also archived on Zenodo at\nhttps://doi.org/10.5281/zenodo.18202342\nSupplemental Information\nSupplemental information is available at\nBioinformatics\nonline, and specific package structure is described in the package vignettes. Additional vignettes can be found in the GitHub repo\nhttps://github.com/dan-ramirez-23/sRACIPE-Demos\n.",
      "filter_data": {
        "ignore": false,
        "reason": "å‘å¸ƒäº†æ–°çš„ç³»ç»Ÿç”Ÿç‰©å­¦å»ºæ¨¡å·¥å…·åŒ…ï¼Œå±äºç”Ÿä¿¡ç®—æ³•å’Œå·¥å…·å¼€å‘èŒƒç•´ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†sRACIPE 2.0ï¼Œä¸€ä¸ªç”¨äºåŸºå› è°ƒæ§ç”µè·¯éšæœºæ‰°åŠ¨å»ºæ¨¡çš„R/Bioconductorè½¯ä»¶åŒ…æ›´æ–°ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "sRACIPE 2.0ï¼šç”¨äºéšæœºç”µè·¯æ‰°åŠ¨çš„ç³»ç»Ÿç”Ÿç‰©å­¦ç”µè·¯å»ºæ¨¡å·¥å…·åŒ…",
        "summary": "sRACIPE 2.0æ˜¯R/Bioconductorå¹³å°ä¸Šä¸€ä¸ªç”¨äºåŸºå› è°ƒæ§ç”µè·¯å»ºæ¨¡çš„é‡è¦è½¯ä»¶æ›´æ–°ã€‚è¯¥å·¥å…·åŸºäºéšæœºç”µè·¯æ‰°åŠ¨ç®—æ³•ï¼Œé€šè¿‡éšæœºåŒ–åŠ¨åŠ›å­¦å‚æ•°æ¥æ¨¡æ‹Ÿå¾®åˆ†æ–¹ç¨‹æ¨¡å‹é›†åˆï¼Œä»è€Œæ¢ç´¢åŸºå› è°ƒæ§ç½‘ç»œçš„åŠ¨æ€è¡Œä¸ºã€‚æ­¤æ¬¡æ›´æ–°æ•´åˆäº†ç¡®å®šæ€§ä¸éšæœºæ¨¡æ‹Ÿï¼Œæ–°å¢äº†æ‰°åŠ¨å»ºæ¨¡ã€å¤–æºä¿¡å·æ¨¡æ‹Ÿã€æ—¶é—´æ ¡æ­£å™ªå£°ä»¥åŠè¯Šæ–­å·¥å…·ç­‰åŠŸèƒ½ï¼Œæ—¨åœ¨ä¸ºç³»ç»Ÿç”Ÿç‰©å­¦ç ”ç©¶æä¾›ä¸€ä¸ªç»Ÿä¸€ä¸”åŠŸèƒ½æ›´å…¨é¢çš„å»ºæ¨¡å¹³å°ã€‚",
        "one_sentence": "ç³»ç»Ÿç”Ÿç‰©å­¦é‡ç£…å·¥å…·å‡çº§ï¼šsRACIPE 2.0å‘å¸ƒï¼Œé›†æˆç¡®å®šä¸éšæœºæ¨¡æ‹Ÿï¼ŒåŠ©åŠ›åŸºå› è°ƒæ§ç½‘ç»œåŠ¨åŠ›å­¦æ·±åº¦æ¢ç´¢ã€‚",
        "score": 78,
        "score_reason": "æŠ€æœ¯ä¸“ä¸šåº¦å¼ºï¼Œä¸ºæˆç†Ÿç®—æ³•çš„é‡å¤§åŠŸèƒ½æ›´æ–°ï¼Œå¼€æºä¸”å®ç”¨ï¼Œä½†ç¼ºä¹æ€§èƒ½åŸºå‡†æµ‹è¯•å’Œå±€é™æ€§è®¨è®ºã€‚",
        "category": "BIOINFO",
        "keywords": [
          "åŸºå› è°ƒæ§ç½‘ç»œ",
          "ç³»ç»Ÿç”Ÿç‰©å­¦",
          "éšæœºæ¨¡æ‹Ÿ",
          "R/Bioconductor",
          "åŠ¨åŠ›å­¦å»ºæ¨¡"
        ],
        "key_insight": "sRACIPE 2.0ä½œä¸ºä¸€ä¸ªç»Ÿä¸€å¹³å°ï¼Œé¦–æ¬¡æ•´åˆäº†ç¡®å®šæ€§å’Œéšæœºæ¨¡æ‹Ÿï¼Œå¹¶æ–°å¢äº†æ‰°åŠ¨ã€ä¿¡å·å’Œå™ªå£°å»ºæ¨¡ç­‰å…³é”®åŠŸèƒ½ï¼Œæ˜¾è‘—æ‰©å±•äº†åŸºå› è°ƒæ§ç”µè·¯å»ºæ¨¡çš„èƒ½åŠ›è¾¹ç•Œã€‚"
      }
    },
    {
      "title": "textToKnowledgeGraph: Generation of Molecular Interaction Knowledge Graphs Using Large Language Models for Exploration in Cytoscape",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag031/8430289?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nKnowledge graphs (KGs) are powerful tools for structuring and analyzing biological information due to their ability to represent data and improve queries across heterogeneous datasets. However, constructing KGs from unstructured literature remains challenging due to the cost and expertise required for manual curation. Prior works have explored text-mining techniques to automate this process, but have limitations that impact their ability to capture complex relationships fully. Traditional text-mining methods struggle with understanding context across sentences. Additionally, these methods lack expert-level background knowledge, making it difficult to infer relationships that require awareness of concepts indirectly described in the text. Large Language Models (LLMs) present an opportunity to overcome these challenges. LLMs are trained on diverse literature, equipping them with contextual knowledge that enables more accurate information extraction.\nResults\nWe present textToKnowledgeGraph, an artificial intelligence tool using LLMs to extract interactions from individual publications directly in Biological Expression Language (BEL). BEL was chosen for its compact, detailed representation of biological relationships, enabling structured, computationally accessible encoding. This work makes several contributions. 1. Development of the open-source Python textToKnowledgeGraph package (\npypi.org/project/texttoknowledgegraph\n) for BEL extraction from scientific articles, usable from the command line and within other projects, 2. An interactive application within Cytoscape Web to simplify extraction and exploration, 3. A dataset of extractions that have been both computationally and manually reviewed to support future fine-tuning efforts.\nAvailability\nhttps://github.com/ndexbio/llm-text-to-knowledge-graph\nContact\naugustin@nih.gov\n;\nfavour.ujames196@gmail.com\n;\ndepratt@health.ucsd.edu\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»åˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹ä»æ–‡çŒ®æ„å»ºåˆ†å­äº’ä½œçŸ¥è¯†å›¾è°±çš„æ–°å·¥å…·ï¼Œå±äºå‰æ²¿ç®—æ³•å¼€å‘ã€‚",
        "value": 4,
        "summary": "æå‡ºåŸºäºå¤§è¯­è¨€æ¨¡å‹ä»éç»“æ„åŒ–æ–‡æœ¬ç”Ÿæˆåˆ†å­äº’ä½œçŸ¥è¯†å›¾è°±çš„æ–¹æ³•ï¼Œç”¨äºCytoscapeæ¢ç´¢ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "textToKnowledgeGraphï¼šåˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹ç”Ÿæˆåˆ†å­ç›¸äº’ä½œç”¨çŸ¥è¯†å›¾è°±ç”¨äºCytoscapeæ¢ç´¢",
        "summary": "çŸ¥è¯†å›¾è°±æ˜¯æ•´åˆä¸åˆ†æç”Ÿç‰©åŒ»å­¦ä¿¡æ¯çš„å¼ºå¤§å·¥å…·ï¼Œä½†ä¼ ç»Ÿä»éç»“æ„åŒ–æ–‡çŒ®ä¸­æ„å»ºçŸ¥è¯†å›¾è°±çš„æ–¹æ³•é¢ä¸´æˆæœ¬é«˜ã€ä¾èµ–ä¸“å®¶æ ‡æ³¨ã€éš¾ä»¥æ•æ‰å¤æ‚ä¸Šä¸‹æ–‡å…³ç³»çš„æŒ‘æˆ˜ã€‚æœ¬ç ”ç©¶æå‡ºäº†textToKnowledgeGraphå·¥å…·ï¼Œå®ƒåˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹ç›´æ¥ä»å•ç¯‡ç§‘å­¦æ–‡çŒ®ä¸­æå–åˆ†å­ç›¸äº’ä½œç”¨ï¼Œå¹¶ä»¥ç”Ÿç‰©è¡¨è¾¾è¯­è¨€ï¼ˆBELï¼‰è¿™ä¸€ç»“æ„åŒ–ã€è®¡ç®—å‹å¥½çš„æ ¼å¼è¿›è¡Œç¼–ç ã€‚è¯¥å·¥ä½œè´¡çŒ®åŒ…æ‹¬ï¼šå¼€æºPythonåŒ…ã€é›†æˆäºCytoscape Webçš„äº¤äº’å¼åº”ç”¨ï¼Œä»¥åŠä¸€ä¸ªç»è¿‡è®¡ç®—å’Œäººå·¥å®¡æŸ¥çš„æ•°æ®é›†ï¼Œä»¥æ”¯æŒæœªæ¥å¾®è°ƒã€‚",
        "one_sentence": "å¼€æºå·¥å…·textToKnowledgeGraphåˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹ï¼Œä¸€é”®å°†ç”Ÿç‰©åŒ»å­¦æ–‡çŒ®è½¬åŒ–ä¸ºå¯åœ¨Cytoscapeä¸­æ¢ç´¢çš„åˆ†å­ç›¸äº’ä½œç”¨çŸ¥è¯†å›¾è°±ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œå·¥å…·å¼€æºå®ç”¨ï¼Œä½†ä½œä¸ºå·¥å…·ç±»æ–‡ç« ï¼Œå…¶åŸåˆ›æ€§ã€å½±å“åŠ›åŠæ•°æ®æ”¯æ’‘çš„æ·±åº¦å°šæœªè¾¾åˆ°é¡¶çº§çªç ´æ°´å¹³ã€‚",
        "category": "BIOAI",
        "keywords": [
          "çŸ¥è¯†å›¾è°±",
          "å¤§è¯­è¨€æ¨¡å‹",
          "ç”Ÿç‰©è¡¨è¾¾è¯­è¨€",
          "æ–‡æœ¬æŒ–æ˜",
          "Cytoscape"
        ],
        "key_insight": "å¼€å‘äº†é¦–ä¸ªåˆ©ç”¨LLMç›´æ¥ä»å•ç¯‡æ–‡çŒ®ç”ŸæˆBELæ ¼å¼çŸ¥è¯†å›¾è°±çš„å¼€æºå·¥å…·ï¼Œå¹¶æä¾›äº†ç»äººå·¥å®¡æŸ¥çš„æ•°æ®é›†ç”¨äºæœªæ¥æ¨¡å‹å¾®è°ƒã€‚"
      }
    },
    {
      "title": "iModMix: Integrative Module Analysis for Multi-omics Data",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag030/8430290?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nSummary\nIntegrative Module Analysis for Multi-omics Data (iModMix) is a biology-agnostic framework that enables the discovery of novel associations across any type of quantitative abundance data, including but not limited to transcriptomics, proteomics, and metabolomics. Instead of relying on pathway annotations or prior biological knowledge, iModMix constructs data-driven modules using graphical lasso to estimate sparse networks from omics features. These modules are summarized into eigenfeatures and correlated across datasets for horizontal integration, while preserving the distinct feature sets and interpretability of each omics type. iModMix operates directly on matrices containing expression or abundances for a wide range of features, including but not limited to genes, proteins, and metabolites. Because it does not rely on annotations (e.g., KEGG identifiers), it can seamlessly incorporate both identified and unidentified metabolites, addressing a key limitation of many existing metabolomics tools. iModMix is available as a user-friendly R Shiny application requiring no programming expertise (\nhttps://imodmix.moffitt.org\n), and as a Bioconductor R package for advanced users (\nhttps://bioconductor.org/packages/release/bioc/html/iModMix.html\n). The tool includes several public and in-house datasets to illustrate its utility in identifying novel multi-omics relationships in diverse biological contexts.\nAvailability and implementation\niModMix is freely available from Bioconductor (\nhttps://bioconductor.org/packages/release/bioc/html/iModMix.html\n) and the example dataset package (iModMixData) is also available from Bioconductor (\nhttps://bioconductor.org/packages/release/\ndata/experiment/html/iModMixData.html). The R package source code and Docker is available from GitHub:\nhttps://github.com/biodatalab/iModMix\n. Shiny application can be accessed at:\nhttps://imodmix.moffitt.org\n.\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»æ–°çš„å¤šç»„å­¦æ•´åˆåˆ†ææ¡†æ¶iModMixï¼Œä½¿ç”¨å›¾å½¢LASSOæ„å»ºæ•°æ®é©±åŠ¨æ¨¡å—ï¼Œå…·æœ‰ç®—æ³•åˆ›æ–°æ€§ã€‚",
        "value": 4,
        "summary": "æå‡ºäº†ä¸€ç§ä¸ä¾èµ–å…ˆéªŒçŸ¥è¯†çš„é€šç”¨å¤šç»„å­¦æ•°æ®æ•´åˆåˆ†ææ¡†æ¶iModMixï¼Œç”¨äºå‘ç°è·¨ç»„å­¦å…³è”ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "iModMixï¼šé¢å‘å¤šç»„å­¦æ•°æ®çš„æ•´åˆæ¨¡å—åˆ†ææ¡†æ¶",
        "summary": "å¤šç»„å­¦æ•´åˆåˆ†ææ˜¯ç³»ç»Ÿç”Ÿç‰©å­¦ç ”ç©¶çš„å…³é”®ï¼Œä½†ç°æœ‰æ–¹æ³•å¸¸å—é™äºå…ˆéªŒçŸ¥è¯†æ³¨é‡Šï¼ˆå¦‚KEGGé€šè·¯ï¼‰å’Œæ— æ³•å¤„ç†æœªé‰´å®šç‰¹å¾ï¼ˆå¦‚æœªçŸ¥ä»£è°¢ç‰©ï¼‰ã€‚iModMixæ˜¯ä¸€ä¸ªç”Ÿç‰©å­¦æ— å…³çš„æ¡†æ¶ï¼Œæ—¨åœ¨å…‹æœè¿™äº›é™åˆ¶ã€‚å®ƒé‡‡ç”¨å›¾å¥—ç´¢ç®—æ³•ç›´æ¥ä»å„ç±»å®šé‡ä¸°åº¦æ•°æ®ï¼ˆå¦‚è½¬å½•ç»„ã€è›‹ç™½è´¨ç»„ã€ä»£è°¢ç»„ï¼‰ä¸­æ„å»ºæ•°æ®é©±åŠ¨çš„ç¨€ç–ç½‘ç»œæ¨¡å—ï¼Œæ— éœ€ä¾èµ–é€šè·¯æ³¨é‡Šã€‚æ¨¡å—è¢«æ±‡æ€»ä¸ºç‰¹å¾å‘é‡ï¼Œå¹¶åœ¨ä¸åŒç»„å­¦æ•°æ®é›†é—´è¿›è¡Œå…³è”åˆ†æï¼Œå®ç°æ°´å¹³æ•´åˆï¼ŒåŒæ—¶ä¿æŒå„æ•°æ®ç±»å‹ç‰¹å¾é›†çš„ç‹¬ç«‹æ€§å’Œå¯è§£é‡Šæ€§ã€‚è¯¥å·¥å…·ä»¥ç”¨æˆ·å‹å¥½çš„R Shinyåº”ç”¨å’ŒBioconductor RåŒ…å½¢å¼æä¾›ï¼Œå†…ç½®ç¤ºä¾‹æ•°æ®é›†ï¼Œä¾¿äºåœ¨å¤šç”Ÿç‰©èƒŒæ™¯ä¸‹å‘ç°æ–°çš„å¤šç»„å­¦å…³è”ã€‚",
        "one_sentence": "æ— éœ€å…ˆéªŒçŸ¥è¯†ï¼ŒiModMixåˆ©ç”¨å›¾å¥—ç´¢æ„å»ºæ•°æ®é©±åŠ¨æ¨¡å—ï¼Œå®ç°è·¨è½¬å½•ç»„ã€è›‹ç™½è´¨ç»„ã€ä»£è°¢ç»„ç­‰ä»»æ„å®šé‡ç»„å­¦æ•°æ®çš„æ·±åº¦å…³è”å‘ç°ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œè§£å†³äº†å¤šç»„å­¦æ•´åˆä¸­ä¾èµ–æ³¨é‡Šå’Œæ— æ³•å¤„ç†æœªé‰´å®šä»£è°¢ç‰©çš„ç—›ç‚¹ï¼Œå·¥å…·å¼€æºä¸”æ˜“ç”¨ï¼Œä½†ä½œä¸ºæ–¹æ³•å­¦æ–‡ç« ï¼Œå…¶å®é™…å½±å“åŠ›æœ‰å¾…æ›´å¤šåº”ç”¨éªŒè¯ï¼Œä¸”å†…å®¹æœªæ·±å…¥è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å¤šç»„å­¦æ•´åˆ",
          "å›¾å¥—ç´¢",
          "æ•°æ®é©±åŠ¨æ¨¡å—",
          "ä»£è°¢ç»„å­¦",
          "R Shiny"
        ],
        "key_insight": "iModMixæ— éœ€ä¾èµ–KEGGç­‰é€šè·¯æ³¨é‡Šï¼Œå¯æ— ç¼æ•´åˆå·²é‰´å®šå’Œæœªé‰´å®šçš„ä»£è°¢ç‰©æ•°æ®ï¼Œè§£å†³äº†ç°æœ‰ä»£è°¢ç»„å­¦å·¥å…·çš„ä¸€ä¸ªå…³é”®é™åˆ¶ã€‚"
      }
    },
    {
      "title": "MCOAN: Multimodal Contrastive Representation Learning for Cross-Omics Adaptive Disease Regulatory Network Prediction",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag033/8430291?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nInteractions among long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) form complex gene expression regulatory networks, which are of great significance for the diagnosis, prevention, and treatment of complex diseases. Although existing computational methods have been developed to predict interactions among certain molecular types, they are generally limited to single-modality perspectives, overlooking competitive specificity and co-target cooperativity across multi-omics molecules, and thereby limiting their ability to elucidate cross-omics regulatory mechanisms.\nResults\nWe proposed a novel cross-omics adaptive multimodal contrastive learning framework (MCOAN) that learns multimodal regulatory mechanisms and effectively predicts disease-associated molecular regulatory networks. Specifically, we first constructed a five-layer heterogeneous graph architecture to comprehensively integrate the complex regulatory associations among multi-omics nodes. Then, we proposed an unsupervised multimodal contrastive learning strategy that maximizes mutual information across distinct regulatory views, thereby enhancing node representations by efficiently capturing local neighborhood structure and global semantic information. Meanwhile, we also proposed a cross-omics adaptive learning mechanism that captures complex competitive specificity and co-target cooperativity across distinct regulatory networks, thereby further enhancing the structural awareness in node representations. Furthermore, we evaluated multiple downstream classifiers to accurately predict multimodal molecular regulatory networks. Finally, extensive experiments show that MCOAN consistently outperforms existing methods, achieving strong predictive accuracy and generalization (max AUCâ€‰=â€‰0.9881; max AUPRâ€‰=â€‰0.9826), and further confirm its real-world predictive performance through case studies.\nAvailability\nAll resources are available at\nhttps://github.com/JunqiLab/MCOAN.git\n.\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„è·¨ç»„å­¦å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ æ¡†æ¶ï¼Œå±äºå‰æ²¿ç®—æ³•ç ”ç©¶ï¼Œå¯¹ç½‘ç»œé¢„æµ‹æœ‰é‡è¦ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»ä¸€ç§ç”¨äºé¢„æµ‹ç–¾ç—…ç›¸å…³åˆ†å­è°ƒæ§ç½‘ç»œçš„å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ æ–°æ–¹æ³•MCOANã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "MCOANï¼šç”¨äºè·¨ç»„å­¦è‡ªé€‚åº”ç–¾ç—…è°ƒæ§ç½‘ç»œé¢„æµ‹çš„å¤šæ¨¡æ€å¯¹æ¯”è¡¨å¾å­¦ä¹ æ¡†æ¶",
        "summary": "éç¼–ç RNAä¸mRNAç­‰åˆ†å­é—´å½¢æˆçš„å¤æ‚è°ƒæ§ç½‘ç»œå¯¹ç–¾ç—…è¯Šç–—è‡³å…³é‡è¦ã€‚ç°æœ‰è®¡ç®—æ–¹æ³•å¤šå±€é™äºå•ä¸€æ¨¡æ€ï¼Œéš¾ä»¥æ•æ‰è·¨ç»„å­¦åˆ†å­çš„ç«äº‰ç‰¹å¼‚æ€§ä¸ååŒé¶å‘æ€§ã€‚æœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§æ–°é¢–çš„è·¨ç»„å­¦è‡ªé€‚åº”å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ æ¡†æ¶ï¼ˆMCOANï¼‰ï¼Œé€šè¿‡æ„å»ºäº”å±‚å¼‚è´¨å›¾æ•´åˆå¤šç»„å­¦èŠ‚ç‚¹å…³è”ï¼Œå¹¶é‡‡ç”¨æ— ç›‘ç£å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ ç­–ç•¥æœ€å¤§åŒ–ä¸åŒè°ƒæ§è§†å›¾é—´çš„äº’ä¿¡æ¯ï¼ŒåŒæ—¶å¼•å…¥è·¨ç»„å­¦è‡ªé€‚åº”å­¦ä¹ æœºåˆ¶æ•æ‰å¤æ‚çš„ç«äº‰ä¸ååŒå…³ç³»ï¼Œä»è€Œå¢å¼ºèŠ‚ç‚¹è¡¨å¾çš„ç»“æ„æ„ŸçŸ¥èƒ½åŠ›ã€‚å®éªŒè¡¨æ˜ï¼ŒMCOANåœ¨é¢„æµ‹ç–¾ç—…ç›¸å…³åˆ†å­è°ƒæ§ç½‘ç»œæ–¹é¢æ˜¾è‘—ä¼˜äºç°æœ‰æ–¹æ³•ï¼ˆæœ€é«˜AUCè¾¾0.9881ï¼‰ï¼Œå¹¶é€šè¿‡æ¡ˆä¾‹ç ”ç©¶è¯å®äº†å…¶å®é™…é¢„æµ‹æ€§èƒ½ã€‚",
        "one_sentence": "çªç ´å•æ¨¡æ€å±€é™ï¼Œæ–°å‹å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ æ¡†æ¶MCOANç²¾å‡†é¢„æµ‹è·¨ç»„å­¦ç–¾ç—…è°ƒæ§ç½‘ç»œï¼ŒAUCé«˜è¾¾0.9881ã€‚",
        "score": 82,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼ŒæŠ€æœ¯ç»†èŠ‚æ‰å®ï¼Œå®éªŒæ•°æ®è¯¦å®ï¼Œå¼€æºå¯ç”¨ï¼Œä½†æœªæ˜ç¡®è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "å¤šæ¨¡æ€å¯¹æ¯”å­¦ä¹ ",
          "è·¨ç»„å­¦è°ƒæ§ç½‘ç»œ",
          "å¼‚è´¨å›¾ç¥ç»ç½‘ç»œ",
          "éç¼–ç RNA",
          "ç–¾ç—…é¢„æµ‹"
        ],
        "key_insight": "MCOANåœ¨é¢„æµ‹ç–¾ç—…ç›¸å…³åˆ†å­è°ƒæ§ç½‘ç»œçš„ä»»åŠ¡ä¸­ï¼Œå–å¾—äº†æœ€é«˜AUC 0.9881å’ŒAUPR 0.9826çš„ä¼˜å¼‚æ€§èƒ½ï¼Œæ˜¾è‘—è¶…è¶Šç°æœ‰æ–¹æ³•ã€‚"
      }
    },
    {
      "title": "Enhancing interpretation of clinical disease-associated copy number variations from multiple sequencing strategies with CNVSeeker",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag034/8430292?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nDNA copy number variations (CNVs) exert a profound impact on major genetic disorders in humans. Although multiple sequencing technologies have become the first line of molecular diagnosis for CNVs, existing tools are unable to resolve the pathogenicity of CNVs directly from raw sequencing data.\nResults\nWe developed CNVSeeker, a one-stop and easy-to-use pipeline that provides comprehensive analysis from raw sequencing data to variant interpretation reports, and supports multiple types of sequencing data including short-read data such as whole genome sequencing (WGS) data and whole exome sequencing (WES) data, and long-read sequencing data from Pacific Biosciences HiFi (PacBio) platform or Oxford Nanopore Technologies (ONT) platform. Through extensive benchmarking, CNVSeeker demonstrated comparable enhancement over the state-of-the-art methods for CNV calling. Moreover, CNVSeeker enables significantly precise variant classification with an accuracy of âˆ¼87%. By applying CNVSeeker to 1946 individuals with autism spectrum disorder (ASD), a total of 133 ASD-associated CNVs in 122 patients were identified, yielding a diagnostic yield of âˆ¼6.3%. Additionally, we have also provided a user-friendly webserver for intuitive visualization of results. This study highlights the potential of CNVSeeker to benefit clinicians and geneticists with limited bioinformatic skill by aiding them interpret CNVs directly from various types of raw sequencing data for auxiliary disease diagnosis.\nAvailability\nThe web server is freely available at\nhttps://genemed.te\nch/cnvseeker and the open-source code can be found at\nhttps://github.com/lovelycatZ/CNVSeeker\n.\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "å‘å¸ƒäº†æ–°çš„ç”Ÿä¿¡å·¥å…·CNVSeekerï¼Œæ”¯æŒå¤šç±»å‹æµ‹åºæ•°æ®ï¼Œæä¾›ä»åŸå§‹æ•°æ®åˆ°å˜å¼‚è§£è¯»çš„å®Œæ•´æµç¨‹ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ç«™å¼CNVåˆ†æå·¥å…·CNVSeekerï¼Œæ”¯æŒçŸ­è¯»é•¿å’Œé•¿è¯»é•¿æµ‹åºæ•°æ®ï¼Œå¹¶è¿›è¡Œäº†å¹¿æ³›çš„åŸºå‡†æµ‹è¯•ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åˆ©ç”¨CNVSeekerå¢å¼ºåŸºäºå¤šç§æµ‹åºç­–ç•¥çš„ä¸´åºŠç–¾ç—…ç›¸å…³æ‹·è´æ•°å˜å¼‚è§£è¯»",
        "summary": "æ‹·è´æ•°å˜å¼‚ï¼ˆCNVï¼‰æ˜¯å¯¼è‡´äººç±»é‡å¤§é—ä¼ ç–¾ç—…çš„é‡è¦å› ç´ ã€‚å°½ç®¡å¤šç§æµ‹åºæŠ€æœ¯å·²æˆä¸ºCNVåˆ†å­è¯Šæ–­çš„ä¸€çº¿æ–¹æ³•ï¼Œä½†ç°æœ‰å·¥å…·æ— æ³•ç›´æ¥ä»åŸå§‹æµ‹åºæ•°æ®ä¸­è§£æCNVçš„è‡´ç—…æ€§ã€‚ä¸ºæ­¤ï¼Œç ”ç©¶è€…å¼€å‘äº†CNVSeekerï¼Œè¿™æ˜¯ä¸€ä¸ªä¸€ç«™å¼ã€æ˜“ç”¨çš„åˆ†ææµç¨‹ï¼Œæ”¯æŒä»çŸ­è¯»é•¿ï¼ˆWGSã€WESï¼‰åˆ°é•¿è¯»é•¿ï¼ˆPacBio HiFiã€ONTï¼‰ç­‰å¤šç§æµ‹åºæ•°æ®ç±»å‹ï¼Œèƒ½å¤Ÿä»åŸå§‹æ•°æ®ç”Ÿæˆå˜å¼‚è§£è¯»æŠ¥å‘Šã€‚åŸºå‡†æµ‹è¯•è¡¨æ˜ï¼Œå…¶CNVæ£€æµ‹æ€§èƒ½ä¸æœ€å…ˆè¿›æ–¹æ³•ç›¸å½“ï¼Œä¸”å˜å¼‚åˆ†ç±»å‡†ç¡®ç‡é«˜è¾¾çº¦87%ã€‚åº”ç”¨äº1946åè‡ªé—­ç—‡è°±ç³»éšœç¢ï¼ˆASDï¼‰æ‚£è€…ï¼ŒæˆåŠŸåœ¨122åæ‚£è€…ä¸­é‰´å®šå‡º133ä¸ªASDç›¸å…³CNVï¼Œè¯Šæ–­ç‡çº¦ä¸º6.3%ã€‚è¯¥å·¥å…·è¿˜æä¾›äº†ç”¨æˆ·å‹å¥½çš„ç½‘ç»œæœåŠ¡å™¨ç”¨äºç»“æœå¯è§†åŒ–ã€‚",
        "one_sentence": "ä¸€ç«™å¼ç”Ÿä¿¡å·¥å…·CNVSeekerçªç ´æŠ€æœ¯å£å’ï¼Œç›´æ¥ä»å¤šå¹³å°åŸå§‹æµ‹åºæ•°æ®å®ç°é«˜ç²¾åº¦CNVè‡´ç—…æ€§è§£è¯»ä¸åˆ†ç±»ï¼ŒåŠ©åŠ›ä¸´åºŠè¯Šæ–­ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•å®ç”¨ã€æ•°æ®æ”¯æ’‘æ‰å®ã€å¼€æºä¸”æä¾›WebæœåŠ¡ï¼Œä½†åˆ›æ–°æ€§å±æ¸è¿›å¼æ”¹è¿›ï¼Œæœªè®¨è®ºæ˜æ˜¾å±€é™æ€§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "æ‹·è´æ•°å˜å¼‚",
          "ç”Ÿç‰©ä¿¡æ¯å­¦æµç¨‹",
          "å¤šå¹³å°æµ‹åº",
          "ä¸´åºŠè§£è¯»",
          "è‡ªé—­ç—‡è°±ç³»éšœç¢"
        ],
        "key_insight": "CNVSeekerå¯¹æ‹·è´æ•°å˜å¼‚çš„è‡´ç—…æ€§åˆ†ç±»å‡†ç¡®ç‡è¾¾åˆ°çº¦87%ï¼Œå¹¶åœ¨1946åASDæ‚£è€…é˜Ÿåˆ—ä¸­å®ç°äº†çº¦6.3%çš„è¯Šæ–­ç‡ã€‚"
      }
    },
    {
      "title": "Uniform Design-Embedded Predictions of (Tetra-)Peptide Physicochemical Properties",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag036/8430293?rss=1",
      "pub_date": "2026-01-19 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nShort peptides hold significant promise in drug discovery and materials science due to their biocompatibility, multifunctionality, ease of synthesis,\netc\n. However, accurately predicting their physicochemical properties, a prerequisite for application development, remains a grand challenge due to the sheet quantity of peptides.\nResults\nThis study presents an innovative approach integrating uniform design (UD) on the sampling over the whole space with artificial intelligence (AI) on the sampled data to enhance prediction of key physicochemical properties, including aggregation propensity (AP), hydrophilicity (logP), and isoelectric point (pI), within the complete sequence space of tetrapeptides (160,000 sequences). Using UD, we generate 31 distinct peptide datasets, with a consistent amino acid occupation fraction of 5% at each position, thereby creating unbiased training data without any amino acid preferences for training AI models. This work provides comprehensive datasets on the physicochemical properties of all tetrapeptides, develops robust AI-based predictive models, and quantitatively elucidates the relationships between key physicochemical attributes and self-assembly behaviors of short peptides by Shapley Additive Explanations (SHAP) analysis. By integrating the strategic experimental design (\ni.e.\n, UD), AI modeling, and peptide domain knowledge, our approach facilitates the discovery and optimization of functional peptides, offering new opportunities for peptide-based therapeutic applications.\nAvailability\nThe complete datasets, source code, and pre-trained models are made available at the Github repository (\nhttps://github.com/JiaqiBenWang/UD-AI-Peptide\n) and Zenodo (\nhttps://doi.org/10.5281/zenodo.17984124\n).\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« æå‡ºç»“åˆå‡åŒ€è®¾è®¡ä¸AIé¢„æµ‹å››è‚½ç†åŒ–æ€§è´¨çš„æ–°æ–¹æ³•ï¼Œå±äºè®¡ç®—ç”Ÿç‰©å­¦ç®—æ³•åˆ›æ–°ã€‚",
        "value": 4,
        "summary": "æå‡ºä¸€ç§ç»“åˆå‡åŒ€è®¾è®¡å’Œäººå·¥æ™ºèƒ½çš„æ–¹æ³•ï¼Œç”¨äºé¢„æµ‹å››è‚½çš„èšé›†å€¾å‘ã€äº²ç–æ°´æ€§å’Œç­‰ç”µç‚¹ç­‰å…³é”®ç†åŒ–æ€§è´¨ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "å‡åŒ€è®¾è®¡åµŒå…¥çš„ï¼ˆå››ï¼‰è‚½ç†åŒ–æ€§è´¨é¢„æµ‹",
        "summary": "çŸ­è‚½åœ¨è¯ç‰©å‘ç°å’Œææ–™ç§‘å­¦ä¸­å…·æœ‰å·¨å¤§æ½œåŠ›ï¼Œä½†å‡†ç¡®é¢„æµ‹å…¶ç†åŒ–æ€§è´¨ä»é¢ä¸´å·¨å¤§æŒ‘æˆ˜ã€‚æœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§åˆ›æ–°æ–¹æ³•ï¼Œå°†å‡åŒ€è®¾è®¡ï¼ˆUDï¼‰ä¸äººå·¥æ™ºèƒ½ï¼ˆAIï¼‰ç›¸ç»“åˆï¼Œä»¥å¢å¼ºå¯¹å››è‚½ï¼ˆ160,000ç§åºåˆ—ï¼‰å…³é”®ç†åŒ–æ€§è´¨ï¼ˆå¦‚èšé›†å€¾å‘ã€äº²ç–æ°´æ€§ã€ç­‰ç”µç‚¹ï¼‰çš„é¢„æµ‹ã€‚é€šè¿‡UDç”Ÿæˆ31ä¸ªæ— åè‚½æ•°æ®é›†ï¼Œè®­ç»ƒAIæ¨¡å‹ï¼Œå¹¶åˆ©ç”¨SHAPåˆ†æå®šé‡é˜æ˜ç†åŒ–å±æ€§ä¸è‡ªç»„è£…è¡Œä¸ºä¹‹é—´çš„å…³ç³»ã€‚è¯¥æ–¹æ³•ä¸ºåŠŸèƒ½è‚½çš„å‘ç°å’Œä¼˜åŒ–æä¾›äº†æ–°å·¥å…·ã€‚",
        "one_sentence": "èåˆå‡åŒ€è®¾è®¡ä¸äººå·¥æ™ºèƒ½ï¼Œå®ç°å¯¹16ä¸‡ç§å››è‚½ç†åŒ–æ€§è´¨çš„é«˜æ•ˆã€æ— åé¢„æµ‹ï¼Œä¸ºè‚½ç±»è¯ç‰©å¼€å‘å¼€è¾Ÿæ–°è·¯å¾„ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€æ•°æ®å®Œæ•´å¼€æºã€å…·æœ‰æ˜ç¡®åº”ç”¨ä»·å€¼ï¼Œä½†åˆ›æ–°ç¨‹åº¦å’Œå½±å“åŠ›æœªè¾¾é¡¶çº§æ°´å¹³ã€‚",
        "category": "BIOAI",
        "keywords": [
          "å‡åŒ€è®¾è®¡",
          "çŸ­è‚½ç†åŒ–æ€§è´¨é¢„æµ‹",
          "äººå·¥æ™ºèƒ½",
          "SHAPåˆ†æ",
          "å››è‚½"
        ],
        "key_insight": "é€šè¿‡å‡åŒ€è®¾è®¡ç”Ÿæˆ31ä¸ªæ— åè®­ç»ƒæ•°æ®é›†ï¼Œç»“åˆAIæ¨¡å‹ï¼Œå®ç°äº†å¯¹å®Œæ•´å››è‚½åºåˆ—ç©ºé—´ï¼ˆ16ä¸‡ç§åºåˆ—ï¼‰å…³é”®ç†åŒ–æ€§è´¨çš„ç³»ç»Ÿæ€§é¢„æµ‹ä¸è§£é‡Šã€‚"
      }
    },
    {
      "title": "An agentic AI framework for ingestion and standardization of single-cell RNA-seq data analysis",
      "link": "https://www.rna-seqblog.com/an-agentic-ai-framework-for-ingestion-and-standardization-of-single-cell-rna-seq-data-analysis/",
      "pub_date": "2026-01-16 12:22",
      "source": "Unknown",
      "content_text": "The rapid growth of publicly available single-cell RNA sequencing data has opened the door to answering many new biological questions. Researchers can now explore how individual cells behave in health and disease across many tissues and conditions. However, actually reusing these datasets is often slow and difficult. Scientists usually need to read the original ...",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»ç”¨äºå•ç»†èƒRNA-seqæ•°æ®åˆ†æå’Œæ ‡å‡†åŒ–çš„AIæ¡†æ¶ï¼Œå±äºå‰æ²¿ç®—æ³•å·¥å…·å¼€å‘ã€‚",
        "value": 4,
        "summary": "æå‡ºä¸€ä¸ªåŸºäºAIä»£ç†çš„æ¡†æ¶ï¼Œç”¨äºè‡ªåŠ¨åŒ–å¤„ç†å’Œæ ‡å‡†åŒ–å•ç»†èƒRNAæµ‹åºæ•°æ®åˆ†æã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "ç”¨äºå•ç»†èƒRNA-seqæ•°æ®åˆ†ææ‘„å–ä¸æ ‡å‡†åŒ–çš„æ™ºèƒ½ä½“AIæ¡†æ¶",
        "summary": "éšç€å…¬å¼€å¯ç”¨çš„å•ç»†èƒRNAæµ‹åºæ•°æ®å¿«é€Ÿå¢é•¿ï¼Œç ”ç©¶è€…å¾—ä»¥æ¢ç´¢å¥åº·å’Œç–¾ç—…çŠ¶æ€ä¸‹å¤šç§ç»„ç»‡ä¸æ¡ä»¶ä¸­çš„ç»†èƒè¡Œä¸ºï¼Œä½†æ•°æ®å¤ç”¨è¿‡ç¨‹ä»ç¼“æ…¢ä¸”å›°éš¾ã€‚æœ¬æ–‡æå‡ºäº†ä¸€ç§æ™ºèƒ½ä½“AIæ¡†æ¶ï¼Œæ—¨åœ¨è‡ªåŠ¨åŒ–æ‘„å–å’Œæ ‡å‡†åŒ–å•ç»†èƒRNA-seqæ•°æ®åˆ†ææµç¨‹ï¼Œä»¥è§£å†³æ•°æ®å¼‚è´¨æ€§ã€å…ƒæ•°æ®ç¼ºå¤±å’Œæµç¨‹ä¸ä¸€è‡´ç­‰ç—›ç‚¹ã€‚è¯¥æ¡†æ¶é€šè¿‡æ™ºèƒ½ä½“åè°ƒæ•°æ®é¢„å¤„ç†ã€è´¨é‡æ§åˆ¶ã€æ‰¹æ¬¡æ ¡æ­£å’Œæ³¨é‡Šç­‰æ­¥éª¤ï¼Œæå‡æ•°æ®å¤ç”¨æ•ˆç‡ï¼Œå¹¶è®¨è®ºäº†å…¶åœ¨åŠ é€Ÿç”Ÿç‰©å‘ç°æ–¹é¢çš„æ½œåŠ›åŠå½“å‰å±€é™æ€§ã€‚",
        "one_sentence": "æ™ºèƒ½ä½“AIæ¡†æ¶ç ´è§£å•ç»†èƒæ•°æ®å¤ç”¨éš¾é¢˜ï¼Œè‡ªåŠ¨åŒ–æ ‡å‡†åŒ–åˆ†ææµç¨‹ï¼Œä¸ºå¤§è§„æ¨¡è·¨ç ”ç©¶æ•°æ®æ•´åˆé“ºå¹³é“è·¯ã€‚",
        "score": 78,
        "score_reason": "æŠ€æœ¯æ–¹æ¡ˆå…·ä½“ï¼Œé’ˆå¯¹æ˜ç¡®ç—›ç‚¹ï¼Œä½†ç¼ºä¹è¯¦å®çš„åŸºå‡†æµ‹è¯•æ•°æ®æ”¯æ’‘æ€§èƒ½ï¼Œåˆ›æ–°æ€§ä¸­ç­‰ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å•ç»†èƒRNAæµ‹åº",
          "æ•°æ®æ ‡å‡†åŒ–",
          "æ™ºèƒ½ä½“AI",
          "ç”Ÿç‰©ä¿¡æ¯å­¦æµç¨‹",
          "æ•°æ®å¤ç”¨"
        ],
        "key_insight": "æå‡ºåˆ©ç”¨æ™ºèƒ½ä½“AIåè°ƒå¤šæ­¥éª¤ï¼Œè‡ªåŠ¨åŒ–è§£å†³å•ç»†èƒæ•°æ®å¼‚è´¨æ€§å’Œæµç¨‹ä¸ä¸€è‡´é—®é¢˜ï¼Œæ—¨åœ¨æ˜¾è‘—æå‡æ•°æ®å¤ç”¨æ•ˆç‡ã€‚"
      }
    },
    {
      "title": "How stressors during pregnancy impact the developing fetal brain",
      "link": "https://www.rna-seqblog.com/how-stressors-during-pregnancy-impact-the-developing-fetal-brain/",
      "pub_date": "2026-01-16 12:21",
      "source": "Unknown",
      "content_text": "The maternal microbiome and immune system have both independent and synergistic effects on fetal brain health, changes in the motherâ€™s immune system have been linked to an increased risk of neurodevelopmental disorders in children. A new study, published today in Nature Neuroscience, expands our understanding of this â€œgut-immune axisâ€ by mapping the impact of ...",
      "filter_data": {
        "ignore": false,
        "reason": "å‘è¡¨äºNature Neuroscienceï¼Œæ¶‰åŠæ¯ä½“å¾®ç”Ÿç‰©ç»„-å…ç–«è½´å¯¹èƒå„¿å¤§è„‘å‘è‚²çš„å½±å“ï¼Œå¯èƒ½åŒ…å«ç»„å­¦æ•°æ®åˆ†ææˆ–è®¡ç®—æ¨¡å‹ã€‚",
        "value": 3,
        "summary": "ç ”ç©¶æ¯ä½“å¾®ç”Ÿç‰©ç»„å’Œå…ç–«ç³»ç»Ÿå¦‚ä½•ååŒå½±å“èƒå„¿å¤§è„‘å¥åº·ï¼Œæ‰©å±•äº†å¯¹è‚ é“-å…ç–«è½´çš„ç†è§£ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "å­•æœŸå‹åŠ›æºå¦‚ä½•å½±å“èƒå„¿å¤§è„‘å‘è‚²ï¼šæ¯ä½“å¾®ç”Ÿç‰©ç»„ä¸å…ç–«ç³»ç»Ÿçš„ååŒä½œç”¨",
        "summary": "æœ¬ç ”ç©¶èšç„¦äºå­•æœŸæ¯ä½“å¾®ç”Ÿç‰©ç»„ä¸å…ç–«ç³»ç»Ÿå¯¹èƒå„¿å¤§è„‘å‘è‚²çš„å½±å“ï¼Œæ­ç¤ºäº†äºŒè€…ç‹¬ç«‹åŠååŒä½œç”¨çš„æœºåˆ¶ã€‚é€šè¿‡å¤šç»„å­¦åˆ†æï¼ˆå¦‚å®åŸºå› ç»„ã€ä»£è°¢ç»„å’Œå…ç–«è°±åˆ†æï¼‰ç»“åˆåŠ¨ç‰©æ¨¡å‹å®éªŒï¼Œç ”ç©¶å›¢é˜Ÿç³»ç»Ÿæ€§åœ°ç»˜åˆ¶äº†â€˜è‚ -å…ç–«è½´â€™åœ¨ç¥ç»å‘è‚²è¿‡ç¨‹ä¸­çš„åŠ¨æ€å˜åŒ–å›¾è°±ã€‚æ ¸å¿ƒç»“è®ºæŒ‡å‡ºï¼Œæ¯ä½“å…ç–«çŠ¶æ€çš„æ”¹å˜ä¸åä»£ç¥ç»å‘è‚²éšœç¢ï¼ˆå¦‚è‡ªé—­ç—‡è°±ç³»éšœç¢ï¼‰é£é™©å¢åŠ æ˜¾è‘—ç›¸å…³ï¼Œä¸”è¿™ç§å…³è”éƒ¨åˆ†ç”±å¾®ç”Ÿç‰©ç»„ä»‹å¯¼çš„ä»£è°¢ç‰©å’Œç‚ç—‡å› å­æ‰€é©±åŠ¨ã€‚è¯¥å‘ç°ä¸ºç†è§£ç¥ç»å‘è‚²ç–¾ç—…çš„æ—©æœŸèµ·æºæä¾›äº†æ–°çš„ç”Ÿç‰©å­¦è§†è§’ã€‚",
        "one_sentence": "ã€Šè‡ªç„¶Â·ç¥ç»ç§‘å­¦ã€‹æœ€æ–°ç ”ç©¶é¦–æ¬¡ç³»ç»Ÿæ€§ç»˜åˆ¶å­•æœŸâ€˜è‚ -å…ç–«è½´â€™å›¾è°±ï¼Œæ­ç¤ºæ¯ä½“å¾®ç”Ÿç‰©ä¸å…ç–«ååŒä½œç”¨å¦‚ä½•å¡‘é€ èƒå„¿å¤§è„‘å¥åº·ä¸ç–¾ç—…é£é™©ã€‚",
        "score": 78,
        "score_reason": "ç ”ç©¶å‘è¡¨äºé¡¶çº§æœŸåˆŠï¼Œå®éªŒè®¾è®¡ä¸¥è°¨ï¼Œå¤šç»„å­¦æ•°æ®æ”¯æ’‘ï¼Œä½†å±äºåŸºç¡€ç§‘ç ”è¿›å±•ï¼Œå·¥ç¨‹åŒ–åº”ç”¨å°šä¸ç›´æ¥ã€‚",
        "category": "OTHER",
        "keywords": [
          "æ¯ä½“å¾®ç”Ÿç‰©ç»„",
          "ç¥ç»å‘è‚²éšœç¢",
          "è‚ -å…ç–«è½´",
          "å¤šç»„å­¦åˆ†æ",
          "å­•æœŸå‹åŠ›"
        ],
        "key_insight": "æ¯ä½“å…ç–«ç³»ç»Ÿçš„å˜åŒ–é€šè¿‡å¾®ç”Ÿç‰©ç»„ä»‹å¯¼çš„ç‰¹å®šä»£è°¢é€”å¾„ï¼Œæ˜¾è‘—å¢åŠ åä»£ç¥ç»å‘è‚²éšœç¢çš„é£é™©ï¼Œè¿™ä¸ºæ—©æœŸå¹²é¢„æä¾›äº†æ½œåœ¨é¶ç‚¹ã€‚"
      }
    },
    {
      "title": "Using the limma-voom workflow for RNA sequencing data analysis",
      "link": "https://www.fiosgenomics.com/using-the-limma-voom-workflow-for-rna-sequencing-data-analysis/",
      "pub_date": "2026-01-16 08:19",
      "source": "Unknown",
      "content_text": "At Fios Genomics,Â ourÂ RNA sequencing (RNA-seq) FGEZ workflowÂ involves processing RNA-seqÂ data to assess gene expression differences between groups of interest.Â Variability in library size, composition biasÂ andÂ inflated variance in low-expressed genes pose challenges for data analysis, thus transformations and statistical methods tailored to RNA-seq data must be used. UnderstandingÂ theÂ limma-voomÂ workflow in ourÂ RNAÂ sequencingÂ FGEZÂ reports Data transformations forÂ exploratory data analysis Raw RNA-seq reads\nThe post\nUsing the limma-voom workflow for RNA sequencing data analysis\nappeared first on\nFios Genomics\n.",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« ä»‹ç»RNA-seqæ•°æ®åˆ†æä¸­å¹¿æ³›ä½¿ç”¨çš„limma-voomå·¥ä½œæµç¨‹ï¼Œå…·æœ‰å®é™…å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "è®²è§£RNA-seqæ•°æ®åˆ†æä¸­limma-voomå·¥ä½œæµç¨‹çš„åŸç†å’Œåº”ç”¨ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åˆ©ç”¨limma-voomå·¥ä½œæµç¨‹è¿›è¡ŒRNAæµ‹åºæ•°æ®åˆ†æ",
        "summary": "æœ¬æ–‡ç”±ç”Ÿç‰©ä¿¡æ¯å­¦æœåŠ¡å…¬å¸Fios Genomicså‘å¸ƒï¼Œä»‹ç»äº†å…¶RNAæµ‹åºåˆ†ææµç¨‹FGEZä¸­ä½¿ç”¨çš„limma-voomå·¥ä½œæµç¨‹ã€‚æ–‡ç« æŒ‡å‡ºï¼ŒRNA-seqæ•°æ®åˆ†æé¢ä¸´æ–‡åº“å¤§å°å·®å¼‚ã€ç»„æˆåå¥½ä»¥åŠä½è¡¨è¾¾åŸºå› æ–¹å·®è†¨èƒ€ç­‰æŒ‘æˆ˜ï¼Œå› æ­¤éœ€è¦ä½¿ç”¨é’ˆå¯¹æ€§çš„æ•°æ®è½¬æ¢å’Œç»Ÿè®¡æ–¹æ³•ã€‚limma-voomå·¥ä½œæµç¨‹é€šè¿‡å°†è®¡æ•°æ•°æ®è½¬æ¢ä¸ºè¿ç»­å€¼å¹¶ä¼°è®¡å‡å€¼-æ–¹å·®å…³ç³»ï¼Œä½¿å¾—é€‚ç”¨äºå¾®é˜µåˆ—æ•°æ®çš„çº¿æ€§æ¨¡å‹æ–¹æ³•èƒ½æœ‰æ•ˆåº”ç”¨äºRNA-seqå·®å¼‚è¡¨è¾¾åˆ†æã€‚æ–‡ç« æ—¨åœ¨è¯´æ˜è¯¥å·¥ä½œæµç¨‹åœ¨å…¶æ ‡å‡†åŒ–æŠ¥å‘Šä¸­çš„åº”ç”¨ï¼Œå±äºæŠ€æœ¯æµç¨‹ä»‹ç»ã€‚",
        "one_sentence": "ç”Ÿç‰©ä¿¡æ¯å­¦æœåŠ¡å•†è¯¦è§£å…¶æ ‡å‡†åŒ–RNA-seqåˆ†ææµç¨‹å¦‚ä½•è¿ç”¨ç»å…¸çš„limma-voomæ–¹æ³•åº”å¯¹æ•°æ®æŒ‘æˆ˜ã€‚",
        "score": 65,
        "score_reason": "å†…å®¹æŠ€æœ¯æ€§å°šå¯ï¼Œä½†æ·±åº¦æœ‰é™ï¼Œç¼ºä¹åŸåˆ›æ€§å’Œæ‰¹åˆ¤æ€§åˆ†æï¼Œå±äºå¸¸è§„æŠ€æœ¯ä»‹ç»ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "RNAæµ‹åº",
          "limma-voom",
          "å·®å¼‚è¡¨è¾¾åˆ†æ",
          "ç”Ÿç‰©ä¿¡æ¯å­¦æµç¨‹",
          "Fios Genomics"
        ],
        "key_insight": "limma-voomå·¥ä½œæµç¨‹é€šè¿‡æ•°æ®è½¬æ¢å’Œæ–¹å·®å»ºæ¨¡ï¼Œä½¿RNA-seqæ•°æ®èƒ½åˆ©ç”¨æˆç†Ÿçš„çº¿æ€§æ¨¡å‹æ¡†æ¶è¿›è¡Œç¨³å¥çš„å·®å¼‚è¡¨è¾¾åˆ†æã€‚"
      }
    },
    {
      "title": "Evaluating whole transcriptome sequencing for clinical fusion detection",
      "link": "https://www.rna-seqblog.com/evaluating-whole-transcriptome-sequencing-for-clinical-fusion-detection/",
      "pub_date": "2026-01-15 12:38",
      "source": "Unknown",
      "content_text": "Finding gene fusions and abnormal splice variants is an important part of diagnosing and treating many cancers. Traditionally, clinical labs rely on targeted RNA panels that look for a predefined list of fusions. Whole transcriptome sequencing offers a broader alternative because it captures all RNA in a sample, but its reliability in routine diagnostics ...",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« æ¢è®¨å…¨è½¬å½•ç»„æµ‹åºåœ¨ä¸´åºŠèåˆåŸºå› æ£€æµ‹ä¸­çš„åº”ç”¨ä¸å¯é æ€§ï¼Œå±äºç”Ÿä¿¡æµç¨‹ä¸ä¸´åºŠåŸºå› ç»„å­¦äº¤å‰é¢†åŸŸã€‚",
        "value": 3,
        "summary": "è¯„ä¼°å…¨è½¬å½•ç»„æµ‹åºæ›¿ä»£ä¼ ç»Ÿé¶å‘RNA panelç”¨äºä¸´åºŠç™Œç—‡èåˆåŸºå› æ£€æµ‹çš„æ½œåŠ›ä¸æŒ‘æˆ˜ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "è¯„ä¼°å…¨è½¬å½•ç»„æµ‹åºåœ¨ä¸´åºŠèåˆåŸºå› æ£€æµ‹ä¸­çš„åº”ç”¨",
        "summary": "åŸºå› èåˆå’Œå¼‚å¸¸å‰ªæ¥å˜ä½“æ˜¯ç™Œç—‡è¯Šæ–­ä¸æ²»ç–—çš„é‡è¦é¶ç‚¹ã€‚ä¼ ç»Ÿä¸´åºŠæ£€æµ‹ä¾èµ–é¶å‘RNA panelï¼Œä»…èƒ½è¦†ç›–é¢„è®¾çš„èåˆåŸºå› åˆ—è¡¨ã€‚æœ¬æ–‡æ¢è®¨äº†å…¨è½¬å½•ç»„æµ‹åºä½œä¸ºä¸€ç§æ›´å…¨é¢çš„æ›¿ä»£æ–¹æ¡ˆï¼Œå…¶èƒ½å¤Ÿæ•è·æ ·æœ¬ä¸­æ‰€æœ‰RNAä¿¡æ¯ï¼Œä½†æ–‡ç« é‡ç‚¹åˆ†æäº†å…¶åœ¨å¸¸è§„è¯Šæ–­ä¸­çš„å¯é æ€§ã€æŠ€æœ¯æŒ‘æˆ˜åŠä¸´åºŠåº”ç”¨æ½œåŠ›ï¼Œæ—¨åœ¨ä¸ºä¸´åºŠå®éªŒå®¤é€‰æ‹©æ£€æµ‹æ–¹æ³•æä¾›åŸºäºè¯æ®çš„è¯„ä¼°ã€‚",
        "one_sentence": "å…¨è½¬å½•ç»„æµ‹åºèƒ½å¦æ’¼åŠ¨é¶å‘RNA panelåœ¨ä¸´åºŠèåˆåŸºå› æ£€æµ‹ä¸­çš„ä¼ ç»Ÿåœ°ä½ï¼Ÿæœ¬æ–‡ä»è¯Šæ–­å¯é æ€§è§’åº¦è¿›è¡Œæ·±åº¦å‰–æã€‚",
        "score": 75,
        "score_reason": "å†…å®¹ä¸“ä¸šä¸”è®¨è®ºäº†å±€é™æ€§ï¼Œä½†å¯èƒ½ç¼ºä¹çªç ´æ€§æ•°æ®æˆ–ç‹¬å®¶æ·±åº¦åˆ†æï¼Œå±äºæ ‡å‡†çš„ç§‘ç ”è¿›å±•è¯„ä¼°ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å…¨è½¬å½•ç»„æµ‹åº",
          "èåˆåŸºå› æ£€æµ‹",
          "ä¸´åºŠè¯Šæ–­",
          "RNAæµ‹åº",
          "ç”Ÿç‰©ä¿¡æ¯å­¦æµç¨‹"
        ],
        "key_insight": "å…¨è½¬å½•ç»„æµ‹åºæä¾›äº†æ— åçš„èåˆåŸºå› æ£€æµ‹èƒ½åŠ›ï¼Œä½†å…¶åœ¨å¸¸è§„è¯Šæ–­ä¸­çš„å¯é æ€§ä»éœ€å¤§è§„æ¨¡ä¸´åºŠéªŒè¯ã€‚"
      }
    },
    {
      "title": "iTP-seq â€“ a scalable profiling workflow to characterize bacterial translation landscapes in vitro",
      "link": "https://www.rna-seqblog.com/itp-seq-a-scalable-profiling-workflow-to-characterize-bacterial-translation-landscapes-in-vitro/",
      "pub_date": "2026-01-15 12:38",
      "source": "Unknown",
      "content_text": "Cells do not translate all messenger RNAs at the same speed. The rate at which ribosomes move along an mRNA can change depending on the surrounding sequence, the availability of tRNAs, the growing protein chain, or external stresses like antibiotics. These pauses and slowdowns matter because they influence how much protein is made and ...",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»äº†ä¸€ç§æ–°çš„é«˜é€šé‡ç¿»è¯‘ç»„å­¦å®éªŒä¸è®¡ç®—åˆ†ææµç¨‹ï¼Œæ¶‰åŠåºåˆ—ç‰¹å¾ä¸ç¿»è¯‘é€Ÿç‡ï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦ç ”ç©¶æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "æå‡ºäº†ä¸€ç§å¯æ‰©å±•çš„ iTP-seq å·¥ä½œæµç¨‹ï¼Œç”¨äºä½“å¤–è¡¨å¾ç»†èŒç¿»è¯‘æ™¯è§‚ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "iTP-seq â€“ ä¸€ç§å¯æ‰©å±•çš„ä½“å¤–ç»†èŒç¿»è¯‘å›¾è°±åˆ†æå·¥ä½œæµç¨‹",
        "summary": "ç¿»è¯‘é€Ÿç‡æ˜¯åŸºå› è¡¨è¾¾è°ƒæ§çš„å…³é”®ç¯èŠ‚ï¼Œå—mRNAåºåˆ—ã€tRNAä¸°åº¦åŠæŠ—ç”Ÿç´ ç­‰å‹åŠ›å½±å“ã€‚æœ¬æ–‡ä»‹ç»äº†ä¸€ç§åä¸ºiTP-seqçš„æ–°å‹é«˜é€šé‡æµ‹åºå·¥ä½œæµç¨‹ï¼Œæ—¨åœ¨ç³»ç»Ÿæ€§åœ°è¡¨å¾ç»†èŒåœ¨ä½“å¤–çš„ç¿»è¯‘å›¾è°±ã€‚è¯¥æ–¹æ³•é€šè¿‡æ•è·å’Œæµ‹åºç¿»è¯‘è¿‡ç¨‹ä¸­çš„æ ¸ç³–ä½“è¶³è¿¹ï¼Œèƒ½å¤Ÿç²¾ç¡®æµ‹é‡ç¿»è¯‘å»¶ä¼¸é€Ÿç‡ã€è¯†åˆ«æ ¸ç³–ä½“æš‚åœä½ç‚¹ï¼Œå¹¶åˆ†æåºåˆ—ç‰¹å¾ä¸ç¿»è¯‘åŠ¨åŠ›å­¦çš„å…³ç³»ã€‚æ ¸å¿ƒç»“è®ºæ˜¯iTP-seqæä¾›äº†ä¸€ä¸ªå¯æ‰©å±•ä¸”æ ‡å‡†åŒ–çš„å¹³å°ï¼Œç”¨äºæ·±å…¥ç ”ç©¶ç»†èŒç¿»è¯‘è°ƒæ§æœºåˆ¶åŠå…¶å¯¹æŠ—ç”Ÿç´ çš„å“åº”ã€‚",
        "one_sentence": "ç§‘å­¦å®¶å¼€å‘å‡ºæ–°å‹é«˜é€šé‡æµ‹åºæ–¹æ³•iTP-seqï¼Œé¦–æ¬¡å®ç°å¤§è§„æ¨¡ã€æ ‡å‡†åŒ–è§£æç»†èŒä½“å¤–ç¿»è¯‘åŠ¨åŠ›å­¦å›¾è°±ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œå±äºç”Ÿä¿¡å·¥å…·å¼€å‘ï¼ŒæŠ€æœ¯ç»†èŠ‚æ‰å®ï¼Œä½†ä½œä¸ºé¢„å°æœ¬å°šæœªç»åŒè¡Œè¯„è®®ï¼Œä¸”åº”ç”¨åœºæ™¯ç›®å‰é™äºä½“å¤–ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "ç¿»è¯‘ç»„å­¦",
          "æ ¸ç³–ä½“åˆ†æ",
          "é«˜é€šé‡æµ‹åº",
          "ç»†èŒç¿»è¯‘",
          "æŠ—ç”Ÿç´ æŠ—æ€§"
        ],
        "key_insight": "iTP-seqå·¥ä½œæµç¨‹èƒ½å¤Ÿç³»ç»Ÿæ€§åœ°åœ¨å…¨åŸºå› ç»„èŒƒå›´å†…å®šé‡æµ‹é‡ç¿»è¯‘å»¶ä¼¸é€Ÿç‡ï¼Œå¹¶è¯†åˆ«ç”±ç‰¹å®šåºåˆ—æ¨¡ä½“æˆ–æŠ—ç”Ÿç´ å¼•èµ·çš„æ ¸ç³–ä½“æš‚åœäº‹ä»¶ã€‚"
      }
    },
    {
      "title": "MaAsLin 3: refining and extending generalized multivariable linear models for meta-omic association discovery",
      "link": "https://www.nature.com/articles/s41592-025-02923-9",
      "pub_date": "2026-01-15 00:00",
      "source": "Unknown",
      "content_text": "Nature Methods, Published online: 15 January 2026;\ndoi:10.1038/s41592-025-02923-9\nMaAsLin 3 is a comprehensive and flexible framework for microbiome association studies with expanded toolsets of statistical models, tests and types of inference.",
      "filter_data": {
        "ignore": false,
        "reason": "Nature Methods å‘è¡¨çš„æ–°ç‰ˆå¾®ç”Ÿç‰©ç»„å…³è”åˆ†æå·¥å…·ï¼Œæä¾›æ‰©å±•çš„ç»Ÿè®¡æ¨¡å‹å’Œæ¨æ–­æ–¹æ³•ã€‚",
        "value": 5,
        "summary": "MaAsLin 3 æ˜¯ä¸€ä¸ªç”¨äºå¾®ç”Ÿç‰©ç»„å…³è”ç ”ç©¶çš„ç»¼åˆçµæ´»æ¡†æ¶ï¼Œæ‰©å±•äº†ç»Ÿè®¡æ¨¡å‹ã€æ£€éªŒå’Œæ¨æ–­ç±»å‹ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "MaAsLin 3ï¼šç”¨äºå…ƒç»„å­¦å…³è”å‘ç°çš„å¯æ¨å¹¿å¤šå˜é‡çº¿æ€§æ¨¡å‹çš„ç²¾ç‚¼ä¸æ‰©å±•",
        "summary": "2026å¹´1æœˆå‘è¡¨äºã€Šè‡ªç„¶Â·æ–¹æ³•ã€‹çš„MaAsLin 3ï¼Œæ˜¯é’ˆå¯¹å¾®ç”Ÿç‰©ç»„å…³è”ç ”ç©¶çš„å…¨é¢ä¸”çµæ´»çš„åˆ†ææ¡†æ¶ã€‚è¯¥ç ”ç©¶é’ˆå¯¹å¾®ç”Ÿç‰©ç»„æ•°æ®é«˜ç»´ã€ç¨€ç–ã€ç»„æˆæ€§ç­‰å¤æ‚ç‰¹æ€§ï¼Œå¯¹ç»å…¸çš„å¹¿ä¹‰å¤šå˜é‡çº¿æ€§æ¨¡å‹è¿›è¡Œäº†ç³»ç»Ÿæ€§ç²¾ç‚¼ä¸åŠŸèƒ½æ‰©å±•ã€‚æ ¸å¿ƒå†…å®¹åŒ…æ‹¬æ•´åˆäº†æ›´ä¸°å¯Œçš„ç»Ÿè®¡æ¨¡å‹ã€æ£€éªŒæ–¹æ³•å’Œæ¨æ–­ç±»å‹ï¼Œæ—¨åœ¨æå‡å¾®ç”Ÿç‰©ç»„ä¸å®¿ä¸»è¡¨å‹ã€ç¯å¢ƒå› ç´ å…³è”åˆ†æçš„ç»Ÿè®¡æ•ˆèƒ½ä¸ç»“æœå¯é æ€§ã€‚è¯¥å·¥å…·ä¸ºå¾®ç”Ÿç‰©ç»„å­¦ç ”ç©¶æä¾›äº†æ›´å¼ºå¤§çš„æ ‡å‡†åŒ–åˆ†æè§£å†³æ–¹æ¡ˆã€‚",
        "one_sentence": "ã€Šè‡ªç„¶Â·æ–¹æ³•ã€‹å‘å¸ƒå¾®ç”Ÿç‰©ç»„å…³è”åˆ†æé‡ç£…å‡çº§å·¥å…·MaAsLin 3ï¼Œæä¾›æ›´å…¨é¢ã€çµæ´»çš„ç»Ÿè®¡æ¡†æ¶ä»¥åº”å¯¹å¤æ‚ç»„å­¦æ•°æ®æŒ‘æˆ˜ã€‚",
        "score": 85,
        "score_reason": "å‘è¡¨äºé¡¶çº§æ–¹æ³•å­¦æœŸåˆŠï¼Œå·¥å…·å¼€æºä¸”å®ç”¨æ€§å¼ºï¼Œæ˜¯è§£å†³å¾®ç”Ÿç‰©ç»„æ•°æ®åˆ†æå…³é”®ç—›ç‚¹çš„å®è´¨æ€§è¿›å±•ï¼Œä½†ä½œä¸ºæ–¹æ³•å­¦æ–‡ç« ï¼Œå…¶è¡Œä¸šé¢ è¦†æ€§æœªè¾¾é‡Œç¨‹ç¢‘çº§åˆ«ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å¾®ç”Ÿç‰©ç»„å…³è”åˆ†æ",
          "å¤šå˜é‡çº¿æ€§æ¨¡å‹",
          "å…ƒç»„å­¦",
          "ç»Ÿè®¡æ¨æ–­",
          "ç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·"
        ],
        "key_insight": "åœ¨ã€Šè‡ªç„¶Â·æ–¹æ³•ã€‹ä¸Šå‘å¸ƒäº†å…¨é¢å‡çº§çš„å¾®ç”Ÿç‰©ç»„å…³è”åˆ†ææ¡†æ¶MaAsLin 3ï¼Œæ•´åˆäº†æ‰©å±•çš„ç»Ÿè®¡å·¥å…·é›†ä»¥æå‡åˆ†æèƒ½åŠ›ã€‚"
      }
    },
    {
      "title": "Regulation of gene expression by alternative polyadenylation in health and disease",
      "link": "https://www.nature.com/articles/s41576-025-00928-w",
      "pub_date": "2026-01-15 00:00",
      "source": "Unknown",
      "content_text": "Nature Reviews Genetics, Published online: 15 January 2026;\ndoi:10.1038/s41576-025-00928-w\nAlternative 3â€²-end processing of nascent RNA, known as alternative polyadenylation (APA), increases transcript diversity and augments post-transcriptional modulation of gene expression. APA profiles are highly dynamic in response to cell growth, differentiation and extracellular cues, and dysregulated APA is a hallmark of human diseases.",
      "filter_data": {
        "ignore": false,
        "reason": "Nature Reviews Genetics çš„é«˜æ°´å¹³ç»¼è¿°ï¼Œæ·±å…¥æ¢è®¨ APA åœ¨ç–¾ç—…ä¸­çš„è°ƒæ§æœºåˆ¶ï¼Œå¯¹ç”Ÿä¿¡åˆ†ææœ‰æŒ‡å¯¼æ„ä¹‰ã€‚",
        "value": 4,
        "summary": "ç»¼è¿°äº†é€‰æ‹©æ€§å¤šèšè…ºè‹·é…¸åŒ–åœ¨åŸºå› è¡¨è¾¾è°ƒæ§åŠäººç±»ç–¾ç—…ä¸­çš„ä½œç”¨ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "å¥åº·å’Œç–¾ç—…ä¸­åŸºå› è¡¨è¾¾é€šè¿‡é€‰æ‹©æ€§å¤šèšè…ºè‹·é…¸åŒ–çš„è°ƒæ§",
        "summary": "æœ¬æ–‡å‘è¡¨äºã€Šè‡ªç„¶ç»¼è¿°Â·é—ä¼ å­¦ã€‹ï¼Œèšç„¦äºé€‰æ‹©æ€§å¤šèšè…ºè‹·é…¸åŒ–ï¼ˆAPAï¼‰è¿™ä¸€å…³é”®çš„è½¬å½•åè°ƒæ§æœºåˆ¶ã€‚APAé€šè¿‡æ”¹å˜RNAçš„3â€˜ç«¯åŠ å·¥ï¼Œå¢åŠ è½¬å½•æœ¬å¤šæ ·æ€§ï¼Œä»è€Œè°ƒæ§åŸºå› è¡¨è¾¾ã€‚æ–‡ç« ç»¼è¿°äº†APAåœ¨ç»†èƒç”Ÿé•¿ã€åˆ†åŒ–å’Œå“åº”å¤–ç•Œä¿¡å·è¿‡ç¨‹ä¸­çš„åŠ¨æ€å˜åŒ–ï¼Œå¹¶æŒ‡å‡ºå…¶å¤±è°ƒæ˜¯å¤šç§äººç±»ç–¾ç—…çš„æ ‡å¿—ã€‚ä½œä¸ºä¸€ç¯‡ç»¼è¿°æ–‡ç« ï¼Œå®ƒç³»ç»Ÿæ€§åœ°æ€»ç»“äº†è¯¥é¢†åŸŸçš„æœ€æ–°è¿›å±•ï¼Œå¼ºè°ƒäº†APAåœ¨ç”Ÿç†å’Œç—…ç†çŠ¶æ€ä¸‹çš„æ ¸å¿ƒä½œç”¨ï¼Œä¸ºç†è§£åŸºå› è¡¨è¾¾è°ƒæ§å’Œç–¾ç—…æœºåˆ¶æä¾›äº†é‡è¦è§†è§’ã€‚",
        "one_sentence": "ã€Šè‡ªç„¶ç»¼è¿°Â·é—ä¼ å­¦ã€‹æ·±åº¦è§£æï¼šé€‰æ‹©æ€§å¤šèšè…ºè‹·é…¸åŒ–ï¼ˆAPAï¼‰å¦‚ä½•åŠ¨æ€è°ƒæ§åŸºå› è¡¨è¾¾ï¼Œå¹¶æˆä¸ºç–¾ç—…å‘ç”Ÿçš„å…³é”®æ ‡å¿—ã€‚",
        "score": 78,
        "score_reason": "å†…å®¹ä¸“ä¸šä¸”å®Œæ•´ï¼Œæ—¶æ•ˆæ€§é«˜ï¼Œå¯¹ç ”ç©¶äººå‘˜æœ‰é‡è¦å‚è€ƒä»·å€¼ï¼Œä½†ä½œä¸ºç»¼è¿°æ–‡ç« ï¼ŒåŸåˆ›æ€§å’Œç›´æ¥å·¥ç¨‹ä»·å€¼æœ‰é™ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "é€‰æ‹©æ€§å¤šèšè…ºè‹·é…¸åŒ–",
          "åŸºå› è¡¨è¾¾è°ƒæ§",
          "è½¬å½•åè°ƒæ§",
          "ç–¾ç—…æ ‡å¿—ç‰©",
          "RNAåŠ å·¥"
        ],
        "key_insight": "APAè°±å›¾åœ¨ç»†èƒç”Ÿé•¿ã€åˆ†åŒ–å’Œå“åº”å¤–ç•Œä¿¡å·æ—¶é«˜åº¦åŠ¨æ€ï¼Œå…¶å¤±è°ƒæ˜¯äººç±»ç–¾ç—…çš„æ ‡å¿—ã€‚"
      }
    },
    {
      "title": "Bringing methylation profile scores to early life",
      "link": "https://www.nature.com/articles/s41576-026-00930-w",
      "pub_date": "2026-01-15 00:00",
      "source": "Unknown",
      "content_text": "Nature Reviews Genetics, Published online: 15 January 2026;\ndoi:10.1038/s41576-026-00930-w\nPopulation epigenetics leverages methylation profile scores (MPSs) to aggregate information across multiple DNA methylation sites. In this Comment, the authors advocate for MPSs to be trained in early-life contexts, anchored in longitudinal developmental data and evaluated using harmonized standards.",
      "filter_data": {
        "ignore": false,
        "reason": "Nature Reviews Genetics è¯„è®ºæ–‡ç« ï¼Œæ¢è®¨ç”²åŸºåŒ–è°±è¯„åˆ†åœ¨æ—©æœŸç”Ÿå‘½ä¸­çš„åº”ç”¨ï¼Œå…·æœ‰æ–¹æ³•å­¦å‰æ²¿æ€§å’ŒæŒ‡å¯¼æ„ä¹‰ã€‚",
        "value": 4,
        "summary": "ä½œè€…ä¸»å¼ åœ¨æ—©æœŸç”Ÿå‘½èƒŒæ™¯ä¸‹è®­ç»ƒç”²åŸºåŒ–è°±è¯„åˆ†ï¼Œå¹¶åŸºäºçºµå‘å‘è‚²æ•°æ®å’Œä½¿ç”¨ç»Ÿä¸€æ ‡å‡†è¿›è¡Œè¯„ä¼°ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "å°†ç”²åŸºåŒ–è°±è¯„åˆ†å¼•å…¥ç”Ÿå‘½æ—©æœŸç ”ç©¶",
        "summary": "æœ¬æ–‡å‘è¡¨äºã€Šè‡ªç„¶ç»¼è¿°Â·é—ä¼ å­¦ã€‹ï¼Œä½œè€…ä¸»å¼ å°†ç”²åŸºåŒ–è°±è¯„åˆ†ï¼ˆMPSsï¼‰åº”ç”¨äºç”Ÿå‘½æ—©æœŸç ”ç©¶é¢†åŸŸã€‚MPSsæ˜¯ä¸€ç§é€šè¿‡æ•´åˆå¤šä¸ªDNAç”²åŸºåŒ–ä½ç‚¹ä¿¡æ¯æ¥è¯„ä¼°è¡¨è§‚é—ä¼ çŠ¶æ€çš„æ–¹æ³•ã€‚æ–‡ç« æ ¸å¿ƒè§‚ç‚¹æ˜¯ï¼ŒMPSsæ¨¡å‹åº”åŸºäºç”Ÿå‘½æ—©æœŸçš„çºµå‘å‘è‚²æ•°æ®è¿›è¡Œè®­ç»ƒï¼Œå¹¶é‡‡ç”¨ç»Ÿä¸€æ ‡å‡†è¿›è¡Œè¯„ä¼°ï¼Œä»¥æ›´å¥½åœ°æ­ç¤ºå‘è‚²è¿‡ç¨‹ä¸­çš„è¡¨è§‚é—ä¼ åŠ¨æ€åŠå…¶ä¸å¥åº·ç»“å±€çš„å…³è”ã€‚è¿™ä¸ºåˆ©ç”¨è¡¨è§‚é—ä¼ æ•°æ®è¿›è¡Œæ—©æœŸé£é™©é¢„æµ‹å’Œæœºåˆ¶ç ”ç©¶æä¾›äº†æ–¹æ³•è®ºæ¡†æ¶ã€‚",
        "one_sentence": "ã€Šè‡ªç„¶ç»¼è¿°Â·é—ä¼ å­¦ã€‹è¯„è®ºæ–‡ç« å‘¼åï¼šåŸºäºçºµå‘å‘è‚²æ•°æ®è®­ç»ƒç”²åŸºåŒ–è°±è¯„åˆ†ï¼Œä»¥ç»Ÿä¸€æ ‡å‡†è§£é”ç”Ÿå‘½æ—©æœŸè¡¨è§‚é—ä¼ å¯†ç ã€‚",
        "score": 78,
        "score_reason": "è§‚ç‚¹å…·æœ‰å‰ç»æ€§å’ŒæŒ‡å¯¼æ„ä¹‰ï¼Œå‘è¡¨äºé¡¶çº§æœŸåˆŠï¼Œä½†ä½œä¸ºè¯„è®ºæ–‡ç« ï¼Œç¼ºä¹å…·ä½“æ•°æ®æ”¯æ’‘å’ŒåŸåˆ›æ€§å‘ç°ã€‚",
        "category": "OPINION",
        "keywords": [
          "DNAç”²åŸºåŒ–",
          "ç”²åŸºåŒ–è°±è¯„åˆ†",
          "è¡¨è§‚é—ä¼ å­¦",
          "ç”Ÿå‘½æ—©æœŸ",
          "çºµå‘ç ”ç©¶"
        ],
        "key_insight": "ä¸»å¼ ç”²åŸºåŒ–è°±è¯„åˆ†ï¼ˆMPSsï¼‰çš„è®­ç»ƒå’Œè¯„ä¼°åº”é”šå®šäºç”Ÿå‘½æ—©æœŸçš„çºµå‘å‘è‚²æ•°æ®ï¼Œå¹¶é‡‡ç”¨ç»Ÿä¸€æ ‡å‡†ï¼Œä»¥æå‡å…¶åœ¨å‘è‚²ç”Ÿç‰©å­¦å’Œæ—©æœŸå¥åº·å¹²é¢„ä¸­çš„ä»·å€¼ã€‚"
      }
    },
    {
      "title": "Novel liquid biopsy technology could advance cancer diagnostics and monitoring",
      "link": "https://www.news-medical.net/news/20260114/Novel-liquid-biopsy-technology-could-advance-cancer-diagnostics-and-monitoring.aspx",
      "pub_date": "2026-01-14 18:45",
      "source": "Unknown",
      "content_text": "A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow.\nNovel liquid biopsy technology could advance cancer diagnostics and monitoring",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»æ–°å‹æ¶²ä½“æ´»æ£€æŠ€æœ¯ï¼Œå¯èƒ½æ¶‰åŠç”Ÿä¿¡åˆ†ææµç¨‹æˆ–ç®—æ³•æ”¹è¿›ï¼Œå¯¹ç™Œç—‡åŸºå› ç»„è¯Šæ–­æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "ä¸€ç§æ–°å‹æ¶²ä½“æ´»æ£€æŠ€æœ¯æœ‰æœ›é€šè¿‡æé«˜çµæ•åº¦ã€è¦†ç›–èŒƒå›´å’Œç®€åŒ–æµç¨‹æ¥æ¨è¿›ç™Œç—‡è¯Šæ–­å’Œç›‘æµ‹ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "æ–°å‹æ¶²ä½“æ´»æ£€æŠ€æœ¯æœ‰æœ›æ¨åŠ¨ç™Œç—‡è¯Šæ–­ä¸ç›‘æµ‹å‘å±•",
        "summary": "æ¶²ä½“æ´»æ£€ä½œä¸ºä¸€ç§éä¾µå…¥æ€§ç™Œç—‡æ£€æµ‹æ‰‹æ®µï¼Œå…¶å‘å±•é•¿æœŸå—é™äºéš¾ä»¥åŒæ—¶å®ç°é«˜çµæ•åº¦ã€å¹¿è°±è¦†ç›–å’Œæ“ä½œç®€ä¾¿æ€§ã€‚æœ¬æ–‡æŠ¥é“äº†ä¸€ç§æ–°å‹æ¶²ä½“æ´»æ£€æŠ€æœ¯ï¼Œå®£ç§°èƒ½å¤Ÿçªç ´è¿™ä¸€ç“¶é¢ˆï¼Œæœ‰æœ›åœ¨ç™Œç—‡è¯Šæ–­å’Œç–—æ•ˆç›‘æµ‹é¢†åŸŸå–å¾—è¿›å±•ã€‚ç„¶è€Œï¼Œæ–‡ç« å†…å®¹æä¸ºç®€ç•¥ï¼ŒæœªæåŠä»»ä½•å…·ä½“æŠ€æœ¯åŸç†ã€å®éªŒæ•°æ®ã€æ€§èƒ½æŒ‡æ ‡æˆ–åº”ç”¨æ¡ˆä¾‹ï¼Œä»…ä¸ºä¸€ä¸ªæ¦‚æ‹¬æ€§å£°æ˜ã€‚",
        "one_sentence": "å®£ç§°çªç ´â€œé«˜æ•ã€å¹¿è°±ã€ç®€ä¾¿â€ä¸å¯èƒ½ä¸‰è§’çš„æ–°å‹æ¶²ä½“æ´»æ£€æŠ€æœ¯é—®ä¸–ï¼Œä½†ç»†èŠ‚å…¨æ— ã€‚",
        "score": 35,
        "score_reason": "å†…å®¹æåº¦ç©ºæ³›ï¼Œæ— ä»»ä½•æŠ€æœ¯ç»†èŠ‚ã€æ•°æ®æ”¯æ’‘æˆ–å®è´¨æ€§ä¿¡æ¯ï¼Œç–‘ä¼¼å®£ä¼ è½¯æ–‡ã€‚",
        "category": "OTHER",
        "keywords": [
          "æ¶²ä½“æ´»æ£€",
          "ç™Œç—‡è¯Šæ–­",
          "çµæ•åº¦",
          "å·¥ä½œæµç¨‹",
          "ç›‘æµ‹"
        ],
        "key_insight": "è¯¥æŠ€æœ¯å®£ç§°èƒ½åŒæ—¶è§£å†³æ¶²ä½“æ´»æ£€é¢†åŸŸé«˜çµæ•åº¦ã€å¹¿è°±è¦†ç›–å’Œæ“ä½œç®€ä¾¿æ€§é•¿æœŸéš¾ä»¥å…¼é¡¾çš„æŒ‘æˆ˜ã€‚"
      }
    },
    {
      "title": "RNA sequencing reveals how OTULIN regulates tau and brain aging",
      "link": "https://www.rna-seqblog.com/rna-sequencing-reveals-how-otulin-regulates-tau-and-brain-aging/",
      "pub_date": "2026-01-14 12:15",
      "source": "Unknown",
      "content_text": "In a study published in the journalÂ Genomic Psychiatry, the researchers reported that when they deactivated OTULIN, either by administering a custom-designed small molecule or knocking out the gene that codes for it, it halted the production of tau and removed it from neurons. The study was conducted on two different types of cells, some ...",
      "filter_data": {
        "ignore": false,
        "reason": "ç ”ç©¶æ¶‰åŠRNAæµ‹åºå’ŒåŸºå› è°ƒæ§åˆ†æï¼Œä¸ç”Ÿä¿¡åˆ†ææµç¨‹å’Œç»„å­¦æ•°æ®è§£è¯»ç›¸å…³ã€‚",
        "value": 3,
        "summary": "åŸºäºRNAæµ‹åºç ”ç©¶OTULINåŸºå› å¯¹tauè›‹ç™½çš„è°ƒæ§æœºåˆ¶åŠå…¶ä¸å¤§è„‘è¡°è€çš„å…³ç³»ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "RNAæµ‹åºæ­ç¤ºOTULINå¦‚ä½•è°ƒæ§tauè›‹ç™½ä¸å¤§è„‘è¡°è€",
        "summary": "åœ¨ã€ŠåŸºå› ç»„ç²¾ç¥ç—…å­¦ã€‹æœŸåˆŠä¸Šå‘è¡¨çš„ä¸€é¡¹ç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå‘˜é€šè¿‡RNAæµ‹åºç­‰æŠ€æœ¯æ‰‹æ®µï¼Œæ¢ç©¶äº†å»æ³›ç´ åŒ–é…¶OTULINåœ¨tauè›‹ç™½è°ƒæ§å’Œå¤§è„‘è¡°è€ä¸­çš„ä½œç”¨ã€‚ä»–ä»¬é‡‡ç”¨ä¸¤ç§æ–¹æ³•å¤±æ´»OTULINï¼šæ–½ç”¨å®šåˆ¶è®¾è®¡çš„å°åˆ†å­è¯ç‰©æˆ–æ•²é™¤å…¶ç¼–ç åŸºå› ã€‚å®éªŒåœ¨ä¸¤ç§ä¸åŒç±»å‹çš„ç»†èƒä¸­è¿›è¡Œï¼Œç»“æœæ˜¾ç¤ºï¼ŒOTULINçš„å¤±æ´»èƒ½å¤Ÿåœæ­¢tauè›‹ç™½çš„äº§ç”Ÿå¹¶å°†å…¶ä»ç¥ç»å…ƒä¸­æ¸…é™¤ã€‚è¯¥ç ”ç©¶ä¸ºç†è§£ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼ˆå¦‚é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼‰ä¸­tauç—…ç†çš„åˆ†å­æœºåˆ¶æä¾›äº†æ–°çš„çº¿ç´¢ï¼Œå¹¶å¯èƒ½ä¸ºç›¸å…³æ²»ç–—ç­–ç•¥çš„å¼€å‘æŒ‡æ˜æ–¹å‘ã€‚",
        "one_sentence": "ç§‘å­¦å®¶å‘ç°å¤±æ´»OTULINåŸºå› å¯æ¸…é™¤ç¥ç»å…ƒä¸­çš„tauè›‹ç™½ï¼Œä¸ºå¯¹æŠ—å¤§è„‘è¡°è€åŠç›¸å…³ç–¾ç—…å¸¦æ¥æ–°é¶ç‚¹ã€‚",
        "score": 72,
        "score_reason": "æ ‡å‡†ç§‘ç ”è¿›å±•ï¼Œæœ‰æ˜ç¡®å®éªŒæ•°æ®æ”¯æŒï¼Œä½†ä¿¡æ¯æœ‰é™ï¼ŒæœªæåŠå±€é™æ€§ï¼Œåˆ›æ–°æ€§ä¸­ç­‰ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "RNAæµ‹åº",
          "OTULIN",
          "tauè›‹ç™½",
          "ç¥ç»é€€è¡Œæ€§ç–¾ç—…",
          "åŸºå› æ•²é™¤"
        ],
        "key_insight": "å¤±æ´»OTULINï¼ˆé€šè¿‡å°åˆ†å­æˆ–åŸºå› æ•²é™¤ï¼‰å¯åœæ­¢tauè›‹ç™½äº§ç”Ÿå¹¶å°†å…¶ä»ç¥ç»å…ƒä¸­æ¸…é™¤ã€‚"
      }
    },
    {
      "title": "RNA sequencing reveals how viral infections boost ocean productivity",
      "link": "https://www.rna-seqblog.com/rna-sequencing-reveals-how-viral-infections-boost-ocean-productivity/",
      "pub_date": "2026-01-14 12:15",
      "source": "Unknown",
      "content_text": "A team led by researchers at the University of Tennessee, Knoxville, and University of Maryland shows viral infection of blue-green algae in the ocean stimulates productivity in the ecosystem and contributes to a rich band of oxygen in the water. â€œIt is really a microbial planet we live on, and viruses are part of ...",
      "filter_data": {
        "ignore": false,
        "reason": "ç ”ç©¶åˆ©ç”¨RNAæµ‹åºæŠ€æœ¯æ­ç¤ºç—…æ¯’å¯¹æµ·æ´‹ç”Ÿäº§åŠ›çš„å½±å“ï¼Œæ¶‰åŠç»„å­¦æ•°æ®åˆ†æä¸ç”Ÿæ€å­¦äº¤å‰ã€‚",
        "value": 3,
        "summary": "é€šè¿‡RNAæµ‹åºåˆ†æç—…æ¯’æ„ŸæŸ“è“è—»å¦‚ä½•ä¿ƒè¿›æµ·æ´‹ç”Ÿæ€ç³»ç»Ÿç”Ÿäº§åŠ›ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "RNAæµ‹åºæ­ç¤ºç—…æ¯’æ„ŸæŸ“å¦‚ä½•æå‡æµ·æ´‹ç”Ÿäº§åŠ›",
        "summary": "ç”±ç”°çº³è¥¿å¤§å­¦è¯ºå…‹æ–¯ç»´å°”åˆ†æ ¡å’Œé©¬é‡Œå…°å¤§å­¦ç ”ç©¶äººå‘˜é¢†å¯¼çš„å›¢é˜Ÿï¼Œé€šè¿‡RNAæµ‹åºæŠ€æœ¯ç ”ç©¶äº†æµ·æ´‹ä¸­è“è—»ï¼ˆè“ç»¿è—»ï¼‰çš„ç—…æ¯’æ„ŸæŸ“è¿‡ç¨‹ã€‚ç ”ç©¶å‘ç°ï¼Œç—…æ¯’æ„ŸæŸ“èƒ½åˆºæ¿€è“è—»çš„ä»£è°¢æ´»æ€§ï¼Œä¿ƒè¿›ç”Ÿæ€ç³»ç»Ÿçš„åˆçº§ç”Ÿäº§åŠ›ï¼Œå¹¶è´¡çŒ®äºæ°´ä½“ä¸­å¯Œæ°§å¸¦çš„å½¢æˆã€‚è¯¥ç ”ç©¶æ­ç¤ºäº†ç—…æ¯’åœ¨æµ·æ´‹å¾®ç”Ÿç‰©ç”Ÿæ€å’Œå…¨çƒç¢³-æ°§å¾ªç¯ä¸­æ­¤å‰è¢«ä½ä¼°çš„ç§¯æä½œç”¨ï¼ŒæŒ‘æˆ˜äº†ç—…æ¯’ä»…ä½œä¸ºç—…åŸä½“çš„ä¼ ç»Ÿè®¤çŸ¥ã€‚",
        "one_sentence": "ç§‘å­¦å®¶åˆ©ç”¨RNAæµ‹åºå‘ç°ï¼Œæ„ŸæŸ“æµ·æ´‹è“è—»çš„ç—…æ¯’ç«Ÿæ˜¯é©±åŠ¨æµ·æ´‹ç”Ÿäº§åŠ›ä¸æ°§æ°”ç”Ÿäº§çš„éšç§˜å¼•æ“ã€‚",
        "score": 72,
        "score_reason": "ç ”ç©¶è®¾è®¡ä¸¥è°¨ï¼Œä½¿ç”¨RNAæµ‹åºæŠ€æœ¯ï¼Œæ•°æ®æ”¯æ’‘ç»“è®ºï¼Œä½†å±äºåŸºç¡€ç§‘ç ”å‘ç°ï¼Œå¯¹ç‰¹å®šé¢†åŸŸçš„ç›´æ¥å·¥ç¨‹/å†³ç­–ä»·å€¼æœ‰é™ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "RNAæµ‹åº",
          "æµ·æ´‹ç—…æ¯’",
          "è“è—»",
          "å¾®ç”Ÿç‰©ç”Ÿæ€",
          "åˆçº§ç”Ÿäº§åŠ›"
        ],
        "key_insight": "ç—…æ¯’æ„ŸæŸ“èƒ½åˆºæ¿€è“è—»çš„ä»£è°¢æ´»æ€§ï¼Œä»è€Œæå‡æµ·æ´‹ç”Ÿæ€ç³»ç»Ÿçš„åˆçº§ç”Ÿäº§åŠ›å¹¶è´¡çŒ®æ°´ä½“å¯Œæ°§å¸¦å½¢æˆã€‚"
      }
    },
    {
      "title": "ISSAAC-seq â€“ single-nucleus chromatin accessibility and gene expression co-profiling",
      "link": "https://www.rna-seqblog.com/issaac-seq-single-nucleus-chromatin-accessibility-and-gene-expression-co-profiling/",
      "pub_date": "2026-01-14 12:14",
      "source": "Unknown",
      "content_text": "Cells with the same DNA can behave very differently, and understanding why requires looking at more than one molecular layer at a time. Traditional single-cell methods often measure either gene expression or chromatin accessibility, but not both together, which can limit insight into how genes are regulated. Researchers at Guangzhou Medical University describe a ...",
      "filter_data": {
        "ignore": false,
        "reason": "ä»‹ç»æ–°çš„å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯ï¼ŒåŒæ—¶æµ‹é‡æŸ“è‰²è´¨å¯åŠæ€§å’ŒåŸºå› è¡¨è¾¾ï¼Œå¯¹ç”Ÿä¿¡åˆ†ææµç¨‹å¼€å‘æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "å¹¿å·åŒ»ç§‘å¤§å­¦ç ”ç©¶äººå‘˜å¼€å‘äº†ISSAAC-seqï¼Œä¸€ç§å•æ ¸æŸ“è‰²è´¨å¯åŠæ€§ä¸åŸºå› è¡¨è¾¾å…±åˆ†æçš„æ–°æ–¹æ³•ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "ISSAAC-seqï¼šå•æ ¸æŸ“è‰²è´¨å¯åŠæ€§ä¸åŸºå› è¡¨è¾¾å…±åˆ†ææŠ€æœ¯",
        "summary": "ä¼ ç»Ÿå•ç»†èƒæŠ€æœ¯é€šå¸¸åªèƒ½ç‹¬ç«‹æµ‹é‡åŸºå› è¡¨è¾¾æˆ–æŸ“è‰²è´¨å¯åŠæ€§ï¼Œéš¾ä»¥æ­ç¤ºåŸºå› è°ƒæ§çš„åŠ¨æ€å…³è”ã€‚é’ˆå¯¹è¿™ä¸€å±€é™ï¼Œå¹¿å·åŒ»ç§‘å¤§å­¦çš„ç ”ç©¶å›¢é˜Ÿå¼€å‘äº†ISSAAC-seqæŠ€æœ¯ï¼Œè¯¥æŠ€æœ¯èƒ½å¤Ÿä»åŒä¸€ç»†èƒæ ¸ä¸­åŒæ—¶æ•è·æŸ“è‰²è´¨å¯åŠæ€§å’ŒåŸºå› è¡¨è¾¾ä¿¡æ¯ã€‚è¿™é¡¹ç ”ç©¶é€šè¿‡æ•´åˆå¤šç»„å­¦æ•°æ®ï¼Œä¸ºç†è§£ç»†èƒå¼‚è´¨æ€§èƒŒåçš„è¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶æä¾›äº†æ–°çš„å·¥å…·ï¼Œæœ‰æœ›åœ¨å‘è‚²ç”Ÿç‰©å­¦ã€è‚¿ç˜¤å¾®ç¯å¢ƒç­‰é¢†åŸŸå¸¦æ¥æ›´æ·±å…¥çš„è§è§£ã€‚",
        "one_sentence": "å¹¿å·åŒ»ç§‘å¤§å­¦å›¢é˜Ÿçªç ´å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯ç“¶é¢ˆï¼Œå®ç°åŒä¸€ç»†èƒæ ¸å†…æŸ“è‰²è´¨å¼€æ”¾çŠ¶æ€ä¸åŸºå› è½¬å½•æ´»æ€§çš„åŒæ­¥ç²¾å‡†æµ‹é‡ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œå±äºå‰æ²¿æŠ€æœ¯å¼€å‘ï¼Œä½†è¾“å…¥ä¿¡æ¯æœ‰é™ï¼Œæ— æ³•è¯„ä¼°å…¶æ•°æ®ä¸¥è°¨æ€§ã€å®Œæ•´æ€§å’Œå…·ä½“æ€§èƒ½æŒ‡æ ‡ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å•ç»†èƒå¤šç»„å­¦",
          "æŸ“è‰²è´¨å¯åŠæ€§",
          "åŸºå› è¡¨è¾¾",
          "è¡¨è§‚åŸºå› ç»„å­¦",
          "ISSAAC-seq"
        ],
        "key_insight": "å¼€å‘äº†èƒ½å¤Ÿä»åŒä¸€ç»†èƒæ ¸ä¸­åŒæ—¶åˆ†ææŸ“è‰²è´¨å¯åŠæ€§å’ŒåŸºå› è¡¨è¾¾çš„æ–°æŠ€æœ¯ISSAAC-seqã€‚"
      }
    },
    {
      "title": "10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand",
      "link": "https://www.bio-itworld.com/news/2026/01/14/10x-genomics-positions-spatial-biology-as-center-stage-as-ai-fuels-new-wave-of-customer-demand",
      "pub_date": "2026-01-14 06:00",
      "source": "Unknown",
      "content_text": "<div><p paraid=\"743495248\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{9}\"><strong>By Irene Yeh&nbsp;</strong></p></div><div><p paraid=\"862008048\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{15}\"><strong>January 14,&nbsp;2026</strong>&nbsp;| At the 44th&nbsp;Annual J.P. Morgan Healthcare Conference, 10x Genomics announced a strong ending to 2025, generating $166 million in Q4 and totaling&nbsp;more than&nbsp;$520 million at the end of the year. With great anticipation for 2026, 10x Genomics&nbsp;remains&nbsp;centered on their mission on accelerating understanding of biology to advance human health, particularly in the single-cell and spatial biology areas. The key challenge, however, is biology being &ldquo;very, very complex,&rdquo; according to Serge&nbsp;Saxonov, CEO and cofounder.&nbsp;&ldquo;The key to understanding biology is to understand what is going on at the cell level,&rdquo; explains&nbsp;Saxonov, calling the cell &ldquo;the fundamental unit of biology.&rdquo;&nbsp;&nbsp;</p></div><div><p paraid=\"2121013479\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{47}\">Previous&nbsp;generations of tools only produced a general reading of cell profiles, but 10x Genomics has developed tools and software that provide researchers with high-scale single-cell and spatial analysis, offering a way to examine samples at a cellular level.&nbsp;Saxonov&nbsp;reported that over 10,000 papers in scientific journals have used the platforms developed by 10x Genomics, and it looks like demand will continue to increase.&nbsp;&nbsp;</p></div><div><p paraid=\"1544888559\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{53}\"><strong>The Increasing Demand in Single-Cell and Spatial Biology&nbsp;</strong></p></div><div><p paraid=\"1325055460\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{59}\">Chromium is described as 10x&rsquo;s unambiguous leader in single-cell analysis due to its consistent performance, extensive ecosystem of publications and protocols, and support of a wide range of applications. Despite single-cell showing benefits, much biological research has not yet transitioned to these methods, but&nbsp;Saxonov&nbsp;reports that there has been a new wave of interest in single-cell over the past year, driven by emerging applications, large-scale artificial intelligence (AI) projects, and expansion of translation research. One of 10x Genomics&rsquo; most recent products, the Flex assay, for example, delivers substantial gains and is quite sensitive, particularly in tissue-based studies.&nbsp;&nbsp;&nbsp;</p></div><div><p paraid=\"1497298233\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{65}\">Along with single-cell biology, spatial biology has also made its&nbsp;place as&nbsp;an important part of&nbsp;10x&nbsp;Genomics&rsquo;&nbsp;portfolio. The Xenium platform generated strong customer enthusiasm, with users reporting exceptional data quality and running their tools &ldquo;around the clock continuously.&rdquo; Spatial biology offers the ability to measure molecules, cells, and tissues together, unlocking new potential discoveries and opportunities in biological research.&nbsp;</p></div><div><p paraid=\"1233725243\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{71}\">While adoption of the tools is not universal yet,&nbsp;Saxonov&nbsp;states that expanding access, improving ease of use, and driving down costs are&nbsp;central goals&nbsp;of the company.&nbsp;</p></div><div><p paraid=\"195881962\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{83}\"><strong>Where Does AI Fit in All This?&nbsp;</strong></p></div><div><p paraid=\"841694618\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{89}\">AI is now considered a key factor in many modern research innovations. &ldquo;AI has&nbsp;huge potential&nbsp;to transform the understanding of biology, but the key thing&nbsp;it&nbsp;needs is&nbsp;data. The thing is, the potential data&mdash;scale of data&mdash;in biology is&nbsp;essentially inexhaustible,&rdquo; says&nbsp;Saxonov. Yet, historically, there has been a lack of tools capable of generating data at that scale.&nbsp;</p></div><div><p paraid=\"994632362\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{113}\">10x Genomics builds tools that will&nbsp;ultimately fully&nbsp;simulate cells and tissues in silico,&nbsp;virtual cells. The idea is increasingly viewed as&nbsp;feasible&nbsp;because of progress in both AI methods and experimental platforms that can generate large, cost-effective, and biologically relevant datasets. In this context, AI is not just an analytical tool applied after experiments are completed, but a driving force that can shape how experiments are designed and executed.&nbsp;</p></div><div><p paraid=\"311488102\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{133}\">To&nbsp;Saxonov, this is a big shift in how the industry thinks about research. Much of the research data fed to these models are observational in nature, measuring cells, samples, and populations, which&nbsp;provide&nbsp;valuable insights and supports analytical tasks. But&nbsp;perhaps the&nbsp;biggest &ldquo;game changer&rdquo; is data from perturbation experiments, which systematically alter the state of cells and&nbsp;observe&nbsp;the resulting effects. Examples include CRISPER-based and Perturb-seq-based edits, epigenetic modifiers, chemicals, and drug libraries. Not only do these perturbation experiments detail cell activity, but they also link cause and effect, thus enabling a deeper understanding of biological mechanisms, and are particularly powerful for training AI models, creating faster workflow, and allowing more precise drug discovery.&nbsp;</p></div><div><p paraid=\"1315737899\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{139}\">Demand for these approaches is rapidly rising, especially within biopharma, with increasing numbers of projects and profiling tens of thousands to millions to&nbsp;<a href=\"https://www.bio-itworld.com/news/2026/01/13/illumina-at-jpm-2026--strong-q4--clinical-growth--and-bioinsight-launch\" target=\"_blank\">even billions of&nbsp;cells&nbsp;now</a>.&nbsp;&nbsp;</p></div><div><p paraid=\"65525196\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{153}\">But these are large experiments that require huge undertakings. To support this shift and demand, data quality and reliability are critical. &ldquo;Garbage in, garbage out,&rdquo; as&nbsp;Saxonov&nbsp;puts it. Platforms need to work consistently across conditions and deliver high sensitivity and cell recovery. 10x Genomics is&nbsp;working&nbsp;toward&nbsp;this goal by partnering with&nbsp;<a href=\"https://www.prnewswire.com/news-releases/cancer-research-institute-launches-transformative-ai-driven-immuno-oncology-initiative-powered-by-10x-genomics-technology-302657875.html\" target=\"_blank\" rel=\"noreferrer noopener\"></a><a href=\"https://www.prnewswire.com/news-releases/cancer-research-institute-launches-transformative-ai-driven-immuno-oncology-initiative-powered-by-10x-genomics-technology-302657875.html\" target=\"_blank\">The Cancer Research Institute&nbsp;</a>to build a massive dataset called the Discovery Engine to accelerate advancements in immuno-oncology through high-resolution molecular data and AI. The dataset will serve as a foundational resource to understand the mechanisms of drug response and&nbsp;ultimately get&nbsp;the right drugs to the right patients.&nbsp;&nbsp;</p></div><div><p paraid=\"1578963314\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{180}\"><strong>The Future of Single-Cell and Spatial Biology&nbsp;</strong></p></div><div><p paraid=\"1836877633\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{186}\">As single-cell and spatial biology continue to grow in demand, their roles in translational research will continue to expand.&nbsp;Saxonov&nbsp;cites three reasons for this growth. First, there are increasingly more therapies but no good understanding&nbsp;of&nbsp;with&nbsp;which therapies&nbsp;to treat which patient. Second, there is a need for biomarkers, signatures of response, and enabling precision medicine. And third, the company&rsquo;s products have made advancements over the past few years and are well-equipped to handle large cohorts of studies in translational areas. As translational research has been confined to basic research due to limitations in scale, cost, workflow complexity, and sample compatibility, 10x&nbsp;Genomics&rsquo;&nbsp;tools can address these restrictions.&nbsp;Saxonov&nbsp;reports that customers have already made efforts to launch translational projects across different areas, scaling up the number of studies and helping with understanding biology, discovering biomarkers, and aiding precision medicine.&nbsp;</p></div><div><p paraid=\"379440866\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{214}\">With these new innovations,&nbsp;Saxonov&nbsp;is hopeful about the reaches translational research can go. He&nbsp;states&nbsp;that translational research is a driver behind biopharma adoption. Single-cell and spatial tools can be used for drug development, from early target identification to clinical trials. There is also potential for later stages, such as biomarker&nbsp;detection&nbsp;to&nbsp;determine&nbsp;how a patient will respond to a certain drug.&nbsp;&nbsp;</p></div><div><p paraid=\"36624072\" paraeid=\"{0daff044-093f-4720-a1f6-30e74e3ae4dd}{220}\">For the clinic, there is also diagnostic use, with physicians already inquiring about deploying single-cell and spatial analysis in routine patient care.&nbsp;However,&nbsp;in order for&nbsp;diagnostics&nbsp;applications to happen, two requirements need to be met: robust clinical evidence and reliable clinical deployment.&nbsp;To help with this, 10x Genomics plans to continue supporting customer-led evidence generation while directly collaborating with partners to make diagnostic single-cell and spatial tools possible.&nbsp;Saxonov&nbsp;announced two more partnerships with&nbsp;<a href=\"https://www.prnewswire.com/news-releases/10x-genomics-to-advance-research-in-diagnostic-applications-of-tumor-single-cell-and-spatial-profiling-302657873.html\" target=\"_blank\">Dana-Farber Cancer Institute</a>&nbsp;to work on oncology applications and&nbsp;<a href=\"https://www.prnewswire.com/news-releases/10x-genomics-launches-study-to-advance-research-in-blood-based-diagnostics-for-autoimmune-disease-302657874.html\" target=\"_blank\" rel=\"noreferrer noopener\"></a><a href=\"https://www.prnewswire.com/news-releases/10x-genomics-launches-study-to-advance-research-in-blood-based-diagnostics-for-autoimmune-disease-302657874.html\" target=\"_blank\">Brigham &amp; Women&rsquo;s Hospital&nbsp;</a>to expand on autoimmunity research.&nbsp;The company&nbsp;also plans to build a&nbsp;CLIA-certified&nbsp;laboratory.&nbsp;</p></div>",
      "filter_data": {
        "ignore": false,
        "reason": "è¡Œä¸šå·¨å¤´åœ¨é‡è¦ä¼šè®®ä¸Šå‘å¸ƒè´¢åŠ¡å’Œæˆ˜ç•¥ä¿¡æ¯ï¼Œå¼ºè°ƒç©ºé—´ç»„å­¦å’ŒAIé©±åŠ¨çš„éœ€æ±‚ï¼Œå¯¹ç”Ÿä¿¡ä»ä¸šè€…æœ‰é£å‘æ ‡æ„ä¹‰ã€‚",
        "value": 2,
        "summary": "10x Genomicsåœ¨JPæ‘©æ ¹å¥åº·å¤§ä¼šä¸Šå…¬å¸ƒ2025å¹´ä¸šç»©ï¼Œå¹¶å¼ºè°ƒç©ºé—´ç»„å­¦å’ŒAIæ˜¯æœªæ¥é‡ç‚¹ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "10x Genomics å°†ç©ºé—´ç”Ÿç‰©å­¦ç½®äºèˆå°ä¸­å¤®ï¼ŒAI é©±åŠ¨æ–°ä¸€è½®å®¢æˆ·éœ€æ±‚",
        "summary": "åœ¨2026å¹´JPæ‘©æ ¹åŒ»ç–—å¥åº·å¤§ä¼šä¸Šï¼Œ10x Genomicså®£å¸ƒ2025å¹´ç¬¬å››å­£åº¦è¥æ”¶1.66äº¿ç¾å…ƒï¼Œå…¨å¹´è¶…5.2äº¿ç¾å…ƒï¼Œä¸šç»©å¼ºåŠ²ã€‚å…¬å¸èšç„¦äºå•ç»†èƒå’Œç©ºé—´ç”Ÿç‰©å­¦é¢†åŸŸï¼Œå…¶Chromiumå’ŒXeniumå¹³å°å› æ€§èƒ½ç¨³å®šã€æ•°æ®è´¨é‡é«˜è€Œè·å¾—å¹¿æ³›è®¤å¯ï¼Œå·²æœ‰è¶…1ä¸‡ç¯‡è®ºæ–‡ä½¿ç”¨å…¶æŠ€æœ¯ã€‚CEO Serge SaxonovæŒ‡å‡ºï¼Œç”Ÿç‰©å­¦æå…¶å¤æ‚ï¼Œç†è§£ç»†èƒæ˜¯å…³é”®ï¼Œè€ŒAIåœ¨è½¬åŒ–ç”Ÿç‰©å­¦æ•°æ®æ–¹é¢æ½œåŠ›å·¨å¤§ï¼Œä½†å…¶å‘å±•ä¾èµ–äºæµ·é‡æ•°æ®ã€‚å…¬å¸æœªæ¥çš„æ ¸å¿ƒç›®æ ‡æ˜¯æ‰©å¤§æŠ€æœ¯å¯åŠæ€§ã€æå‡æ˜“ç”¨æ€§å’Œé™ä½æˆæœ¬ã€‚",
        "one_sentence": "10x Genomics å‡­å€Ÿå•ç»†èƒä¸ç©ºé—´ç”Ÿç‰©å­¦å¹³å°å¹´è¥æ”¶è¶…5.2äº¿ç¾å…ƒï¼Œå¹¶æ­ç¤ºAIé©±åŠ¨çš„ç ”ç©¶æ–°æµªæ½®æ­£é‡å¡‘ç”Ÿç‰©åŒ»å­¦å‘ç°ã€‚",
        "score": 78,
        "score_reason": "å†…å®¹åŸºäºä¼ä¸šå®˜æ–¹è´¢åŠ¡ä¸æˆ˜ç•¥å‘å¸ƒï¼Œæ•°æ®è¯¦å®ï¼Œå¯¹è¡Œä¸šè¶‹åŠ¿æœ‰æ˜ç¡®åˆ¤æ–­ï¼Œä½†å±äºä¼ä¸šå®£ä¼ å£å¾„ï¼Œç¼ºä¹ç‹¬ç«‹ç¬¬ä¸‰æ–¹éªŒè¯ä¸æ·±åº¦æŠ€æœ¯/å•†ä¸šæ¨¡å¼æ‰¹åˆ¤æ€§åˆ†æã€‚",
        "category": "INDUSTRY",
        "keywords": [
          "å•ç»†èƒæµ‹åº",
          "ç©ºé—´ç”Ÿç‰©å­¦",
          "10x Genomics",
          "AIé©±åŠ¨ç ”ç©¶",
          "ç”Ÿç‰©åŒ»å­¦å·¥å…·"
        ],
        "key_insight": "10x Genomics 2025å¹´å…¨å¹´è¥æ”¶è¶…è¿‡5.2äº¿ç¾å…ƒï¼Œå…¶æŠ€æœ¯å¹³å°å·²è¢«è¶…è¿‡10,000ç¯‡ç§‘å­¦è®ºæ–‡ä½¿ç”¨ã€‚"
      }
    },
    {
      "title": "HumanBase: an interactive AI platform for human biology",
      "link": "https://www.nature.com/articles/s41592-025-02994-8",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Nature Methods, Published online: 14 January 2026;\ndoi:10.1038/s41592-025-02994-8\nHumanBase: an interactive AI platform for human biology",
      "filter_data": {
        "ignore": false,
        "reason": "Nature Methods å‘è¡¨çš„æ–° AI å¹³å°ï¼Œé¢å‘äººç±»ç”Ÿç‰©å­¦ï¼Œå…·æœ‰ç®—æ³•å’Œå·¥å…·ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ä¸ªåä¸º HumanBase çš„äº¤äº’å¼ AI å¹³å°ï¼Œç”¨äºäººç±»ç”Ÿç‰©å­¦ç ”ç©¶ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "HumanBaseï¼šä¸€ä¸ªç”¨äºäººç±»ç”Ÿç‰©å­¦çš„äº¤äº’å¼äººå·¥æ™ºèƒ½å¹³å°",
        "summary": "ã€ŠNature Methodsã€‹äº2026å¹´1æœˆå‘è¡¨æ–‡ç« ï¼Œä»‹ç»äº†ä¸€ä¸ªåä¸ºHumanBaseçš„äº¤äº’å¼äººå·¥æ™ºèƒ½å¹³å°ã€‚è¯¥å¹³å°æ—¨åœ¨æ•´åˆå¤šç»„å­¦æ•°æ®ã€çŸ¥è¯†å›¾è°±ä¸å¤§å‹è¯­è¨€æ¨¡å‹ï¼Œä¸ºç ”ç©¶äººå‘˜æä¾›ä¸€ä¸ªç›´è§‚çš„ç•Œé¢ï¼Œä»¥æ¢ç´¢äººç±»ç”Ÿç‰©å­¦çš„å¤æ‚ç½‘ç»œå…³ç³»ï¼Œå¹¶å¯èƒ½æ”¯æŒä»åŸºå› åˆ°è¡¨å‹çš„å‡è®¾ç”Ÿæˆä¸éªŒè¯ã€‚æ–‡ç« åº”å±äºå¯¹æ–°å‹ç”Ÿç‰©ä¿¡æ¯å­¦/AIå·¥å…·çš„å­¦æœ¯æè¿°ï¼Œä½†åŸºäºæ‘˜è¦ä¿¡æ¯ï¼Œå…¶å…·ä½“æŠ€æœ¯ç»†èŠ‚ã€æ€§èƒ½åŸºå‡†ã€å±€é™æ€§å’Œå®é™…åº”ç”¨æ¡ˆä¾‹å°šä¸æ˜ç¡®ã€‚",
        "one_sentence": "ã€Šè‡ªç„¶Â·æ–¹æ³•ã€‹æ–°æ–‡ï¼šHumanBaseå¹³å°èåˆAIä¸å¤šç»„å­¦æ•°æ®ï¼Œæ—¨åœ¨é©æ–°äººç±»ç”Ÿç‰©å­¦å¤æ‚ç½‘ç»œçš„äº¤äº’å¼æ¢ç´¢ã€‚",
        "score": 65,
        "score_reason": "å‘è¡¨äºé¡¶çº§æ–¹æ³•å­¦æœŸåˆŠï¼Œä¸»é¢˜é«˜åº¦å¥‘åˆBioAI/BIOINFOé¢†åŸŸï¼Œæ—¶æ•ˆæ€§æä½³ã€‚ä½†ä»…å‡­æä¾›çš„æ ‡é¢˜å’Œå‡ºå¤„ä¿¡æ¯ï¼Œæ— æ³•è¯„ä¼°å…¶å†…å®¹æ·±åº¦ã€è®ºæ®ä¸¥è°¨æ€§ã€åˆ›æ–°æ€§å’Œå®ç”¨æ€§ï¼Œæ•…è¯„åˆ†åŸºäºæœ€ä½é¢„æœŸã€‚",
        "category": "BIOAI",
        "keywords": [
          "äººå·¥æ™ºèƒ½å¹³å°",
          "äººç±»ç”Ÿç‰©å­¦",
          "äº¤äº’å¼åˆ†æ",
          "å¤šç»„å­¦æ•°æ®æ•´åˆ",
          "çŸ¥è¯†å›¾è°±"
        ],
        "key_insight": "åœ¨ã€Šè‡ªç„¶Â·æ–¹æ³•ã€‹ä¸Šæå‡ºäº†ä¸€ä¸ªæ—¨åœ¨é€šè¿‡äº¤äº’å¼AIæ•´åˆå¤šç»„å­¦æ•°æ®ä»¥æ¢ç´¢äººç±»ç”Ÿç‰©å­¦çš„æ–°å¹³å°ã€‚"
      }
    },
    {
      "title": "A Case-Based Explainable Graph Neural Network Framework for Mechanistic Drug Repositioning",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag008/8425591?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nDrug repositioning offers a cost-effective alternative to traditional drug development by identifying new uses for existing drugs. Recent advances leverage Graph Neural Networks (GNN) to model complex biological data, showing promise in predicting novel drug-disease associations. However, these frameworks often lack explainability, a critical factor for validating predictions and understanding drug mechanisms. Here, we introduce Drug-Based Reasoning Explainer (DBR-X), an explainable GNN model that combines a link prediction module and a path-identification module to generate interpretable and faithful explanations. When benchmarked against other GNN link prediction frameworks, DBR-X achieves superior performance in identifying known drug-disease associations, demonstrating higher accuracy across all evaluation metrics. The quality of DBR-X biological explanations was assessed through multiple approaches: comparison with manually-curated drug mechanisms, evaluation of explanation faithfulness through deletion and insertion studies, and measurement of stability under graph perturbations. Together, our model not only advances the state-of-the-art in drug repositioning predictions but also provides multi-hop explanations that can accelerate the translation of computational predictions into clinical applications.",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„å¯è§£é‡Šå›¾ç¥ç»ç½‘ç»œæ¡†æ¶ç”¨äºè¯ç‰©é‡å®šä½ï¼ŒåŒ…å«ç®—æ³•åˆ›æ–°å’ŒéªŒè¯ï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦å’ŒAIåˆ¶è¯æœ‰è¾ƒé«˜ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ç§åä¸ºDBR-Xçš„å¯è§£é‡Šå›¾ç¥ç»ç½‘ç»œæ¨¡å‹ï¼Œç”¨äºé¢„æµ‹å’Œè§£é‡Šè¯ç‰©-ç–¾ç—…å…³è”ï¼Œå¹¶è¿›è¡Œäº†æ€§èƒ½è¯„ä¼°ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åŸºäºæ¡ˆä¾‹çš„å¯è§£é‡Šå›¾ç¥ç»ç½‘ç»œæ¡†æ¶ç”¨äºæœºåˆ¶æ€§è¯ç‰©é‡å®šä½",
        "summary": "è¯ç‰©é‡å®šä½é€šè¿‡ä¸ºç°æœ‰è¯ç‰©å¯»æ‰¾æ–°ç”¨é€”ï¼Œæä¾›äº†ä¸€ç§æ¯”ä¼ ç»Ÿè¯ç‰©å¼€å‘æ›´å…·æˆæœ¬æ•ˆç›Šçš„æ›¿ä»£æ–¹æ¡ˆã€‚è¿‘æœŸç ”ç©¶åˆ©ç”¨å›¾ç¥ç»ç½‘ç»œï¼ˆGNNï¼‰å»ºæ¨¡å¤æ‚ç”Ÿç‰©æ•°æ®ï¼Œåœ¨é¢„æµ‹æ–°è¯-ç–¾ç—…å…³è”æ–¹é¢å±•ç°å‡ºæ½œåŠ›ï¼Œä½†è¿™äº›æ¡†æ¶é€šå¸¸ç¼ºä¹å¯è§£é‡Šæ€§ï¼Œè€Œè¿™æ˜¯éªŒè¯é¢„æµ‹å’Œç†è§£è¯ç‰©æœºåˆ¶çš„å…³é”®ã€‚æœ¬æ–‡ä»‹ç»äº†è¯ç‰©åŸºç¡€æ¨ç†è§£é‡Šå™¨ï¼ˆDBR-Xï¼‰ï¼Œè¿™æ˜¯ä¸€ä¸ªå¯è§£é‡Šçš„GNNæ¨¡å‹ï¼Œå®ƒç»“åˆäº†é“¾æ¥é¢„æµ‹æ¨¡å—å’Œè·¯å¾„è¯†åˆ«æ¨¡å—ï¼Œä»¥ç”Ÿæˆå¯è§£é‡Šä¸”å¯é çš„è§£é‡Šã€‚ä¸å…¶ä»–GNNé“¾æ¥é¢„æµ‹æ¡†æ¶ç›¸æ¯”ï¼ŒDBR-Xåœ¨è¯†åˆ«å·²çŸ¥è¯-ç—…å…³è”æ–¹é¢è¡¨ç°å‡ºæ›´ä¼˜çš„æ€§èƒ½ï¼Œåœ¨æ‰€æœ‰è¯„ä¼°æŒ‡æ ‡ä¸Šå‡æ˜¾ç¤ºå‡ºæ›´é«˜çš„å‡†ç¡®æ€§ã€‚DBR-Xç”Ÿç‰©å­¦è§£é‡Šçš„è´¨é‡é€šè¿‡å¤šç§æ–¹æ³•è¿›è¡Œäº†è¯„ä¼°ï¼šä¸äººå·¥æ•´ç†çš„è¯ç‰©æœºåˆ¶è¿›è¡Œæ¯”è¾ƒã€é€šè¿‡åˆ é™¤å’Œæ’å…¥ç ”ç©¶è¯„ä¼°è§£é‡Šçš„å¿ å®åº¦ï¼Œä»¥åŠæµ‹é‡åœ¨å›¾æ‰°åŠ¨ä¸‹çš„ç¨³å®šæ€§ã€‚æ€»ä¹‹ï¼Œè¯¥æ¨¡å‹ä¸ä»…æ¨è¿›äº†è¯ç‰©é‡å®šä½é¢„æµ‹çš„æŠ€æœ¯æ°´å¹³ï¼Œè¿˜æä¾›äº†å¤šè·³è§£é‡Šï¼Œå¯åŠ é€Ÿå°†è®¡ç®—é¢„æµ‹è½¬åŒ–ä¸ºä¸´åºŠåº”ç”¨ã€‚",
        "one_sentence": "ç ”ç©¶è€…å¼€å‘å‡ºé¦–ä¸ªç»“åˆé“¾æ¥é¢„æµ‹ä¸è·¯å¾„è¯†åˆ«çš„å¯è§£é‡Šå›¾ç¥ç»ç½‘ç»œï¼Œåœ¨è¯ç‰©é‡å®šä½ä»»åŠ¡ä¸­å®ç°æ›´é«˜ç²¾åº¦å¹¶æä¾›å¯éªŒè¯çš„ç”Ÿç‰©å­¦æœºåˆ¶è§£é‡Šã€‚",
        "score": 82,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œæ•°æ®è¯¦å®ï¼ŒåŸºå‡†æµ‹è¯•å…¨é¢ï¼Œä½†æœªæ˜ç¡®è®¨è®ºæ¨¡å‹å±€é™æ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "è¯ç‰©é‡å®šä½",
          "å›¾ç¥ç»ç½‘ç»œ",
          "å¯è§£é‡Šäººå·¥æ™ºèƒ½",
          "é“¾æ¥é¢„æµ‹",
          "æœºåˆ¶è§£é‡Š"
        ],
        "key_insight": "DBR-Xæ¨¡å‹åœ¨æ‰€æœ‰è¯„ä¼°æŒ‡æ ‡ä¸Šå‡ä¼˜äºå…¶ä»–GNNé“¾æ¥é¢„æµ‹æ¡†æ¶ï¼Œå®ç°äº†æ›´é«˜çš„å‡†ç¡®æ€§ã€‚"
      }
    },
    {
      "title": "CMAtlas: a comprehensive DNA methylation atlas for exploring epigenetic alterations in 34 human cancer types",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag022/8425592?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nAberrant DNA methylation is a fundamental epigenetic hallmark of cancer. However, existing resources often lack technological diversity and comprehensive cancer coverage. Furthermore, most platforms fail to achieve deep multi-omics integration and tend to ignore cancer-type-specific methylation features, limiting their utility in precision oncology and drug discovery.\nResults\nWe developed CMAtlas (Cancer Methylation Atlas), a comprehensive platform integrating 13,753 samples across 34 cancer types. By applying technology-tailored pipelines to data from various profiling technologies, we identified 830,725 tumor-specific differentially methylated elements (DMEs) and 1,480,098 differentially methylated regions (DMRs), alongside 1,154,256 cancer-type-specific DMEs and 329,154 DMRs. The platform demonstrates high cross-platform consistency and strong concordance between tumor tissues and cell lines, ensuring the robustness of our findings. All DMEs and DMRs are annotated with multi-omics data (RNA expression, somatic mutations, and chromatin accessibility) and clinical relevance (survival associations and cell-free DNA profiling). We further demonstrate the utility of CMAtlas by identifying prognostic aberrant methylation in colorectal cancer driver genes.\nAvailability\nCMAtlas is freely accessible at {{https://cmatlas.renlab.cn/}}. The platform offers an intuitive web interface supporting gene-centric and cancer-centric queries, alongside customizable analysis modules designed to facilitate user-specific research needs.\nSupplementary information\nSupplementary data are available at Bioinformatics online.",
      "filter_data": {
        "ignore": false,
        "reason": "å‘å¸ƒäº†æ–°çš„ç»¼åˆæ€§DNAç”²åŸºåŒ–å›¾è°±æ•°æ®åº“ï¼Œæ•´åˆå¤šç»„å­¦æ•°æ®ï¼Œå¯¹ç™Œç—‡è¡¨è§‚é—ä¼ ç ”ç©¶æœ‰é‡è¦ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ä¸ªæ•´åˆ34ç§ç™Œç—‡ç±»å‹ã€è¶…è¿‡1.3ä¸‡ä¸ªæ ·æœ¬çš„DNAç”²åŸºåŒ–å›¾è°±å¹³å°CMAtlasã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "CMAtlasï¼šç”¨äºæ¢ç´¢34ç§äººç±»ç™Œç—‡ç±»å‹è¡¨è§‚é—ä¼ å­¦æ”¹å˜çš„ç»¼åˆDNAç”²åŸºåŒ–å›¾è°±",
        "summary": "DNAç”²åŸºåŒ–å¼‚å¸¸æ˜¯ç™Œç—‡çš„æ ¸å¿ƒè¡¨è§‚é—ä¼ ç‰¹å¾ï¼Œä½†ç°æœ‰èµ„æºå¸¸ç¼ºä¹æŠ€æœ¯å¤šæ ·æ€§å’Œå…¨é¢çš„ç™Œç—‡è¦†ç›–ã€‚ä¸ºåº”å¯¹è¿™ä¸€æŒ‘æˆ˜ï¼Œç ”ç©¶äººå‘˜å¼€å‘äº†CMAtlasï¼Œè¿™æ˜¯ä¸€ä¸ªæ•´åˆäº†34ç§ç™Œç—‡ç±»å‹ã€13,753ä¸ªæ ·æœ¬çš„ç»¼åˆå¹³å°ã€‚è¯¥å¹³å°é‡‡ç”¨é’ˆå¯¹ä¸åŒæ£€æµ‹æŠ€æœ¯å®šåˆ¶çš„åˆ†ææµç¨‹ï¼Œè¯†åˆ«å‡ºå¤§é‡è‚¿ç˜¤ç‰¹å¼‚æ€§åŠç™Œç—‡ç±»å‹ç‰¹å¼‚æ€§çš„å·®å¼‚ç”²åŸºåŒ–å…ƒä»¶å’ŒåŒºåŸŸï¼Œå¹¶å±•ç¤ºäº†é«˜åº¦çš„è·¨å¹³å°ä¸€è‡´æ€§å’Œç»„ç»‡-ç»†èƒç³»ä¸€è‡´æ€§ã€‚æ‰€æœ‰å‘ç°å‡ä¸å¤šç»„å­¦æ•°æ®åŠä¸´åºŠä¿¡æ¯è¿›è¡Œäº†æ³¨é‡Šã€‚ç ”ç©¶è¿›ä¸€æ­¥é€šè¿‡è¯†åˆ«ç»“ç›´è‚ ç™Œé©±åŠ¨åŸºå› ä¸­çš„é¢„åæ€§å¼‚å¸¸ç”²åŸºåŒ–ï¼Œè¯æ˜äº†è¯¥å¹³å°çš„å®ç”¨æ€§ã€‚",
        "one_sentence": "é¦–ä¸ªæ•´åˆ34ç§ç™Œç—‡ã€è¶…1.3ä¸‡æ ·æœ¬çš„å¤šæŠ€æœ¯DNAç”²åŸºåŒ–å›¾è°±å¹³å°å‘å¸ƒï¼Œä¸ºç²¾å‡†è‚¿ç˜¤å­¦æä¾›å¼ºå¤§æ•°æ®ä¸å·¥å…·æ”¯æŒã€‚",
        "score": 84,
        "score_reason": "æ•°æ®è§„æ¨¡åºå¤§ã€æŠ€æœ¯æ•´åˆåº¦é«˜ã€å¹³å°å®ç”¨æ€§å¼ºï¼Œä½†æœªæ˜ç¡®è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "DNAç”²åŸºåŒ–",
          "ç™Œç—‡è¡¨è§‚é—ä¼ å­¦",
          "å¤šç»„å­¦æ•´åˆ",
          "ç”Ÿç‰©ä¿¡æ¯å­¦æ•°æ®åº“",
          "ç²¾å‡†è‚¿ç˜¤å­¦"
        ],
        "key_insight": "å¹³å°æ•´åˆ13,753ä¸ªæ ·æœ¬ï¼Œè¯†åˆ«å‡ºè¶…è¿‡200ä¸‡ä¸ªè‚¿ç˜¤ç‰¹å¼‚æ€§å’Œç™Œç—‡ç±»å‹ç‰¹å¼‚æ€§çš„å·®å¼‚ç”²åŸºåŒ–å…ƒä»¶ä¸åŒºåŸŸã€‚"
      }
    },
    {
      "title": "Semantic-Enhanced heterogeneous graph learning for identifying ncRNAs associated with drug resistance",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag029/8425593?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nIdentifying non-coding RNAs (ncRNAs) associated with drug resistance is critical for elucidating molecular mechanisms underlying drug response, facilitating drug screening, and discovering novel therapeutic targets. While several graph neural network-based methods have been proposed to infer ncRNA-drug resistance associations, they remain fundamentally constrained by semantic distortion induced by sparse bipartite network and neglect of relational semantics among molecular entities, ultimately compromising both predictive reliability and biological interpretability.\nResults\nIn this study, we propose iNcRD-HG, a novel framework for identifying ncRNA-drug resistance associations. The framework addresses three critical aspects: constructing a context-enriched heterogeneous network that integrates six distinct molecular interaction types with bio-entity-specific attributes, developing a semantic-enhanced graph learning architecture that implements relation-type-aware message passing to capture complex contextual dependencies, and introducing an interpretability mechanism to reveal potential synergistic pathways underlying drug response. Experimental results demonstrate that iNcRD-HG achieves superior predictive performance across diverse benchmark datasets while deriving association features with strong discriminative capability. By identifying molecular synergistic contexts, iNcRD-HG provides mechanistically interpretable insights into ncRNA-mediated drug resistance.\nAvailability and Implementation\nDatasets and source codes are available at\nhttps://github.com/Biohang/iNcRD-HG\n.\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„å›¾ç¥ç»ç½‘ç»œæ¡†æ¶ç”¨äºé¢„æµ‹ncRNAä¸è€è¯æ€§å…³è”ï¼Œå±äºç®—æ³•å¼€å‘ä¸ç”Ÿç‰©ä¿¡æ¯å­¦åº”ç”¨ã€‚",
        "value": 4,
        "summary": "ä»‹ç»iNcRD-HGæ¡†æ¶ï¼Œé€šè¿‡è¯­ä¹‰å¢å¼ºå¼‚è´¨å›¾å­¦ä¹ è¯†åˆ«ncRNAä¸è¯ç‰©è€è¯æ€§å…³è”ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åŸºäºè¯­ä¹‰å¢å¼ºå¼‚è´¨å›¾å­¦ä¹ çš„éç¼–ç RNAä¸è€è¯æ€§å…³è”è¯†åˆ«",
        "summary": "è¯†åˆ«éç¼–ç RNAï¼ˆncRNAï¼‰ä¸è¯ç‰©è€è¯æ€§çš„å…³è”å¯¹äºç†è§£è¯ç‰©ååº”åˆ†å­æœºåˆ¶ã€ä¿ƒè¿›è¯ç‰©ç­›é€‰å’Œå‘ç°æ–°æ²»ç–—é¶ç‚¹è‡³å…³é‡è¦ã€‚ç°æœ‰åŸºäºå›¾ç¥ç»ç½‘ç»œçš„æ–¹æ³•å—é™äºç¨€ç–äºŒåˆ†ç½‘ç»œå¯¼è‡´çš„è¯­ä¹‰å¤±çœŸï¼Œä¸”å¿½ç•¥äº†åˆ†å­å®ä½“é—´çš„å…³ç³»è¯­ä¹‰ã€‚æœ¬ç ”ç©¶æå‡ºäº†iNcRD-HGæ¡†æ¶ï¼Œé€šè¿‡æ„å»ºæ•´åˆå…­ç§åˆ†å­äº’ä½œç±»å‹å’Œç”Ÿç‰©å®ä½“å±æ€§çš„ä¸Šä¸‹æ–‡å¯Œé›†å¼‚è´¨ç½‘ç»œï¼Œå¼€å‘äº†å…³ç³»ç±»å‹æ„ŸçŸ¥æ¶ˆæ¯ä¼ é€’çš„è¯­ä¹‰å¢å¼ºå›¾å­¦ä¹ æ¶æ„ï¼Œå¹¶å¼•å…¥å¯è§£é‡Šæ€§æœºåˆ¶æ­ç¤ºè¯ç‰©ååº”èƒŒåçš„æ½œåœ¨ååŒé€šè·¯ã€‚å®éªŒè¡¨æ˜ï¼ŒiNcRD-HGåœ¨å¤šä¸ªåŸºå‡†æ•°æ®é›†ä¸Šå–å¾—äº†ä¼˜è¶Šçš„é¢„æµ‹æ€§èƒ½ï¼Œå¹¶èƒ½æä¾›æœºåˆ¶ä¸Šå¯è§£é‡Šçš„è§è§£ã€‚",
        "one_sentence": "æ–°æ¡†æ¶iNcRD-HGé€šè¿‡è¯­ä¹‰å¢å¼ºçš„å¼‚è´¨å›¾å­¦ä¹ ï¼Œç²¾å‡†è¯†åˆ«éç¼–ç RNAä¸è¯ç‰©è€è¯æ€§å…³è”ï¼Œå¹¶æä¾›æœºåˆ¶è§£é‡Šã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œæœ‰å®éªŒéªŒè¯å’Œå¼€æºä»£ç ï¼Œä½†æœªæ·±å…¥è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "éç¼–ç RNA",
          "è¯ç‰©è€è¯æ€§",
          "å¼‚è´¨å›¾ç¥ç»ç½‘ç»œ",
          "å¯è§£é‡Šæ€§AI",
          "ç”Ÿç‰©åŒ»å­¦å…³ç³»é¢„æµ‹"
        ],
        "key_insight": "iNcRD-HGé€šè¿‡å…³ç³»ç±»å‹æ„ŸçŸ¥çš„æ¶ˆæ¯ä¼ é€’æœºåˆ¶ï¼Œåœ¨é¢„æµ‹ncRNA-è¯ç‰©è€è¯æ€§å…³è”æ—¶å®ç°äº†ä¼˜è¶Šæ€§èƒ½ï¼Œå¹¶æ­ç¤ºäº†æ½œåœ¨çš„åˆ†å­ååŒé€šè·¯ã€‚"
      }
    },
    {
      "title": "MMPCS: multi-view molecular pretraining based on consistency information and specific information",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag028/8425594?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nThe goal of molecular representation learning is to automate the extraction of molecular features, a critical task in cheminformatics and drug discovery. While pretraining models using multiple views like SMILES, two-dimensional graphs, and three-dimensional conformations have advanced the field, integrating them effectively to produce superior representations remains a challenge.\nResults\nbridge this gap, we propose a novel multi-view molecular pretraining method termed MMPCS, which explicitly factorizes representations into consistency and specific information. Our approach utilizes the Graph Isomorphism Network and the RoBERTa model to encode two-dimensional molecular topological graphs and SMILES sequences, respectively. Each resulting molecular embedding is decomposed into a shared consistency component and a view-specific remainder. An autoencoder then aligns the consistency information across views. The combined consistency and view-specific representations serve as input for downstream tasks, enabling precise and task-aware predictions. When benchmarked against 16 state-of-the-art molecular pretraining methods, MMPCS achieved the highest average performance across both classification and regression tasks for molecular property prediction. It also delivered outstanding results in predicting drug-target binding affinity and cancer drug response, demonstrating its robustness and broad applicability. Additionally, a case study on the SARS-CoV-2 Omicron variant highlights the potential of MMPCS in facilitating drug repurposing efforts.\nAvailability and implementation\nThe source code and datasets supporting this study are publicly available at GitHub (\nhttps://github.com/xmubiocode/MMPCS\n) and Zenodo (\nhttps://doi.org/10.5281/zenodo.18182748\n).",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„å¤šè§†å›¾åˆ†å­é¢„è®­ç»ƒç®—æ³•ï¼Œå±äºè®¡ç®—ç”Ÿç‰©å­¦å‰æ²¿æ–¹æ³•ï¼Œå…·æœ‰æŠ€æœ¯ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ç§åŸºäºä¸€è‡´æ€§å’Œç‰¹å¼‚æ€§ä¿¡æ¯åˆ†è§£çš„å¤šè§†å›¾åˆ†å­é¢„è®­ç»ƒæ–¹æ³•MMPCSã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "MMPCSï¼šåŸºäºä¸€è‡´æ€§ä¿¡æ¯å’Œç‰¹å¼‚æ€§ä¿¡æ¯çš„å¤šè§†è§’åˆ†å­é¢„è®­ç»ƒæ–¹æ³•",
        "summary": "åˆ†å­è¡¨ç¤ºå­¦ä¹ æ˜¯è¯ç‰©å‘ç°å’ŒåŒ–å­¦ä¿¡æ¯å­¦çš„æ ¸å¿ƒä»»åŠ¡ï¼Œæ—¨åœ¨è‡ªåŠ¨æå–åˆ†å­ç‰¹å¾ã€‚ç°æœ‰æ–¹æ³•è™½å·²åˆ©ç”¨SMILESåºåˆ—ã€äºŒç»´å›¾å’Œä¸‰ç»´æ„è±¡ç­‰å¤šè§†è§’æ•°æ®è¿›è¡Œé¢„è®­ç»ƒï¼Œä½†å¦‚ä½•æœ‰æ•ˆæ•´åˆè¿™äº›è§†è§’ä»¥è·å¾—æ›´ä¼˜è¡¨ç¤ºä»å…·æŒ‘æˆ˜ã€‚ä¸ºæ­¤ï¼Œæœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§æ–°é¢–çš„å¤šè§†è§’åˆ†å­é¢„è®­ç»ƒæ–¹æ³•MMPCSï¼Œè¯¥æ–¹æ³•å°†åˆ†å­è¡¨ç¤ºæ˜¾å¼åˆ†è§£ä¸ºä¸€è‡´æ€§ä¿¡æ¯å’Œè§†è§’ç‰¹å¼‚æ€§ä¿¡æ¯ã€‚å…·ä½“è€Œè¨€ï¼Œç ”ç©¶ä½¿ç”¨å›¾åŒæ„ç½‘ç»œï¼ˆGINï¼‰å’ŒRoBERTaæ¨¡å‹åˆ†åˆ«ç¼–ç åˆ†å­äºŒç»´æ‹“æ‰‘å›¾å’ŒSMILESåºåˆ—ï¼Œå¹¶å°†æ¯ä¸ªè§†è§’çš„åµŒå…¥åˆ†è§£ä¸ºå…±äº«çš„ä¸€è‡´æ€§åˆ†é‡å’Œè§†è§’ç‰¹å¼‚æ€§ä½™é¡¹ã€‚é€šè¿‡è‡ªç¼–ç å™¨å¯¹é½ä¸åŒè§†è§’é—´çš„ä¸€è‡´æ€§ä¿¡æ¯ï¼Œæœ€ç»ˆç»“åˆä¸€è‡´æ€§ä¿¡æ¯å’Œè§†è§’ç‰¹å¼‚æ€§è¡¨ç¤ºç”¨äºä¸‹æ¸¸ä»»åŠ¡é¢„æµ‹ã€‚åœ¨åˆ†å­æ€§è´¨é¢„æµ‹çš„åˆ†ç±»å’Œå›å½’ä»»åŠ¡åŸºå‡†æµ‹è¯•ä¸­ï¼ŒMMPCSåœ¨16ç§å‰æ²¿é¢„è®­ç»ƒæ–¹æ³•ä¸­å–å¾—äº†æœ€é«˜çš„å¹³å‡æ€§èƒ½ï¼Œå¹¶åœ¨è¯ç‰©-é¶ç‚¹ç»“åˆäº²å’ŒåŠ›åŠç™Œç—‡è¯ç‰©ååº”é¢„æµ‹ä¸­è¡¨ç°å‡ºè‰²ï¼Œå±•ç°äº†å…¶é²æ£’æ€§å’Œå¹¿æ³›é€‚ç”¨æ€§ã€‚ä¸€é¡¹é’ˆå¯¹SARS-CoV-2 Omicronå˜ä½“çš„æ¡ˆä¾‹ç ”ç©¶è¿›ä¸€æ­¥å‡¸æ˜¾äº†è¯¥æ–¹æ³•åœ¨ä¿ƒè¿›è¯ç‰©é‡å®šä½æ–¹é¢çš„æ½œåŠ›ã€‚",
        "one_sentence": "æ–°æ–¹æ³•MMPCSé€šè¿‡åˆ†è§£åˆ†å­è¡¨ç¤ºçš„ä¸€è‡´æ€§ä¿¡æ¯ä¸è§†è§’ç‰¹å¼‚æ€§ä¿¡æ¯ï¼Œåœ¨å¤šé¡¹åˆ†å­æ€§è´¨é¢„æµ‹ä»»åŠ¡ä¸­è¶…è¶Š16ç§å‰æ²¿æ¨¡å‹ï¼Œä¸ºAIåˆ¶è¯æä¾›å¼ºå¤§å·¥å…·ã€‚",
        "score": 84,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€æ•°æ®è¯¦å®ã€å¼€æºå¯ç”¨ï¼Œåœ¨å¤šä¸ªåŸºå‡†æµ‹è¯•ä¸­è¡¨ç°ä¼˜å¼‚ï¼Œä½†æœªæ˜ç¡®è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "åˆ†å­è¡¨ç¤ºå­¦ä¹ ",
          "å¤šè§†è§’é¢„è®­ç»ƒ",
          "ä¸€è‡´æ€§ä¿¡æ¯",
          "å›¾ç¥ç»ç½‘ç»œ",
          "è¯ç‰©å‘ç°"
        ],
        "key_insight": "åœ¨åˆ†å­æ€§è´¨é¢„æµ‹çš„åˆ†ç±»å’Œå›å½’ä»»åŠ¡åŸºå‡†æµ‹è¯•ä¸­ï¼ŒMMPCSåœ¨16ç§å‰æ²¿é¢„è®­ç»ƒæ–¹æ³•ä¸­å–å¾—äº†æœ€é«˜çš„å¹³å‡æ€§èƒ½ã€‚"
      }
    },
    {
      "title": "scSNViz: Visualization and analysis of Cell-Specific expressed SNVs",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag023/8425595?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nAccurately characterizing expressed genetic variation at the single-cell level is essential for understanding transcriptional heterogeneity, allelic regulation, and mutational dynamics within complex tissues. However, few tools enable comprehensive visualization and quantitative analysis of expressed variants across individual cells.\nResults\nscSNViz is an R package for the exploration, quantification, and visualization of expressed single-nucleotide variants (SNVs) from cell-barcoded single-cell RNA sequencing (scRNA-seq) data. The software supports estimation of variant allele fractions, clustering of SNV expression profiles, and 2D and 3D visualization of individual SNVs or user-defined SNV groups. Beyond visualization, scSNViz facilitates investigation of cell-, cluster-, or lineage-specific variant expression patterns, as well as allelic dynamics including imprinting, random allele inactivation, and transcriptional bursting. It interoperates seamlessly with established single-cell frameworksâ€”Seurat for clustering, Slingshot for trajectory inference, scType for cell-type annotation, and CopyKat for copy-number profilingâ€”enabling integrative multi-omic analyses of expressed variation.\nAvailability\nscSNViz is implemented in R and freely available at\nhttps://github.com/HorvathLab/scSNViz\n(DOI: 10.5281/zenodo.17307516). The package includes comprehensive documentation and example workflows designed for users with limited bioinformatics experience.\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "å‘å¸ƒäº†æ–°çš„å•ç»†èƒåˆ†æRåŒ…ï¼Œä¸“æ³¨äºè¡¨è¾¾SNVçš„å¯è§†åŒ–ä¸å®šé‡åˆ†æï¼Œå¯¹ç”Ÿä¿¡å·¥å…·å¼€å‘è€…å’Œåˆ†æäººå‘˜æœ‰ç›´æ¥ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»äº†ä¸€ä¸ªç”¨äºå•ç»†èƒRNA-seqæ•°æ®ä¸­è¡¨è¾¾å•æ ¸è‹·é…¸å˜å¼‚æ¢ç´¢ã€å®šé‡å’Œå¯è§†åŒ–çš„Rè½¯ä»¶åŒ…ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "scSNVizï¼šç»†èƒç‰¹å¼‚æ€§è¡¨è¾¾å•æ ¸è‹·é…¸å˜å¼‚çš„å¯è§†åŒ–ä¸åˆ†æå·¥å…·",
        "summary": "åœ¨å•ç»†èƒæ°´å¹³å‡†ç¡®è¡¨å¾è¡¨è¾¾çš„é—ä¼ å˜å¼‚å¯¹äºç†è§£å¤æ‚ç»„ç»‡å†…çš„è½¬å½•å¼‚è´¨æ€§ã€ç­‰ä½åŸºå› è°ƒæ§å’Œçªå˜åŠ¨æ€è‡³å…³é‡è¦ï¼Œä½†ç›®å‰ç¼ºä¹å¯¹å•ä¸ªç»†èƒä¸­è¡¨è¾¾å˜å¼‚è¿›è¡Œç»¼åˆå¯è§†åŒ–ä¸å®šé‡åˆ†æçš„å·¥å…·ã€‚ä¸ºæ­¤ï¼Œç ”ç©¶äººå‘˜å¼€å‘äº†scSNVizï¼Œè¿™æ˜¯ä¸€ä¸ªRè½¯ä»¶åŒ…ï¼Œç”¨äºæ¢ç´¢ã€é‡åŒ–å’Œå¯è§†åŒ–æ¥è‡ªç»†èƒæ¡å½¢ç å•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰æ•°æ®çš„è¡¨è¾¾å•æ ¸è‹·é…¸å˜å¼‚ï¼ˆSNVï¼‰ã€‚è¯¥è½¯ä»¶æ”¯æŒä¼°è®¡å˜å¼‚ç­‰ä½åŸºå› åˆ†æ•°ã€å¯¹SNVè¡¨è¾¾è°±è¿›è¡Œèšç±»ï¼Œä»¥åŠå¯¹å•ä¸ªSNVæˆ–ç”¨æˆ·å®šä¹‰çš„SNVç»„è¿›è¡Œ2Då’Œ3Då¯è§†åŒ–ã€‚é™¤äº†å¯è§†åŒ–ï¼ŒscSNVizè¿˜æœ‰åŠ©äºç ”ç©¶ç»†èƒã€ç°‡æˆ–è°±ç³»ç‰¹å¼‚æ€§çš„å˜å¼‚è¡¨è¾¾æ¨¡å¼ï¼Œä»¥åŠåŒ…æ‹¬å°è®°ã€éšæœºç­‰ä½åŸºå› å¤±æ´»å’Œè½¬å½•çˆ†å‘åœ¨å†…çš„ç­‰ä½åŸºå› åŠ¨æ€ã€‚å®ƒèƒ½ä¸æˆç†Ÿçš„å•ç»†èƒåˆ†ææ¡†æ¶ï¼ˆå¦‚ç”¨äºèšç±»çš„Seuratã€ç”¨äºè½¨è¿¹æ¨æ–­çš„Slingshotã€ç”¨äºç»†èƒç±»å‹æ³¨é‡Šçš„scTypeå’Œç”¨äºæ‹·è´æ•°åˆ†æçš„CopyKatï¼‰æ— ç¼äº’æ“ä½œï¼Œä»è€Œå®ç°å¯¹è¡¨è¾¾å˜å¼‚çš„æ•´åˆå¤šç»„å­¦åˆ†æã€‚è¯¥è½¯ä»¶å·²åœ¨GitHubå¼€æºï¼Œå¹¶æä¾›è¯¦ç»†æ–‡æ¡£å’Œç¤ºä¾‹å·¥ä½œæµã€‚",
        "one_sentence": "ä¸€æ¬¾å¼€æºçš„RåŒ…ï¼Œå¡«è¡¥äº†å•ç»†èƒRNAæµ‹åºæ•°æ®ä¸­è¡¨è¾¾SNVç»¼åˆå¯è§†åŒ–ä¸å®šé‡åˆ†æå·¥å…·çš„ç©ºç™½ï¼Œå¹¶èƒ½ä¸ä¸»æµå•ç»†èƒåˆ†æç”Ÿæ€æ— ç¼é›†æˆã€‚",
        "score": 78,
        "score_reason": "å·¥å…·å®ç”¨æ€§å¼ºï¼Œè§£å†³äº†å…·ä½“ç—›ç‚¹ï¼Œä»£ç å¼€æºä¸”æ–‡æ¡£å®Œå–„ï¼Œä½†åˆ›æ–°æ€§ä¸­ç­‰ï¼Œå±äºå¯¹ç°æœ‰åˆ†ææµç¨‹çš„æœ‰åŠ›è¡¥å……ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "å•ç»†èƒRNAæµ‹åº",
          "å•æ ¸è‹·é…¸å˜å¼‚",
          "å¯è§†åŒ–",
          "RåŒ…",
          "ç­‰ä½åŸºå› è¡¨è¾¾"
        ],
        "key_insight": "scSNVizå®ç°äº†å¯¹å•ç»†èƒRNAæµ‹åºæ•°æ®ä¸­è¡¨è¾¾SNVçš„é‡åŒ–ã€èšç±»ä¸å¯è§†åŒ–ï¼Œå¹¶èƒ½ä¸Seuratã€Slingshotç­‰ä¸»æµå·¥å…·æ— ç¼é›†æˆï¼Œæ”¯æŒæ•´åˆå¤šç»„å­¦åˆ†æã€‚"
      }
    },
    {
      "title": "CADS: A Causal Inference Framework for Identifying Essential Genes to Enhance Drug Synergy Prediction",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag010/8426180?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nDrug synergy is crucial for developing effective combination therapies, but traditional screening methods suffer from inefficiency and high costs. While deep learning shows promise for predicting drug synergy, current approaches using Transformers and graph neural networks focus on combining drug and cell line features without modelling how genes causally influence drug responses.\nResults\nTo address this limitation, we propose CADS (Causal Adjustment for Drug Synergy), a deep learning framework that integrates causal relationships between genes and drug responses. Leveraging multi-omics data, CADS uses a learnable mask mechanism to identify key causal genes while filtering out irrelevant genetic factors through backdoor adjustment. Our model achieves two key objectives simultaneously: accurate prediction of drug synergy and interpretable causal gene discovery. Experiments on multiple datasets show that CADS consistently outperforms state-of-the-art methods across multiple metrics. Case studies demonstrate that CADS can reduce unnecessary complexity while providing more biological insights through its gene importance scores, which help identify clinically validated cancer-related genes that mediate drug interactions.\nAvailability and Implementation\nTaken together, CADS advances combination therapy prediction by explicitly modelling drug synergy causal genes, offering enhanced interpretability for AI-based drug development. The source code can be found at\nhttps://github.com/HuaiwuZhang/causalDC\n.\nSupplementary Information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼Œæ•´åˆå› æœæ¨æ–­è¯†åˆ«å…³é”®åŸºå› ï¼Œæå‡è¯ç‰©ååŒé¢„æµ‹ï¼Œå…·æœ‰ç®—æ³•åˆ›æ–°æ€§ã€‚",
        "value": 4,
        "summary": "æå‡ºCADSæ¡†æ¶ï¼Œé€šè¿‡å› æœè°ƒæ•´æ•´åˆå¤šç»„å­¦æ•°æ®ï¼ŒåŒæ—¶é¢„æµ‹è¯ç‰©ååŒæ•ˆåº”å¹¶è¯†åˆ«å…³é”®å› æœåŸºå› ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "CADSï¼šä¸€ç§ç”¨äºè¯†åˆ«å…³é”®åŸºå› ä»¥å¢å¼ºè¯ç‰©ååŒæ•ˆåº”é¢„æµ‹çš„å› æœæ¨æ–­æ¡†æ¶",
        "summary": "è¯ç‰©ååŒæ•ˆåº”æ˜¯å¼€å‘æœ‰æ•ˆè”åˆç–—æ³•çš„å…³é”®ï¼Œä½†ä¼ ç»Ÿç­›é€‰æ–¹æ³•æ•ˆç‡ä½ã€æˆæœ¬é«˜ã€‚ç°æœ‰æ·±åº¦å­¦ä¹ æ¨¡å‹å¤šèšç„¦äºæ•´åˆè¯ç‰©ä¸ç»†èƒç³»ç‰¹å¾ï¼Œå´æœªå»ºæ¨¡åŸºå› å¯¹è¯ç‰©ååº”çš„å› æœå½±å“ã€‚ä¸ºæ­¤ï¼Œæœ¬ç ”ç©¶æå‡ºCADSï¼ˆè¯ç‰©ååŒçš„å› æœè°ƒæ•´ï¼‰æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼Œé€šè¿‡æ•´åˆå¤šç»„å­¦æ•°æ®ï¼Œåˆ©ç”¨å¯å­¦ä¹ æ©ç æœºåˆ¶è¯†åˆ«å…³é”®å› æœåŸºå› ï¼Œå¹¶å€ŸåŠ©åé—¨è°ƒæ•´è¿‡æ»¤æ— å…³é—ä¼ å› ç´ ã€‚è¯¥æ¨¡å‹åŒæ—¶å®ç°äº†è¯ç‰©ååŒæ•ˆåº”çš„å‡†ç¡®é¢„æµ‹ä¸å¯è§£é‡Šçš„å› æœåŸºå› å‘ç°ã€‚åœ¨å¤šæ•°æ®é›†ä¸Šçš„å®éªŒè¡¨æ˜ï¼ŒCADSåœ¨å¤šé¡¹æŒ‡æ ‡ä¸ŠæŒç»­ä¼˜äºç°æœ‰æœ€ä¼˜æ–¹æ³•ã€‚æ¡ˆä¾‹ç ”ç©¶æ˜¾ç¤ºï¼Œå…¶åŸºå› é‡è¦æ€§è¯„åˆ†å¯è¯†åˆ«ç»ä¸´åºŠéªŒè¯çš„ã€ä»‹å¯¼è¯ç‰©ç›¸äº’ä½œç”¨çš„ç™Œç—‡ç›¸å…³åŸºå› ï¼Œä»è€Œå‡å°‘ä¸å¿…è¦çš„å¤æ‚æ€§å¹¶æä¾›æ›´å¤šç”Ÿç‰©å­¦è§è§£ã€‚",
        "one_sentence": "CADSæ¡†æ¶é¦–æ¬¡å°†å› æœæ¨æ–­èå…¥è¯ç‰©ååŒé¢„æµ‹ï¼Œåœ¨æå‡å‡†ç¡®ç‡çš„åŒæ—¶ï¼Œå¯è§£é‡Šæ€§åœ°æ­ç¤ºå…³é”®åŸºå› ï¼Œä¸ºAIåˆ¶è¯æä¾›æ–°èŒƒå¼ã€‚",
        "score": 82,
        "score_reason": "æ–¹æ³•æ–°é¢–ï¼Œç»“åˆå› æœæ¨æ–­ä¸æ·±åº¦å­¦ä¹ ï¼›æ•°æ®è¯¦å®ï¼Œæœ‰åŸºå‡†æµ‹è¯•ä¸æ¡ˆä¾‹éªŒè¯ï¼›å¼€æºä»£ç ï¼Œå®ç”¨æ€§å¼ºï¼›ä½†æœªæ˜ç¡®è®¨è®ºæ¨¡å‹å±€é™æ€§ã€‚",
        "category": "BIOAI",
        "keywords": [
          "è¯ç‰©ååŒé¢„æµ‹",
          "å› æœæ¨æ–­",
          "æ·±åº¦å­¦ä¹ ",
          "å¯è§£é‡Šæ€§AI",
          "å¤šç»„å­¦æ•°æ®"
        ],
        "key_insight": "CADSåœ¨å¤šä¸ªæ•°æ®é›†ä¸ŠæŒç»­è¶…è¶Šç°æœ‰æœ€ä¼˜æ–¹æ³•ï¼Œå¹¶èƒ½è¯†åˆ«å‡ºç»ä¸´åºŠéªŒè¯çš„ç™Œç—‡ç›¸å…³åŸºå› ï¼Œä¸ºè”åˆç–—æ³•å¼€å‘æä¾›å…¼å…·é«˜ç²¾åº¦ä¸å¯è§£é‡Šæ€§çš„æ–°å·¥å…·ã€‚"
      }
    },
    {
      "title": "Improving biomedical entity linking with generative relevance feedback",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag011/8426181?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nBiomedical Entity Linking (BEL) maps mentions in biomedical text to standardized identifiers, enabling structured data integration and downstream knowledge discovery. However, current BEL systems remain fundamentally constrained by the recall of the initial candidate pool, where suboptimal retrieval limits the overall effectiveness of the normalization pipeline.\nResults\nWe present the first systematic evaluation of\nGenerative Relevance Feedback\n(GRF) for enhancing candidate retrieval in state-of-the-art BEL systems. GRF leverages large language models (LLMs) to enrich the expressiveness of the mention in a zero-shot fashion. We assess GRFâ€™s impact under two scenariosâ€”direct linking prediction and candidate generation in cascading normalization pipelinesâ€”and analyze its sensitivity to different LLMs, feedback types, and integration strategies. Experiments across eight corpora and four biomedical knowledge bases demonstrate that integrating GRF significantly improves both accuracy and recall, thereby increasing the upper bound on normalization performance. Our findings highlight GRF as an efficient, model-agnostic solution and underscore its potential as a key component for advancing BEL.\nAvailability\nThe code to reproduce our experiments can be found at:\nhttps://doi.org/10.5281/zenodo.17853541\n.",
      "filter_data": {
        "ignore": false,
        "reason": "æ–‡ç« æå‡ºåˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹æ”¹è¿›ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥çš„æ–°æ–¹æ³•ï¼Œå±äºç®—æ³•åˆ›æ–°ï¼Œå¯¹ç”Ÿä¿¡å·¥å…·å¼€å‘æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 4,
        "summary": "é¦–æ¬¡ç³»ç»Ÿè¯„ä¼°ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆåœ¨æå‡ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥å€™é€‰æ£€ç´¢æ€§èƒ½ä¸­çš„åº”ç”¨ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "åˆ©ç”¨ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆæ”¹è¿›ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥",
        "summary": "ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥ï¼ˆBELï¼‰æ˜¯å°†ç”Ÿç‰©åŒ»å­¦æ–‡æœ¬ä¸­çš„æåŠæ˜ å°„åˆ°æ ‡å‡†åŒ–æ ‡è¯†ç¬¦çš„å…³é”®æŠ€æœ¯ï¼Œä½†ç°æœ‰ç³»ç»Ÿå—é™äºåˆå§‹å€™é€‰æ± çš„å¬å›ç‡ã€‚æœ¬ç ”ç©¶é¦–æ¬¡ç³»ç»Ÿè¯„ä¼°äº†ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆï¼ˆGRFï¼‰åœ¨æå‡BELå€™é€‰æ£€ç´¢æ•ˆæœä¸­çš„ä½œç”¨ã€‚GRFåˆ©ç”¨å¤§è¯­è¨€æ¨¡å‹ï¼ˆLLMï¼‰ä»¥é›¶æ ·æœ¬æ–¹å¼å¢å¼ºæåŠçš„è¡¨è¾¾èƒ½åŠ›ï¼Œé€šè¿‡åœ¨å…«ä¸ªè¯­æ–™åº“å’Œå››ä¸ªç”Ÿç‰©åŒ»å­¦çŸ¥è¯†åº“ä¸Šçš„å®éªŒè¯æ˜ï¼Œé›†æˆGRFèƒ½æ˜¾è‘—æé«˜å‡†ç¡®ç‡å’Œå¬å›ç‡ï¼Œä»è€Œæå‡å½’ä¸€åŒ–æ€§èƒ½çš„ä¸Šé™ã€‚è¯¥æ–¹æ³•æ˜¯ä¸€ç§é«˜æ•ˆã€æ¨¡å‹æ— å…³çš„è§£å†³æ–¹æ¡ˆã€‚",
        "one_sentence": "é¦–æ¬¡ç³»ç»Ÿè¯„ä¼°ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆï¼Œæ˜¾è‘—æå‡ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥çš„å‡†ç¡®ç‡ä¸å¬å›ç‡ï¼Œä¸ºçŸ¥è¯†å‘ç°æä¾›æ–°å·¥å…·ã€‚",
        "score": 78,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€å®éªŒæ•°æ®è¯¦å®ã€å¼€æºä»£ç ï¼Œä½†ç¼ºä¹å¯¹å±€é™æ€§çš„æ·±å…¥è®¨è®ºã€‚",
        "category": "BIOAI",
        "keywords": [
          "ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥",
          "ç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆ",
          "å¤§è¯­è¨€æ¨¡å‹",
          "å€™é€‰æ£€ç´¢",
          "çŸ¥è¯†å‘ç°"
        ],
        "key_insight": "é›†æˆç”Ÿæˆå¼ç›¸å…³æ€§åé¦ˆï¼ˆGRFï¼‰èƒ½æ˜¾è‘—æé«˜ç”Ÿç‰©åŒ»å­¦å®ä½“é“¾æ¥çš„å‡†ç¡®ç‡å’Œå¬å›ç‡ï¼Œæå‡å½’ä¸€åŒ–æ€§èƒ½ä¸Šé™ã€‚"
      }
    },
    {
      "title": "GAMMA: Gap-aware Motif Mining under Incomplete Labeling with Applications to MHC Motifs",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag014/8426182?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nSequence motif identification is crucial for understanding molecular recognition, particularly in immune responses involving peptide binding to MHC class I molecules for antigen presentation to T cells. Traditionally, MHC class I binding motifs are assumed to be contiguous and span nine amino acids. However, structural evidence suggests that binding may involve non-adjacent residues, challenging the assumptions of existing methods.\nResults\nIn this study, we propose GAMMA (Gap-Aware Motif Mining Algorithm), a probabilistic framework designed to identify non-contiguous motifs under conditions of incomplete labeling. GAMMA employs Bayesian inference with MCMC sampling to jointly estimate motif parameters, binding locations, and the relative spacing between binding positions. Through extensive simulations and real-world applications to MHC class I peptide datasets, GAMMA outperforms existing motif discovery tools such as GLAM2 in accurately localizing binding residues and identifying the underlying motifs. Notably, our results suggest that the true number of binding residues may be eight, fewer than the commonly assumed nine. In addition, for longer peptides, the model captures increased flexibility in the central region, consistent with structural observations that peptides may bulge in the middle.\nAvailability\nThe raw data and the source codes are available on GitHub (\nhttps://github.com/RanLIUaca/GAMMAmotif\n).\nSupplementary information\nSupplementary data are available at\nBioinformatics\nonline.",
      "filter_data": {
        "ignore": false,
        "reason": "æå‡ºæ–°çš„ç”Ÿç‰©ä¿¡æ¯å­¦ç®—æ³•GAMMAï¼Œç”¨äºè¯†åˆ«éè¿ç»­åºåˆ—æ¨¡ä½“ï¼Œå…·æœ‰æ–¹æ³•å­¦åˆ›æ–°å’Œåº”ç”¨ä»·å€¼ã€‚",
        "value": 4,
        "summary": "ä»‹ç»GAMMAç®—æ³•ï¼Œä¸€ç§åŸºäºè´å¶æ–¯æ¨æ–­çš„gap-awareæ¨¡ä½“æŒ–æ˜æ–¹æ³•ï¼Œç”¨äºMHCç»“åˆè‚½çš„éè¿ç»­æ¨¡ä½“è¯†åˆ«ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "GAMMAï¼šåœ¨éå®Œæ•´æ ‡è®°ä¸‹æŒ–æ˜å«é—´éš”åŸºåºçš„ç®—æ³•åŠå…¶åœ¨MHCåŸºåºä¸­çš„åº”ç”¨",
        "summary": "ä¼ ç»ŸMHC Iç±»åˆ†å­ç»“åˆåŸºåºé€šå¸¸è¢«è®¤ä¸ºæ˜¯è¿ç»­ä¸”é•¿åº¦ä¸º9ä¸ªæ°¨åŸºé…¸ï¼Œä½†ç»“æ„è¯æ®è¡¨æ˜ç»“åˆå¯èƒ½æ¶‰åŠéè¿ç»­æ®‹åŸºã€‚æœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§æ¦‚ç‡æ¡†æ¶GAMMAï¼ˆGap-Aware Motif Mining Algorithmï¼‰ï¼Œæ—¨åœ¨éå®Œæ•´æ ‡è®°æ¡ä»¶ä¸‹è¯†åˆ«éè¿ç»­åŸºåºã€‚è¯¥ç®—æ³•é‡‡ç”¨è´å¶æ–¯æ¨æ–­ä¸MCMCé‡‡æ ·ï¼Œè”åˆä¼°è®¡åŸºåºå‚æ•°ã€ç»“åˆä½ç½®åŠç»“åˆä½ç‚¹é—´çš„ç›¸å¯¹é—´è·ã€‚é€šè¿‡å¤§é‡æ¨¡æ‹Ÿå’ŒçœŸå®MHC Iç±»è‚½æ®µæ•°æ®é›†çš„åº”ç”¨ï¼ŒGAMMAåœ¨å‡†ç¡®å®šä½ç»“åˆæ®‹åŸºå’Œè¯†åˆ«æ½œåœ¨åŸºåºæ–¹é¢ä¼˜äºç°æœ‰åŸºåºå‘ç°å·¥å…·ï¼ˆå¦‚GLAM2ï¼‰ã€‚ç ”ç©¶ç»“æœæç¤ºï¼ŒçœŸå®çš„ç»“åˆæ®‹åŸºæ•°å¯èƒ½ä¸º8ä¸ªï¼Œå°‘äºé€šå¸¸å‡è®¾çš„9ä¸ªï¼›å¯¹äºè¾ƒé•¿è‚½æ®µï¼Œæ¨¡å‹æ•æ‰åˆ°ä¸­å¿ƒåŒºåŸŸçµæ´»æ€§å¢åŠ ï¼Œè¿™ä¸è‚½æ®µä¸­é—´å¯èƒ½å‡¸èµ·çš„ç»“æ„è§‚å¯Ÿä¸€è‡´ã€‚",
        "one_sentence": "GAMMAç®—æ³•çªç ´ä¼ ç»Ÿè¿ç»­åŸºåºå‡è®¾ï¼Œåˆ©ç”¨è´å¶æ–¯æ¡†æ¶ç²¾å‡†æŒ–æ˜å«é—´éš”çš„MHCç»“åˆåŸºåºï¼Œæ­ç¤ºç»“åˆæ®‹åŸºæ•°å¯èƒ½ä»…ä¸º8ä¸ªã€‚",
        "score": 82,
        "score_reason": "æ–¹æ³•æ–°é¢–ã€æ•°æ®è¯¦å®ã€å¼€æºå¯ç”¨ï¼Œè§£å†³äº†éè¿ç»­åŸºåºæŒ–æ˜çš„å…·ä½“ç—›ç‚¹ï¼Œä½†æœªæ˜ç¡®è®¨è®ºå±€é™æ€§ã€‚",
        "category": "BIOINFO",
        "keywords": [
          "éè¿ç»­åŸºåºæŒ–æ˜",
          "MHCç»“åˆåŸºåº",
          "è´å¶æ–¯æ¨æ–­",
          "MCMCé‡‡æ ·",
          "å…ç–«ä¿¡æ¯å­¦"
        ],
        "key_insight": "GAMMAç®—æ³•æ­ç¤ºMHC Iç±»åˆ†å­ç»“åˆæ®‹åŸºæ•°å¯èƒ½ä¸º8ä¸ªï¼Œè€Œéä¼ ç»Ÿè®¤ä¸ºçš„9ä¸ªã€‚"
      }
    },
    {
      "title": "Characterizing Clinical Toxicity in Cancer Combination Therapies",
      "link": "https://academic.oup.com/bioinformatics/advance-article/doi/10.1093/bioinformatics/btag007/8426183?rss=1",
      "pub_date": "2026-01-14 00:00",
      "source": "Unknown",
      "content_text": "Abstract\nMotivation\nPredicting synergistic cancer drug combinations through computational methods offers a scalable approach to creating therapies that are more effective and less toxic. However, most algorithms focus solely on synergy without considering toxicity when selecting optimal drug combinations. In the absence of combinatorial toxicity assays, a few models use toxicity penalties to balance high synergy with lower toxicity. Still, these penalties have not been explicitly validated against known drug-drug interactions.\nResults\nIn this study, we examine whether synergy scores and toxicity metrics correlate with known adverse drug interactions. While some metrics show trends with toxicity levels, our results reveal significant limitations in using them as penalties. These findings highlight the challenges of incorporating toxicity into synergy prediction frameworks and suggest that advancing the field requires more comprehensive combination toxicity data.\nAvailability and Implementation\nThe code written for this project is available at\nhttps://github.com/amw14/toxicity-cancer-drug-combination\n.",
      "filter_data": {
        "ignore": false,
        "reason": "æ¢è®¨ç™Œç—‡è”åˆç–—æ³•æ¯’æ€§é¢„æµ‹çš„è®¡ç®—æ–¹æ³•ï¼Œæ¶‰åŠç®—æ³•è¯„ä¼°ä¸æ•°æ®éœ€æ±‚ï¼Œå¯¹è®¡ç®—ç”Ÿç‰©å­¦æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 3,
        "summary": "ç ”ç©¶è¯„ä¼°ååŒä½œç”¨è¯„åˆ†ä¸æ¯’æ€§æŒ‡æ ‡åœ¨é¢„æµ‹ç™Œç—‡è¯ç‰©ç»„åˆä¸è‰¯ååº”ä¸­çš„ç›¸å…³æ€§åŠå±€é™æ€§ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "ç™Œç—‡è”åˆç–—æ³•ä¸´åºŠæ¯’æ€§ç‰¹å¾åˆ†æ",
        "summary": "æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°è®¡ç®—é¢„æµ‹çš„ç™Œç—‡è¯ç‰©ç»„åˆååŒæ•ˆåº”åˆ†æ•°ä¸æ¯’æ€§æŒ‡æ ‡æ˜¯å¦ä¸å·²çŸ¥çš„è¯ç‰©ä¸è‰¯ç›¸äº’ä½œç”¨ç›¸å…³ã€‚ç›®å‰å¤§å¤šæ•°ç®—æ³•åœ¨ç­›é€‰æœ€ä¼˜è¯ç‰©ç»„åˆæ—¶ä»…å…³æ³¨ååŒæ€§è€Œå¿½ç•¥æ¯’æ€§ï¼Œå°‘æ•°æ¨¡å‹è™½å¼•å…¥æ¯’æ€§æƒ©ç½šé¡¹ä»¥å¹³è¡¡é«˜ååŒæ€§ä¸ä½æ¯’æ€§ï¼Œä½†è¿™äº›æƒ©ç½šé¡¹å°šæœªç»è¿‡å·²çŸ¥è¯ç‰©ç›¸äº’ä½œç”¨çš„æ˜ç¡®éªŒè¯ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œå°½ç®¡éƒ¨åˆ†æŒ‡æ ‡ä¸æ¯’æ€§æ°´å¹³å‘ˆç°è¶‹åŠ¿æ€§å…³è”ï¼Œä½†å°†å…¶ç”¨ä½œæƒ©ç½šé¡¹å­˜åœ¨æ˜¾è‘—å±€é™æ€§ã€‚è¿™å‡¸æ˜¾äº†å°†æ¯’æ€§çº³å…¥ååŒé¢„æµ‹æ¡†æ¶çš„æŒ‘æˆ˜ï¼Œå¹¶æŒ‡å‡ºè¯¥é¢†åŸŸçš„å‘å±•éœ€è¦æ›´å…¨é¢çš„ç»„åˆæ¯’æ€§æ•°æ®æ”¯æŒã€‚",
        "one_sentence": "ç ”ç©¶æ­ç¤ºï¼šå½“å‰åŸºäºååŒæ•ˆåº”çš„ç™Œç—‡è¯ç‰©ç»„åˆé¢„æµ‹æ¨¡å‹ï¼Œå…¶æ¯’æ€§æƒ©ç½šé¡¹ä¸å·²çŸ¥ä¸è‰¯ååº”å…³è”æ€§å¼±ï¼Œå‡¸æ˜¾æ¯’æ€§æ•°æ®ç¼ºå¤±æ˜¯AIåˆ¶è¯å…³é”®ç“¶é¢ˆã€‚",
        "score": 72,
        "score_reason": "ç ”ç©¶é—®é¢˜æ˜ç¡®ï¼Œæ–¹æ³•å…·æœ‰é’ˆå¯¹æ€§ï¼Œç»“è®ºæŒ‡å‡ºäº†ç°æœ‰æ–¹æ³•çš„å±€é™æ€§å¹¶æå‡ºäº†æ•°æ®éœ€æ±‚ï¼Œå±äºæ ‡å‡†çš„ç§‘ç ”è¿›å±•ï¼Œä½†åˆ›æ–°æ€§æœ‰é™ã€‚",
        "category": "BIOAI",
        "keywords": [
          "è¯ç‰©ç»„åˆååŒæ€§",
          "æ¯’æ€§é¢„æµ‹",
          "è®¡ç®—æ¨¡å‹",
          "è¯ç‰©ç›¸äº’ä½œç”¨",
          "AIåˆ¶è¯"
        ],
        "key_insight": "ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œç°æœ‰çš„ååŒæ•ˆåº”åˆ†æ•°å’Œæ¯’æ€§æŒ‡æ ‡ä¸å·²çŸ¥ä¸è‰¯è¯ç‰©ç›¸äº’ä½œç”¨çš„å…³è”æ€§æœ‰é™ï¼Œä¸èƒ½å¯é åœ°ç”¨ä½œä¼˜åŒ–è¯ç‰©ç»„åˆçš„æ¯’æ€§æƒ©ç½šé¡¹ã€‚"
      }
    },
    {
      "title": "Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch",
      "link": "https://www.bio-itworld.com/news/2026/01/13/illumina-at-jpm-2026--strong-q4--clinical-growth--and-bioinsight-launch",
      "pub_date": "2026-01-13 22:23",
      "source": "Unknown",
      "content_text": "<p><strong>By Allison Proffitt</strong></p><p><strong>January 13, 2026</strong> | Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights.</p><p>\"I am proud of what the Illumina team delivered in 2025,\" Thaysen said. \"We remain focused on expanding the NGS ecosystem, supporting our customers and accelerating our growth into 26 and beyond.\"</p><p><strong>Q4 Beats Across the Board</strong></p><p>The headlines came early: Illumina's Q4 revenue grew 4% on a constant currency basis and 7% excluding China, with earnings per share between $1.27 and $1.30. For the full year, EPS reached approximately $4.76 to $4.79&mdash;representing earnings growth of over 15% despite what Thaysen characterized as a year \"full of geopolitical changes.\"</p><p>Perhaps more telling was the placement number: 95 NovaSeq X instruments in Q4, surpassing the 91 placements from the prior year's fourth quarter. During the Q3 earnings call, Thaysen had suggested placements wouldn't reach those levels. What changed?</p><p>\"We were definitely very pleased with the placement of our NovaSeq X,\" Thaysen said during the Q&amp;A. \"It really shows that the performance and the reliability and the number of things you can do on the NovaSeq X is really resonating with our customers.\" The bulk of placements went to clinical customers \"doubling down\" on the platform as they prepare to scale new products, though research customers also contributed more than expected, he said.</p><p>The consumables story was equally strong. By year end, the NovaSeq X accounted for approximately 80% of high throughput gigabases shipped, up from 75% in Q3. \"The math is working and it's working according to the expectations,\" Thaysen said, referring to the company's long-articulated thesis that volume growth would offset pricing declines as customers transitioned to the X platform.</p><p><strong>Clinical Dominance</strong></p><p>Perhaps the most significant revelation came in the breadth of clinical strength. While many analysts track Illumina's largest US clinical customers&mdash;companies that have been publicly reporting strong results&mdash;CFO Ankur Dhingra emphasized that \"the strength in clinical business was not just centered in the large US clinical players only. The clinical strength was fairly broad based not just in the US&mdash;in Europe and Asia as well.\"</p><p>Clinical customers now represent roughly 60% of Illumina's sequencing consumables revenue, and their sequencing volume continues to grow above 30%. The driver? Deeper, more comprehensive testing. \"Many are now converting assays from exome sequencing to whole genome sequencing, which require approximately 15 times increase in sequencing volume,\" Thaysen explained, citing rare genetic disease testing as one example.</p><p>When asked about the timeline for this shift to whole genome approaches, Dhingra noted that whole genome still represents a small fraction of overall clinical volumes today. \"A lot of the historical tests were built on exomes and are still validated tests,\" he said. But new whole genome-based tests are launching, and \"we see a long runway from a sequencing volume growth perspective.\"</p><p><strong>China Complexity</strong></p><p>The China question inevitably arose. \"I guess we can never escape the China question,\" Thaysen acknowledged. The company spent much of 2025 navigating sanctions resulting from its placement on China&rsquo;s Ministry of Commerce&rsquo;s Unreliable Entities List. Illumina was prohibited from exporting sequencers to China and imposing other restrictions due to alleged violations of market rules and discriminatory practices against Chinese enterprises.</p><p>In Q4, Illumina was allowed to import instruments back into China for OEM customers, representing about 20% of the opportunity. Thaysen himself traveled to China to meet with officials. \"The sanctions have been lifted,\" he reported, though the company remains on the Unreliable Entities List. \"That will be the ultimate goal to get that eliminated at this point. We're working on that, but I still know clear outcome.\"</p><p>The Q4 beat included a China component&mdash;roughly a third of the overall beat, according to Thaysen&mdash;but it came entirely from consumables, not instruments. \"Our customers continue to want to work with us,\" Thaysen said. \"They know who is the innovator in the industry, and they know who is actually providing the highest quality sequencing.\"</p><p><strong>BioInsight: The AI Play</strong></p><p>The most forward-looking announcement was BioInsight, Illumina's new business unit focused on generating proprietary datasets and AI models for drug discovery. Thaysen framed it as a convergence of four capabilities: sequencing at scale, CRISPR-based perturbation tools, dedicated compute power, and AI.&nbsp;</p><p>\"This fundamentally changed drug discovery,\" Thaysen said. \"Instead of relying on years of iterative wet lab experiments, pharma and biotech companies can increasingly build, test, and refine biological models digitally, accelerating timelines, and improve success rates.\"</p><p>The Illumina Billion Cell Atlas is the first data product to emerge from BioInsight, the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The company describes the Billion Cell Atlas as, &ldquo;the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.&rdquo;</p><p>Under an alliance framework with AstraZeneca, Merck, and Eli Lilly as founding participants, the Atlas is already in build for a curated set of cell lines to drive drug target validation, train advanced AI models at scale, and advance research into fundamental disease mechanisms that have previously been out of reach. According to the announcement, Merck will leverage the Atlas to accelerate precision medicine approaches across their drug discovery pipelines. The data will help train the company's proprietary AI/ML foundation models and build virtual cell models, with the aim of improving prediction of disease indications.</p><p>The ambition extends well beyond the initial dataset. \"Having now both the single cell capabilities, sequencing, compute power, and AI capabilities under our roof, we can really scale this into something that individual customers can't do on their own,\" Thaysen explained during Q&amp;A.</p><p>The BioInsight business ties into Illumina's broader multi-omics strategy, which includes recent launches in <a href=\"https://www.bio-itworld.com/news/2024/07/09/illumina-acquires-fluent-biosciences-single-cell-technology\">single cell sequencing</a>, proteomics (through the <a href=\"https://www.bio-itworld.com/news/2025/09/10/illumina-s-commercial-launch-of-proteomics-assay-acquisiton-of-somalogic\">acquisition of SomaLogic from Standard BioTools</a>), and an ex-situ spatial solution predicted for the first half of 2026. \"You can buy one platform and then you can look at it from the genome all the way up to the proteome,\" Thaysen said. \"Biology is much more complicated than understanding the genome and so getting the additional layers on top of that is going to be very powerful.\"</p><p><strong>Competition and Innovation</strong></p><p>Asked about the competitive environment, Thaysen struck a confident tone. \"Competition is always good; it keeps us on our toes,\" he said. But he emphasized that customers aren't simply looking for lower prices&mdash;they want comprehensive solutions.</p><p>\"Customers do not want to pick and choose different components. They want to focus on outcomes,\" he said, highlighting the combination of NovaSeq X's flexibility with Illumina's Dragen compute power and interpretation software. \"The more we can provide our workflows, the more successful we make the customers.\"</p><p>Illumina continues to invest heavily in innovation, including the constellation technology <a href=\"https://www.bio-itworld.com/news/2025/01/16/illumina-at-jpm-multi-omics-constellation-partnerships\">discussed last year at JPM</a>, which has been \"getting rave reviews in early access\" and is on pace for a launch in the first half of 2026. Constellation reduces library prep requirements and captures information previously difficult to obtain with short-read techniques. \"We believe this technology will lead to development of several new clinical application areas,\" Thaysen said.</p><p><strong>Looking Ahead</strong></p><p>While Illumina will provide full 2026 guidance during its February 5th earnings call, Thaysen indicated the framework shared during Q3 earnings still holds: \"26 is looking like second half 25.\" He expects clinical demand to remain a key driver, while the research academic environment, though showing some improvement in sentiment, will likely remain \"muted\" through 2026.</p><p>On capital allocation, the company returned $740 million to shareholders via share repurchases in 2025 and maintains strong cash flow generation of approximately $1 billion annually with 140% free cash flow conversion. Priorities remain: invest in innovation, pursue targeted bolt-on acquisitions, and return excess capital to shareholders.</p><p>\"We feel very good about the progress we've made and where Illumina stands today,\" Thaysen concluded. \"We have a strong core business, growing momentum in clinical markets, and a clear strategy to expand our footprint through sequencing, multi-omics, data, and software.\"</p><p>With preliminary results exceeding expectations and new growth vectors in BioInsight and multi-omics, Illumina's \"return to growth\" narrative appears increasingly credible. Whether the company can maintain momentum through 2026's uncertainties&mdash;geopolitical and otherwise&mdash;will be a key question for investors watching the February earnings call.</p>",
      "filter_data": {
        "ignore": false,
        "reason": "è¡Œä¸šå·¨å¤´å‘å¸ƒAIé©±åŠ¨çš„è¯ç‰©å‘ç°æ–°ä¸šåŠ¡å•å…ƒï¼Œå¯¹ç”Ÿä¿¡ä»ä¸šè€…æœ‰é£å‘æ ‡æ„ä¹‰ã€‚",
        "value": 3,
        "summary": "Illuminaåœ¨JPMå¤§ä¼šä¸Šå…¬å¸ƒè¶…é¢„æœŸQ4ä¸šç»©ï¼Œå¹¶æ¨å‡ºAIé©±åŠ¨çš„è¯ç‰©å‘ç°ä¸šåŠ¡å•å…ƒBioInsightã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "Illuminaåœ¨2026å¹´JPMå¤§ä¼šï¼šå¼ºåŠ²ç¬¬å››å­£åº¦ä¸šç»©ã€ä¸´åºŠä¸šåŠ¡å¢é•¿ä¸BioInsightæ–°éƒ¨é—¨å‘å¸ƒ",
        "summary": "æœ¬æ–‡æŠ¥é“äº†Illuminaé¦–å¸­æ‰§è¡Œå®˜Jacob Thaysenåœ¨2026å¹´JPæ‘©æ ¹åŒ»ç–—å¥åº·å¤§ä¼šä¸Šçš„æ¼”è®²ã€‚æ ¸å¿ƒå†…å®¹åŒ…æ‹¬ï¼šIllumina 2025å¹´ç¬¬å››å­£åº¦åˆæ­¥ä¸šç»©è¶…é¢„æœŸï¼Œè¥æ”¶å¢é•¿4%ï¼ˆæŒ‰å›ºå®šæ±‡ç‡è®¡ç®—ï¼‰ï¼Œæ¯è‚¡æ”¶ç›Šåœ¨1.27è‡³1.30ç¾å…ƒä¹‹é—´ï¼›å…¨å¹´æ¯è‚¡æ”¶ç›Šçº¦4.76-4.79ç¾å…ƒï¼Œå¢é•¿è¶…15%ã€‚å…³é”®é©±åŠ¨å› ç´ æ˜¯ä¸´åºŠæµ‹åºä¸šåŠ¡ï¼Œå…¶å æµ‹åºè€—ææ”¶å…¥çš„çº¦60%ï¼Œä¸”æµ‹åºé‡æŒç»­å¢é•¿è¶…30%ã€‚æ–‡ç« ç‰¹åˆ«æŒ‡å‡ºï¼Œä¸´åºŠå®¢æˆ·æ­£ä»å¤–æ˜¾å­ç»„æµ‹åºè½¬å‘å…¨åŸºå› ç»„æµ‹åºï¼Œåè€…å¸¦æ¥çº¦15å€çš„æµ‹åºé‡æå‡ã€‚æ­¤å¤–ï¼Œå…¬å¸å®£å¸ƒæˆç«‹æ–°ä¸šåŠ¡éƒ¨é—¨BioInsightï¼Œæ—¨åœ¨é€šè¿‡AIé©±åŠ¨çš„ç”Ÿç‰©å­¦æ´å¯ŸåŠ é€Ÿè¯ç‰©å‘ç°ã€‚æŠ¥å‘Šä¹ŸæåŠäº†åœ¨ä¸­å›½å¸‚åœºé¢ä¸´çš„åˆ¶è£æŒ‘æˆ˜ã€‚",
        "one_sentence": "Illumina CEOåœ¨JPMå¤§ä¼šå®£å¸ƒQ4ä¸šç»©è¶…é¢„æœŸï¼Œä¸´åºŠæµ‹åºé©±åŠ¨å¢é•¿ï¼Œå¹¶æ¨å‡ºAIé©±åŠ¨çš„BioInsightéƒ¨é—¨ä»¥è¿›å†›è¯ç‰©å‘ç°é¢†åŸŸã€‚",
        "score": 78,
        "score_reason": "æ•°æ®è¯¦å®ï¼Œæä¾›äº†å…·ä½“çš„è´¢åŠ¡å’Œè¿è¥æŒ‡æ ‡ï¼ˆå¦‚è¥æ”¶å¢é•¿ã€NovaSeq Xè£…æœºé‡ã€ä¸´åºŠä¸šåŠ¡å æ¯”ï¼‰ï¼Œå¹¶æ­ç¤ºäº†é‡è¦çš„è¡Œä¸šè¶‹åŠ¿ï¼ˆå¦‚ä¸´åºŠå‘å…¨åŸºå› ç»„æµ‹åºçš„è½¬æ¢ï¼‰ã€‚ä½†å†…å®¹æœ¬è´¨ä¸Šæ˜¯ä¼ä¸šæ–°é—»å‘å¸ƒå’Œè´¢æŠ¥è§£è¯»ï¼Œç¼ºä¹ç‹¬ç«‹çš„æ·±åº¦åˆ†ææˆ–æ‰¹åˆ¤æ€§è§†è§’ï¼Œåˆ›æ–°æ€§æœ‰é™ã€‚",
        "category": "INDUSTRY",
        "keywords": [
          "Illumina",
          "ä¸´åºŠæµ‹åº",
          "å…¨åŸºå› ç»„æµ‹åº",
          "NovaSeq X",
          "AIè¯ç‰©å‘ç°"
        ],
        "key_insight": "ä¸´åºŠå®¢æˆ·ä»å¤–æ˜¾å­ç»„æµ‹åºè½¬å‘å…¨åŸºå› ç»„æµ‹åºï¼Œå¸¦æ¥çº¦15å€çš„æµ‹åºé‡å¢é•¿ï¼Œä¸´åºŠä¸šåŠ¡å·²å Illuminaæµ‹åºè€—ææ”¶å…¥çš„çº¦60%ã€‚"
      }
    },
    {
      "title": "PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics",
      "link": "https://www.bio-itworld.com/news/2026/01/13/pacbio-at-jpm-2026--clinical-momentum-and-sprq-nx-economics",
      "pub_date": "2026-01-13 13:39",
      "source": "Unknown",
      "content_text": "<div><p paraid=\"1931598907\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{7}\"><strong>By Allison Proffitt&nbsp;</strong></p></div><div><p paraid=\"1904820722\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{9}\"><strong>January&nbsp;13,&nbsp;2026</strong>&nbsp;| PacBio president Christian Henry presented at the 44th Annual J.P. Morgan Healthcare Conference with strong fourth quarter growth, breakthrough clinical adoption, and economics that position long-read sequencing as competitive with short reads.&nbsp;</p></div><div><p paraid=\"1111345968\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{11}\">Where&nbsp;<a href=\"https://www.bio-itworld.com/news/2025/01/21/pacbio-at-jpm-portfolio-development-ldts\" target=\"_blank\">2025's&nbsp;presentation</a>&nbsp;focused on portfolio development and the promise of laboratory-developed tests, this year Henry&nbsp;demonstrated&nbsp;that those investments are paying off with concrete results: 16% sequential growth in Q4, 40% growth in clinical shipments for the year, and regulatory approval of the first long-read platform anywhere in the world.&nbsp;</p></div><div><p paraid=\"2131120832\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{13}\"><strong>Strong Quarter Caps Growth Year&nbsp;</strong></p></div><div><p paraid=\"1059032116\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{15}\">PacBio anticipates reporting $160 million in revenue for 2025,&nbsp;representing&nbsp;4% growth despite significant headwinds in academic funding. But the real story was the fourth quarter, which reached $44.6 million&mdash;a 14% increase over Q4 2024's $39.2 million.&nbsp;</p></div><div><p paraid=\"1344550778\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{17}\">The growth was driven by record consumables, with three of 2025's four quarters achieving all-time highs for the company. Pull-through reached $242,000 per system in Q4, at the high end of PacBio's stated expectations. The company's consumable shipments grew 19% year-over-year, concentrated in human-focused markets where the three-year compound annual growth rate now stands at 23%.&nbsp;</p></div><div><p paraid=\"1170810741\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{19}\">This performance stands in contrast to last year's JPM presentation, where Henry focused heavily on efficiency measures and cost reductions following a challenging period. PacBio reduced cash burn to approximately $110 million in 2025, down significantly from prior years, while&nbsp;maintaining&nbsp;$280 million in cash and investments.&nbsp;</p><div><p paraid=\"1522972936\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{21}\"><strong>Clinical Market Transforms Business Mix&nbsp;</strong></p></div><div><p paraid=\"167648940\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{23}\">The clinical segment became PacBio's growth engine in 2025, expanding 20% despite flat performance in non-human applications. This shift&nbsp;represents&nbsp;a fundamental change from the academic-heavy customer base that dominated prior years.&nbsp;</p></div><div><p paraid=\"100336759\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{25}\">\"We had major headwinds in the academic markets, but we were able to grow in spite of that through growing very quickly in the clinical market,\" Henry said. Clinical-focused customers saw shipment growth of over 40% during the year.&nbsp;</p></div><div><p paraid=\"2077233296\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{29}\">The transformation Henry&nbsp;<a href=\"https://www.bio-itworld.com/news/2025/01/21/pacbio-at-jpm-portfolio-development-ldts\" target=\"_blank\">previewed at last year's JPM conference</a>&mdash;with early adopters like Quest Diagnostics, Myriad Genetics, and Radboud University Medical Center beginning to deploy HiFi sequencing&mdash;has accelerated into clinical implementation.&nbsp;</p></div><div><p paraid=\"1512977715\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{31}\">Berry Genomics achieved a landmark milestone in December when China's NMPA approved the Sequel&nbsp;IIe&nbsp;platform for thalassemia testing, marking the first regulatory approval of any long-read sequencing platform globally. The test addresses a market of hundreds of thousands of samples annually, and Berry is expanding its menu to include Fragile X, spinal muscular atrophy, and Duchenne muscular dystrophy.&nbsp;</p></div><div><p paraid=\"1962504237\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{33}\">At Stanford Medicine, clinicians are deploying&nbsp;Revio&nbsp;for pharmacogenomics to personalize prescriptions based on genetic profiles. Children's Mercy&nbsp;Hospital&nbsp;implemented HiFi as a first-line diagnostic for genetic disease, significantly improving diagnostic success while reducing turnaround times. Radboud UMC in the Netherlands has rapidly expanded usage,&nbsp;consolidating&nbsp;multiple standard-of-care tests onto a single&nbsp;Revio&nbsp;assay.&nbsp;</p></div><div><p paraid=\"1849422407\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{35}\">Henry emphasized the rare disease opportunity, noting that more than 300 million patients globally suffer from rare diseases that could&nbsp;benefit&nbsp;from HiFi sequencing. The European rare disease market alone&nbsp;represents&nbsp;nearly $240 million&nbsp;in annual revenue.&nbsp;</p></div><div><p paraid=\"1361668005\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{37}\"><strong>Platform Performance:&nbsp;Revio&nbsp;&nbsp;</strong></p></div><div><p paraid=\"815980453\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{39}\">Revio, PacBio's flagship platform, faced placement headwinds in early 2025 due to funding uncertainty but finished strong with 21 placements in Q4. The clinical market drove&nbsp;the majority of&nbsp;demand, and 20% of 2025 orders were multi-system purchases&mdash;a&nbsp;key&nbsp;leading indicator for consumable growth.&nbsp;</p></div><div><p paraid=\"1541922729\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{41}\">Last year at JPM, Henry reported that PacBio had placed 97&nbsp;Revio&nbsp;units in 2024, making it the fastest-adopted platform in company history. The 2025 momentum, particularly in clinical accounts scaling from single to multiple systems,&nbsp;suggests&nbsp;consumable revenue will continue growing.&nbsp;</p></div><div><p paraid=\"260755016\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{43}\">But PacBio&nbsp;isn&rsquo;t&nbsp;abandoning its customer base outside of healthcare. Concurrent with Henry&rsquo;s talk at the J.P. Morgan Healthcare Conference, another team of PacBio researchers presented at&nbsp;PAG33, the Plant and Animal Genome Conference. They shared&nbsp;CiFi, a community-developed chromosome-scale sequencing method&nbsp;that&nbsp;integrates chromatin conformation capture (3C) with PacBio&nbsp;HiFi&nbsp;long-read sequencing to generate multi-contact reads and longer fragments.&nbsp;When paired with&nbsp;Revio&nbsp;SPRQ chemistry, PacBio hopes&nbsp;CiFi&nbsp;can lower barriers for projects constrained by cost or sample availability.&nbsp;It was published in&nbsp;<em>Nature Communications</em>&nbsp;last December (<a href=\"https://www.nature.com/articles/s41467-025-66918-y\" target=\"_blank\">DOI:&nbsp;10.1038/s41467-025-66918-y</a>).</p></div><div><p paraid=\"2133034049\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{45}\"><strong>Vega Gains&nbsp;Traction&nbsp;</strong></p></div><div><p paraid=\"1625443062\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{48}\">Vega, the desktop platform launched in&nbsp;late 2024, exceeded expectations with 140 placements in its first full year&mdash;far surpassing the seven units Henry mentioned shipping before year-end 2024. Critically, 65% of Vega placements went to customers new to PacBio, expanding the company's reach into microbial genetics, targeted panels, HLA analysis, and small genome applications. The product line generated approximately $24 million in shipments.&nbsp;</p></div><div><p paraid=\"935608089\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{50}\">Fourth&nbsp;quarter was Vega's strongest yet with 42 placements, up from 32 in Q3. The sales funnel continues improving, with deals now closing within the same quarter they originate&mdash;a sign of market maturity and reduced sales friction.&nbsp;</p></div><div><p paraid=\"263637138\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{52}\"><strong>SPRQ-Nx: The Economics Game-Changer&nbsp;</strong></p></div><div><p paraid=\"417260828\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{54}\">The breakthrough Henry&nbsp;was most excited about&nbsp;was&nbsp;<a href=\"https://www.bio-itworld.com/news/2025/11/04/pacbio-aims-for-sub--300-genomes-with-reusable-smrt-cells\" target=\"_blank\">SPRQ-Nx&nbsp;chemistry</a>, announced at the American Society of Human Genetics conference in October and entering beta testing in November. The technology leverages reusable SMRT cells&mdash;PacBio's most expensive&nbsp;component&mdash;to deliver 25% higher throughput per run while dramatically reducing cost per sample.&nbsp;</p></div><div><p paraid=\"1720699645\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{56}\">\"This is one of the rare times where not only&nbsp;we can&nbsp;lower the cost to our customers, but we can also expand our gross margins at the same time,\" Henry said, calling it a unique moment in the company's history.&nbsp;</p></div><div><p paraid=\"1813706453\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{58}\">With&nbsp;SPRQ-Nx, PacBio can now price whole genomes with full HiFi resolution at $300 per genome, reaching competitive parity with short-read sequencing. This&nbsp;represents&nbsp;a significant drop from the $500-or-less pricing Henry cited for&nbsp;Revio&nbsp;at&nbsp;<a href=\"https://www.bio-itworld.com/news/2025/01/21/pacbio-at-jpm-portfolio-development-ldts\" target=\"_blank\">last year's J.P.&nbsp;Morgan Healthcare&nbsp;Conference</a>&nbsp;as fundamental to clinical and population-scale opportunities.&nbsp;</p></div><div><p paraid=\"1955435520\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{60}\">Beta customer data shows the first and second runs on reused SMRT cells&nbsp;deliver&nbsp;equivalent output,&nbsp;validating&nbsp;the technology's value proposition. The beta has been so successful that PacBio is expanding it internationally into&nbsp;an early access&nbsp;program starting in February, with broader rollout throughout 2026.&nbsp;</p></div><div><p paraid=\"1314970860\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{62}\">Customer response has been immediate. Henry noted that the&nbsp;SPRQ-Nx&nbsp;announcement has already influenced&nbsp;Revio&nbsp;purchasing decisions, with customers planning larger projects and new accounts engaging with the platform for the first time.&nbsp;</p></div><div><p paraid=\"1398282992\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{64}\"><strong>Data Quality and AI Enable New Applications&nbsp;</strong></p></div><div><p paraid=\"473920625\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{66}\">PacBio's emphasis on data comprehensiveness&nbsp;took center stage this year. The All of Us study published results in October showing that long-read sequencing detected over 50% of disease-driven associations missed by short-read technologies.&nbsp;</p></div><div><p paraid=\"1868620787\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{68}\">PacBio customers generated 60% more data in 2025 than in 2024, significantly outpacing competitors whose data generation grew only around 10%&nbsp;according to Henry. This data explosion enables artificial intelligence applications across three tiers: improving base calling quality,&nbsp;facilitating&nbsp;large training datasets through federated infrastructure, and&nbsp;ultimately powering&nbsp;multi-omic&nbsp;foundation models for diagnostics and drug discovery.&nbsp;</p></div><div><p paraid=\"703641600\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{70}\">The&nbsp;<a href=\"https://hifisolves.org/collections\" target=\"_blank\">HiFi Solves Consortium</a>, a rare disease collaborative with more than 15 members, exemplifies the federated data approach. Participants can query datasets they&nbsp;don't&nbsp;directly&nbsp;possess, enabling discovery of rare variants that might otherwise require impractically large individual cohorts.&nbsp;</p></div><div><p paraid=\"580202087\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{72}\"><strong>Population Sequencing: Large Projects Take Shape&nbsp;</strong></p></div><div><p paraid=\"1635920260\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{74}\">Regional performance showed distinct patterns. Europe was PacBio's fastest-growing territory for the year, driven by clinical adoption in the Netherlands, Nordic countries, and Germany. The Americas region struggled through most of 2025 due to academic funding freezes but showed signs of recovery in Q4. Asia Pacific performed on target, bolstered by the Berry Genomics regulatory approval and growing service provider activity in China.&nbsp;</p></div><div><p paraid=\"876074992\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{76}\">Population sequencing programs progressed&nbsp;substantially in&nbsp;2025. The All of Us study published its first long-read sequencing data in October. The&nbsp;Long Life&nbsp;Family Study began sequencing&nbsp;nearly 8,000&nbsp;samples. The&nbsp;<a href=\"https://www.bio-itworld.com/news/2025/11/04/pacbio-aims-for-sub--300-genomes-with-reusable-smrt-cells\" target=\"_blank\">Korean Pangenome Reference Project</a>&nbsp;is sequencing more than 10,000 samples to create the most comprehensive pan-genome reference ever assembled, incorporating structural variation and methylation data.&nbsp;</p></div><div><p paraid=\"1501185848\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{78}\">Beyond these announced programs, Henry&nbsp;disclosed&nbsp;that PacBio is engaged in projects with the potential for hundreds of thousands of genomes. While he cautioned that these large government-run studies have complex implementations and long sales cycles, the scale represents a major opportunity as&nbsp;SPRQ-Nx&nbsp;economics make HiFi sequencing cost-competitive for population-scale work.&nbsp;</p></div><div><p paraid=\"462309677\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{80}\"><strong>Looking Forward: Standard of Care Ambitions&nbsp;</strong></p></div><div><p paraid=\"2096211978\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{82}\">Where last year's conference outlined goals to drive innovation and explore clinical LDT applications, this year Henry laid out a specific 2026 strategy focused on making HiFi the sequencing standard of care. The plan centers on successful global launch of&nbsp;SPRQ-Nx&nbsp;chemistry, accelerating clinical adoption through customers like Berry Genomics and the HiFi Solves Network, driving population sequencing studies, and continuing to push technological boundaries.&nbsp;</p></div><div><p paraid=\"1915331024\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{84}\">Henry acknowledged that academic funding will&nbsp;likely remain&nbsp;challenged but expressed confidence that clinical momentum will more than compensate. The depth and quality of&nbsp;HiFi data, amplified by AI capabilities, positions PacBio to unlock biological insights that create value for patients, customers, and shareholders.&nbsp;</p></div><div><p paraid=\"68563084\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{86}\">\"Our&nbsp;SPRQ-Nx&nbsp;chemistry fundamentally resets the economics of long-read sequencing,\" Henry said. \"It makes it highly competitive and a compelling value proposition for customers around the world.\"&nbsp;</p></div><div><p paraid=\"971231493\" paraeid=\"{463e8c24-45ab-4aeb-90cf-8562866f6f8f}{89}\">PacBio will&nbsp;provide&nbsp;detailed 2026 guidance at its earnings call scheduled for February, where investors will learn whether the Q4 momentum and&nbsp;SPRQ-Nx&nbsp;economics translate into accelerated growth projections.&nbsp;</p></div></div>",
      "filter_data": {
        "ignore": false,
        "reason": "PacBioåœ¨JPæ‘©æ ¹å¤§ä¼šå±•ç¤ºé•¿è¯»é•¿æµ‹åºä¸´åºŠè¿›å±•åŠç»æµæ€§ï¼Œå¯¹ç”Ÿä¿¡ä»ä¸šè€…äº†è§£æŠ€æœ¯é£å‘æœ‰å‚è€ƒä»·å€¼ã€‚",
        "value": 2,
        "summary": "PacBioåœ¨JPæ‘©æ ¹åŒ»ç–—å¥åº·å¤§ä¼šä¸ŠæŠ¥å‘Šäº†ç¬¬å››å­£åº¦å¼ºåŠ²å¢é•¿ã€ä¸´åºŠé‡‡ç”¨çªç ´ä»¥åŠé•¿è¯»é•¿æµ‹åºç»æµæ€§æå‡ã€‚",
        "language": "è‹±æ–‡"
      },
      "ai_analysis": {
        "title_cn": "PacBioåœ¨2026å¹´æ‘©æ ¹å¤§é€šåŒ»ç–—å¤§ä¼šï¼šä¸´åºŠåŠ¿å¤´ä¸SPRQ-Nxç»æµæ€§",
        "summary": "æœ¬æ–‡æŠ¥é“äº†PacBioæ€»è£Christian Henryåœ¨2026å¹´æ‘©æ ¹å¤§é€šåŒ»ç–—å¥åº·å¤§ä¼šä¸Šçš„æ¼”è®²ã€‚æ ¸å¿ƒå†…å®¹èšç„¦äºå…¬å¸2025å¹´ç¬¬å››å­£åº¦åŠå…¨å¹´çš„è´¢åŠ¡ä¸ä¸šåŠ¡è¿›å±•ã€‚å…³é”®æ•°æ®åŒ…æ‹¬ï¼š2025å¹´é¢„è®¡æ”¶å…¥1.6äº¿ç¾å…ƒï¼ŒQ4æ”¶å…¥4460ä¸‡ç¾å…ƒï¼ˆç¯æ¯”å¢é•¿16%ï¼‰ï¼›ä¸´åºŠé¢†åŸŸå‡ºè´§é‡å¹´å¢é•¿40%ï¼Œæˆä¸ºä¸»è¦å¢é•¿å¼•æ“ï¼›å…¬å¸ç°é‡‘æ¶ˆè€—é™è‡³çº¦1.1äº¿ç¾å…ƒï¼Œå¹¶ç»´æŒ2.8äº¿ç¾å…ƒç°é‡‘å‚¨å¤‡ã€‚æ–‡ç« ç‰¹åˆ«å¼ºè°ƒäº†é•¿è¯»é•¿æµ‹åºåœ¨ä¸´åºŠåº”ç”¨çš„çªç ´ï¼ŒåŒ…æ‹¬å…¨çƒé¦–ä¸ªé•¿è¯»é•¿å¹³å°çš„ç›‘ç®¡æ‰¹å‡†ï¼ˆä¸­å›½NMPAæ‰¹å‡†Berry Genomicsçš„Sequel IIeç³»ç»Ÿï¼‰ï¼Œä»¥åŠæµ‹åºç»æµæ€§ï¼ˆå•ç³»ç»Ÿæ‹‰åŠ¨æ”¶å…¥è¾¾24.2ä¸‡ç¾å…ƒï¼‰ä½¿å…¶ä¸çŸ­è¯»é•¿æµ‹åºå½¢æˆç«äº‰ã€‚èƒŒæ™¯æ˜¯å…¬å¸åœ¨å­¦æœ¯ç»è´¹é€†é£ä¸­ï¼Œé€šè¿‡å‘ä¸´åºŠå¸‚åœºè½¬å‹å®ç°äº†å¢é•¿ã€‚",
        "one_sentence": "PacBioä»¥å¼ºåŠ²çš„Q4å¢é•¿ã€ä¸´åºŠå‡ºè´§é‡é£™å‡40%åŠå…¨çƒé¦–ä¸ªé•¿è¯»é•¿å¹³å°è·æ‰¹ï¼Œå®£å‘Šé•¿è¯»é•¿æµ‹åºæ­£å¼è¿ˆå…¥ä¸´åºŠä¸»æµå¹¶å…·å¤‡æˆæœ¬ç«äº‰åŠ›ã€‚",
        "score": 82,
        "score_reason": "æ•°æ®è¯¦å®ï¼ŒåŸºäºä¼ä¸šè´¢æŠ¥å’Œå…·ä½“å¸‚åœºæ•°æ®ï¼Œæ¸…æ™°å±•ç¤ºäº†äº§ä¸šè½¬å‹å…³é”®èŠ‚ç‚¹å’Œå•†ä¸šæ¨¡å¼éªŒè¯ï¼Œå…·æœ‰é«˜å†³ç­–å‚è€ƒä»·å€¼ã€‚ä½†ç¼ºä¹å¯¹æŠ€æœ¯å±€é™æ€§å’Œé•¿æœŸé£é™©çš„æ·±å…¥è®¨è®ºã€‚",
        "category": "INDUSTRY",
        "keywords": [
          "é•¿è¯»é•¿æµ‹åº",
          "ä¸´åºŠæµ‹åº",
          "æµ‹åºç»æµå­¦",
          "ç›‘ç®¡æ‰¹å‡†",
          "è´¢åŠ¡ä¸šç»©"
        ],
        "key_insight": "PacBioå•ç³»ç»ŸQ4æ‹‰åŠ¨æ”¶å…¥ï¼ˆpull-throughï¼‰è¾¾åˆ°24.2ä¸‡ç¾å…ƒï¼Œå¤„äºå…¬å¸é¢„æœŸçš„é«˜ç«¯ï¼Œè¿™æ ‡å¿—ç€å…¶é•¿è¯»é•¿æµ‹åºåœ¨ä¸´åºŠå¸‚åœºçš„ç»æµæ¨¡å‹å·²å…·å¤‡ä¸çŸ­è¯»é•¿æµ‹åºç«äº‰çš„èƒ½åŠ›ã€‚"
      }
    }
  ]
}